UCB   [ADDRESS_593058] Number: 2017 -003065 -95 
IND Number: 128708  
Sponsor:  
UCB Biopharma SRL  
Allée de la Recherche 60  
1070 Brussels  
BELGIUM  
Protocol/Amendment number  Date  Type of amendment  
Final protocol  26 Nov 2018  Not applicable  
Protocol Amendment 0.1 (Japan)  26 Feb 2019  Not applicable  
Protocol Amendment 0.2 ([LOCATION_013])  23 Apr 2019  Nonsubstantial  
Protocol Amendment 1  11 Sep 2019  Substantial  
Protocol Amendment 1.1 (Japan)  13 Sep 2019  Substantial  
Protocol Amendment 1.2 ([LOCATION_013])  [ADDRESS_593059] 2019  Substantial  
Protocol Amendment 2.1 (Japan)  [ADDRESS_593060] 2019  Substantial  
Protocol Amendment 2.2 ([LOCATION_013])  [ADDRESS_593061] 2019  Substantial  
Protocol Amendment 3  16 Dec 2019  Nonsubstantial  
Protocol Amendment 3.1 (Japan)  16 Dec 2019  Nonsubstantial  
Protocol Amendment 3.2 ([LOCATION_013])  16 Dec 2019  Nonsubstantial  
Protocol Amendment 4  16 Feb 2021  Substantial  
Confidential Material  
Confidential  
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593062] INFORMATION  
Sponsor  
UCB Biopharma SRL  
Allée de la Recherche 60  
1070 Brussels  
BELGIUM  
Sponsor Study Physician  
Name:   
[CONTACT_2761]:  UCB BIOSCIENCES GmbH  
Alfred -Nobel -Straße 10  
[ZIP_CODE] Monheim am Rhein  
GERMANY  
Phone:   
Clinical Project Manager  
Name:   
[CONTACT_2761]:  UCB BIOSCIENCES GmbH  
Alfred -Nobel -Straße 10  
[ZIP_CODE] Monheim am Rhein  
GERMANY  
Phone:   
Clinical Trial Biostatistician  
Name:   
[CONTACT_2761]:  UCB BIOSCIENCES Ltd.  
[ADDRESS_593063]  
Slough SL1 3WE  
UNITED KINGDOM  
Phone:   
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593064] Research Organization  
Name:  [CONTACT_352338] (IRL) Limited -Ireland  
Address:  Ireland Limited at 70 Sir John Rogerson’s Quay  
Dublin 2  
Ireland  
Phone:  +353 (1) 477 3171  
Fax: +353 (1) 477 3308  
  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 4 of 187 SERIOUS ADVERSE EVENT REPORTING  
Serious adverse event reporting (24h)  
All SAEs will be reported and transmitted to Patient Safety through the eCRF 
system. The numbers below are to be used to send ancillary documentation only 
(discharge summaries, death certificates, etc) or in the event that the electronic 
reporting (eCRF) is not ava ilable.  
Fax Europe and Rest of the World: [PHONE_301] 21  
US and Canada: +[PHONE_299] or +[PHONE_300]  
Email  Global:  [EMAIL_311]  
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593065] OF ABBREVIATION S ................................ ................................ ................................ .. 12 
1 SUMMARY  ................................ ................................ ................................ .....................  17 
2 INTRODUCTION  ................................ ................................ ................................ ...........  18 
2.1 Axial spondyloarthritis  ................................ ................................ ................................ ..... 18 
2.1.1  axSpA epi[INVESTIGATOR_623]  ................................ ................................ ...........................  18 
2.1.2  Current treatments for axSpA  ................................ ................................ ..............  19 
2.2 Bimekizumab  ................................ ................................ ................................ ...................  19 
2.2.1  Nonclinical  ................................ ................................ ................................ ...........  19 
2.2.2  Clinical  ................................ ................................ ................................ .................  20 
[IP_ADDRESS]  Completed studies  ................................ ................................ .....................  20 
[IP_ADDRESS]  Ongoing studies  ................................ ................................ .........................  20 
3 STUDY OBJECTIVE(S)  ................................ ................................ ................................ . 21 
3.1 Primary objective  ................................ ................................ ................................ .............  21 
3.2 Secondary objectives  ................................ ................................ ................................ ....... 21 
3.3 Other objectives  ................................ ................................ ................................ ...............  21 
4 STUDY VARIABLES  ................................ ................................ ................................ ..... 21 
4.1 Primary variable  ................................ ................................ ................................ ...............  21 
4.1.1  Primar y efficacy variable  ................................ ................................ .....................  21 
4.2 Secondary variables  ................................ ................................ ................................ .........  21 
4.2.1  Secondary efficacy variables  ................................ ................................ ...............  21 
4.2.2  Secondary safety variables  ................................ ................................ ..................  22 
4.3 Other variables  ................................ ................................ ................................ .................  22 
4.3.1  Other efficacy variables  ................................ ................................ .......................  22 
4.3.2  Other safety variables  ................................ ................................ ..........................  24 
4.3.3 Pharmacokinetic variable  ................................ ................................ .....................  24 
4.3.4  Pharmacogenomic variables  ................................ ................................ ................  24 
4.3.5  Immunological variables  ................................ ................................ .....................  24 
5 STUDY DESIGN  ................................ ................................ ................................ .............  25 
5.1 Study description  ................................ ................................ ................................ .............  25 
5.1.1  Screening Period/Baseline  ................................ ................................ ...................  25 
[IP_ADDRESS]  Within -study rescreening/retesting requirements  ................................ ...... 26 
[IP_ADDRESS]  Cross -study screening requirements  ................................ ..........................  26 
5.1.2  Treatment Period  ................................ ................................ ................................ . 27 
[IP_ADDRESS]  Double -Blind Treatment Period  ................................ ................................  27 
[IP_ADDRESS]  Maintenance Period  ................................ ................................ ...................  [ADDRESS_593066]  ................................ ................................ ...................  29 
5.1.6  Planned number of subjects and site(s)  ................................ ...............................  [ADDRESS_593067] AWAL OF SUBJECTS  ................................ ...................  36 
6.1 Inclusion criteria  ................................ ................................ ................................ ..............  36 
6.2 Exclusion criteria  ................................ ................................ ................................ .............  38 
6.3 Withdrawal criteria  ................................ ................................ ................................ ..........  41 
6.3.1  Potential drug -induced liver injury IMP discontinuation criteria  ........................  44 
7 STUDY TREATMENTS  ................................ ................................ ................................ . 45 
7.1 Description of investigational medicinal products  ................................ ..........................  45 
7.2 Treatment(s) to be administered  ................................ ................................ ......................  [ADDRESS_593068] compliance  ................................ ................................  47 
7.8 Concomitant medications/treatments  ................................ ................................ ...............  47 
7.8.1  Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])  ..........................  54 
7.8.2  Prohibited concomitant treatments (medications and  therapi[INVESTIGATOR_014])  .........................  54 
7.8.3  Nonbiologic rescue therapy  ................................ ................................ .................  54 
7.8.4  Vaccines  ................................ ................................ ................................ ...............  54 
7.9 Blinding  ................................ ................................ ................................ ............................  54 
7.9.1  Procedures for maintaining and breaking the treatment blind  .............................  54 
[IP_ADDRESS]  Maintenance of study treatment blind  ................................ .......................  54 
[IP_ADDRESS]  Breaking the treatment blind in an emergency situation  ...........................  55 
7.10  Randomization and numbering of subjects  ................................ ................................ ...... 55 
8 STUDY PROCEDURES BY [CONTACT_16990]  ................................ ................................ ...............  55 
8.1 Screening (Visit 1)  ................................ ................................ ................................ ...........  56 
8.2 Baseline (Visit 2, Day 1, first dose of IMP)  ................................ ................................ .... 57 
8.3 Double -Blind Treatment  Period  ................................ ................................ .......................  59 
8.3.1  Week 1 (±3 days) (Visit 3)  ................................ ................................ ..................  59 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 7 of 187 8.3.2  Week 2 (±3 days) (Visit 4)  ................................ ................................ ..................  59 
8.3.3  Week 4 (±3 days) (Visit 5)  ................................ ................................ ..................  59 
8.3.4  Week 8 (±3 days) (Visit 6)  ................................ ................................ ..................  60 
8.3.5  Week 12 (±3 days) (Visit 7)  ................................ ................................ ................  61 
8.3.6  Week 16 (±3 days) (Visit 8)  ................................ ................................ ................  61 
8.4 Maintenance Period  ................................ ................................ ................................ .........  63 
8.4.1  Week 20 (±4 days) (Visit 9)  ................................ ................................ ................  63 
8.4.2  Week 24 (±4 days) (Visit 10)  ................................ ................................ ..............  63 
8.4.3  Week 28 (± 4 days) (Visit 11)  ................................ ................................ ..............  64 
8.4.4  Week 32 (± 4 days) (Visit 12)  ................................ ................................ ..............  64 
8.4.5  Week 36 (±4 days) (Visit 13)  ................................ ................................ ..............  65 
8.4.6  Week 40 (± 4 days) (Visit 14)  ................................ ................................ ..............  66 
8.4.7  Week  44 (± 4 days) (Visit 15)  ................................ ................................ ..............  66 
8.4.8  Week 48 (±4 days) (Visit 16)  ................................ ................................ ..............  66 
8.4.9  Week 52 (±4 days) (Visit 17)  ................................ ................................ ..............  67 
8.5 Early Termination Visit (if applicable)  ................................ ................................ ............  68 
8.6 Safety Follow -Up Visit ( -3 days/+7 days)  ................................ ................................ ....... 69 
8.7 Unscheduled Visit  ................................ ................................ ................................ ............  69 
9 ASSESSMENT OF EFFICA CY ................................ ................................ ......................  70 
9.1 ASAS20, 40, ASAS 5/6 response, and ASAS -PR ................................ ...........................  70 
9.2 ASQoL  ................................ ................................ ................................ .............................  71 
9.3 Inflammation – BASDAI (mean of Questions 5 and 6)  ................................ ..................  71 
9.4 BASDAI  ................................ ................................ ................................ ...........................  71 
9.5 Physical function – BASFI  ................................ ................................ ..............................  72 
9.6 SF-36 72 
9.7 MOS -12 ................................ ................................ ................................ ............................  73 
9.8 PGADA  ................................ ................................ ................................ ............................  73 
9.9 Total and nocturnal spi[INVESTIGATOR_18172]  ................................ ................................ ........................  73 
9.10  FACIT -Fatigue subscale  ................................ ................................ ................................ .. 73 
9.11  EQ-5D-3L ................................ ................................ ................................ ........................  73 
9.12  TJC and SJC (44/44)  ................................ ................................ ................................ ........  74 
9.13  WPAI -SHP v2.0  ................................ ................................ ................................ ...............  74 
9.14  CRP  74 
9.15  ASDAS  ................................ ................................ ................................ ............................  75 
9.16  MASES  ................................ ................................ ................................ ............................  75 
9.17  BASMI  ................................ ................................ ................................ .............................  75 
9.18  PhGADA  ................................ ................................ ................................ ..........................  76 
9.19  Occurrence of extra -articular manifestations  ................................ ................................ ... 76 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 8 of 187 9.20  Imaging evaluation  ................................ ................................ ................................ ...........  76 
9.20.1  Sacroiliac joint x -ray (AP Pelvis Joint Film for modified [LOCATION_001] Criteria)  ... 76 
9.20.2  Spi[INVESTIGATOR_050] x -ray ................................ ................................ ................................ ...........  77 
9.20.3  Sacroiliac joint and spi[INVESTIGATOR_463117]  ................................ ..........  77 
10 ASSESSMENT OF PHARMA COKINETIC AND PHARMA COGENOMIC 
VARIABLES  ................................ ................................ ................................ ...................  78 
10.1  Pharmacokinetic variables  ................................ ................................ ...............................  78 
10.2  Pharmacogenomic variables  ................................ ................................ ............................  79 
11 ASSESSMENT OF IMMUNO LOGICAL VARIABLES  ................................ ...............  79 
12 ASSESSMENT OF SAFETY  ................................ ................................ ..........................  80 
12.1  Adverse events  ................................ ................................ ................................ .................  80 
12.1.1  Definitions  ................................ ................................ ................................ ...........  80 
[IP_ADDRESS]  Adverse event  ................................ ................................ ............................  80 
[IP_ADDRESS]  Serious adverse event  ................................ ................................ ................  80 
[IP_ADDRESS]  Adverse events of special interest  ................................ .............................  82 
[IP_ADDRESS]  Other safety topi[INVESTIGATOR_23254]  ................................ ................................ .... 83 
12.1.2  Procedures for reporting and recording adverse events  ................................ ....... 83 
[IP_ADDRESS]  Description of advers e events  ................................ ................................ .... 83 
[IP_ADDRESS]  Rule for repetition of an adverse event ................................ ......................  83 
[IP_ADDRESS]  Additional procedures for reporting serious adverse events  .....................  [ADDRESS_593069]  ......................  92 
[IP_ADDRESS]  Immediate action: determination of IMP discontinuation  .........................  92 
[IP_ADDRESS]  Testing: identification/exclusion of alternative etiology  ...........................  93 
[IP_ADDRESS]  Follow -up evaluation  ................................ ................................ .................  95 
12.7  Other safety measurements  ................................ ................................ ..............................  95 
12.7.1  Vital signs  ................................ ................................ ................................ ............  95 
12.7.2  Body weight and height  ................................ ................................ .......................  96 
12.7.3  Physical examination  ................................ ................................ ...........................  96 
12.7.4  12-lead electrocardiogram  ................................ ................................ ...................  96 
12.7.5  Assessment and management of TB and TB risk factors  ................................ .... 96 
[IP_ADDRESS]  Tuberculosis assessment by [CONTACT_18406]  ................................ ..........................  100 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 9 of 187 [IP_ADDRESS]  Chest x -ray for tubercu losis ................................ ................................ .... 100 
[IP_ADDRESS]  Tuberculosis questionnaire  ................................ ................................ ...... 100 
[IP_ADDRESS]  Tuberculosis management  ................................ ................................ ....... [ADDRESS_593070] Screening and Enrollment log/Subject Identification Code list ............  104 
14.4  Termination of the study  ................................ ................................ ................................  104 
14.5  Archiving and data retention  ................................ ................................ ..........................  105 
14.6  Audit and inspection  ................................ ................................ ................................ ...... 105 
14.7  Good Clinical Practice  ................................ ................................ ................................ ... 105 
15 STATISTICS  ................................ ................................ ................................ .................  106 
15.1  Definition of analysis sets  ................................ ................................ ..............................  106 
15.2  General statistical considerations  ................................ ................................ ...................  106 
15.3  Planned efficacy analyses  ................................ ................................ ..............................  107 
15.3.1 Analysis of the primary and secondary efficacy variables  ................................  107 
[IP_ADDRESS]  Analysis of the primary efficacy variable  ................................ ...............  108 
[IP_ADDRESS]  Analyses of the secondary efficacy variables  ................................ ..........  [ADDRESS_593071] privacy  ................................ ................................ ................................ ...............  119 
16.5  Protocol amendments  ................................ ................................ ................................ ..... 119 
17 FINAN CE, INSURANCE, AND P UBLICATION  ................................ .......................  119 
18 REFERENCES  ................................ ................................ ................................ ..............  120 
19 APPENDICES  ................................ ................................ ................................ ...............  125 
19.1  ASAS classification criteria for axial SpA  ................................ ................................ .... 125 
19.2  Modified [LOCATION_001] (mNY) Classification Criteria for AS  ................................ ..........  [ADDRESS_593072] OF TABLES  
Table  5‒1:  Cross -study screening requirements  ................................ ................................  27 
Table  5-2: Schedule of study assessments ................................ ................................ .........  30 
Table  7‒1:  Overview on dosing during the Double -Blind Treatment Period  ....................  45 
Table  7‒2:  Exclusionary, concomitant, and rescue medication  ................................ .........  48 
Table  9‒1:  Tenderness and swelling grading  ................................ ................................ ..... 74 
Table  12‒1:  Anticipated serious adverse events for the population of subjects with AS  .... 82 
Table  12‒2:  Laboratory measurements  ................................ ................................ ................  87 
Table  12‒3:  Required investigations and follow -up for PDILI  ................................ ...........  89 
Table  12‒4:  PDILI laboratory measurement s ................................ ................................ ...... 94 
Table  12‒5:  PDILI information to be collected  ................................ ................................ ... 95 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 11 of 187 Table  19‒1:  ASAS classification criteria for axial SpA (for subjects with chronic back 
pain of at least 3 months and age at onset <45 years)  ................................ .... 125 
Table  19‒2:  Modified [LOCATION_001] (mNY) Classification Criteria for AS  ..........................  [ADDRESS_593073] OF FIGURES  
Figure  5‒1:  Schematic diagram: study overview  ................................ ................................  35 
Figure  12‒1:  Schematic diagram of TB test results and study eligibility  .............................  98 
Figure  12‒2:  Schematic diagram of TB test results during the study  ................................ ... 99 
Figure  15‒1:  Sequential testing procedure of primary/secondary efficacy endpoints  ........  [ADDRESS_593074]  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
ANCOVA  analysis of covariance  
AP Anterior Posterior  
AS ankylosing spondylitis  
ASAS  Assessment of SpondyloArthritis International Society  
ASAS20, 40, 5/6  Assessment of SpondyloArthritis International Society 20%, 40%, [ADDRESS_593075] Rheumatism  
FACIT  Functional assessment of chronic illness therapy  
FAS Full Analysis Set  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
GI gastrointestinal  
GMP  Good Manufacturing practice  
HbcAb   hepatitis B core antibody  
HbsAg   hepatitis B surface antigen  
HBV  hepatitis B virus  
HCQ  hydroxychloroquine  
HCV  hepatitis C virus  
HD high disease  
HIV human immunodeficiency virus  
HLA  human leukocyte antigen  
HRQoL  health -related quality of life  
IB Investigator’s Brochure  
IBD inflammatory bowel disease  
ICF Informed Consent Form  
ICH International Council for Harmonisation  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593076]  
IUD intrauterine device  
IUS intrauterine hormone -releasing system  
iv intravenous  
IXRS  interactive voice or web response system  
LEF leflunomide  
LD low disease  
LTB  latent tuberculosis  
LTBI  latent tuberculosis infection  
MAR  missing at random  
MASES  Maastricht Ankylosing Spondylitis Enthesitis Index  
MCID  minimal clinically important difference  
MCMC  Markov -Chain Monte Carlo  
MCP  metacarpophalangeals  
MCS  mental component summary  
MedDRA® Medical Dictionary for Regulatory Activities  
MI multiple imputation  
MNAR  missing not at random  
mNY  Modified [LOCATION_001] (criteria)  
MOS  Medical Outcomes Study  
MRI  magnetic resonance imaging  
MTX  methotrexate  
nr-axSpA  nonradiographic axial spondyloarthritis  
NRI nonresponder imputation  
NRS  Numeric Rating Scale  
NSAID  nonsteroidal anti -inflammatory drug  
NTMB  nontuberculous mycobacteria  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593077]  Outcome Measures in Rheumatology Clinical Trials  
PASI   Psoriasis Area and Severity Index  
PCS physical component summary  
PD pharmacodynamics  
PDILI  potential drug -induced liver injury  
PFS prefilled syringe  
PGADA  Patient’s Global Assessment of Disease Activity  
PhGADA  Physician’s Global Assessment of Disease Activity  
PHQ -9 Patient Health Questionnaire 9  
PIP proximal interphalangeal  
PK pharmacokinetics  
PK-PPS Pharmacokinetic Per -Protocol Set  
PPS Per-Protocol Set  
PRN  as needed  
PS Patient Safety  
PsA psoriatic arthritis  
PSO psoriasis  
Q4W  every 4  weeks  
r-axSpA  radiographic axSpA  
RA rheumatoid arthritis  
RNA  ribonucleic acid  
RS Randomized Set  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
sc subcutaneous(ly)  
SD standard deviation  
SF-[ADDRESS_593078]  upper limit of normal  
VAS  visual analog scale  
vHD  very high disease  
WHO  World Health Organization  
WPAI -SHP Work Productivity and Activity Impairment Questionnaire -specific health  
problem  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 17 of 187 1 SUMMARY  
This is a multicenter, Phase 3, randomized, double -blind, placebo -controlled study to evaluate 
the efficacy and safety of bimekizumab in subjects with active ankylosing spondylitis (AS), a 
subtype of axial spondyloarthritis (axSpA) with radiographic evidence of disease (also known as 
radiographic axSpA [r -axSpA]). To be eligible to participate in this study, subjects must be 
adults with a d iagnosis of active AS, determined by [CONTACT_58943] (x -ray) 
fulfilling the Modified [LOCATION_001] (mNY) criteria for AS (1984) ( Section  19.2), including at least 
3 months of symptoms and age at symptom onset <45  years, and moderate -to-severe active 
disease at Baseline as defined by [CONTACT_240076]:  
• Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥4 AND spi[INVESTIGATOR_18172] ≥4 on a 
0 to 10 numeric rating scale (NRS) (from BASDAI Item  2). 
As bimekizumab will be evaluated in axSpA, UCB will also perform a randomized, 
double -blind, placebo -controlled Phase 3 study (AS0010) in subjects with nonradiographic axial 
spondyloarthritis (nr -axSp A) in parallel to the present study in AS (AS0011).  
The primary objective of AS0011 is to demonstrate the efficacy of bimekizumab administered 
subcutaneously (sc) every 4 weeks (Q4W) compared with placebo in the treatment of subjects 
with active AS. The s econdary objectives of the study are listed in Section  3.2, and other 
objectives are listed in Section  3.3.  
The primary efficacy variable for this study is the Assessment of SpondyloArthritis International 
Society 40% response criteria  (ASAS 40) response at Week  16. The secondary and other 
efficacy variables are listed in Section  4.2.1  and Section  4.3.1 , respectively.  
Safety variables are listed in Section  4.2.2  (second ary safety variables) and Section  4.3.2  (other 
safety variables). The pharmacokinetic (PK), pharmacogenomic, and immunological variables 
are listed i n Section  4.3.3 , Section  4.3.4 , and Sectio n 4.3.5  respectively.  
AS0011 will evaluate the efficacy, safety, and PK of bimekizumab in adult subjects with 
active  AS at a dose level of bimekizumab 160mg Q4W administered by [CONTACT_181508].  
The ove rall study design consists of a Screening Period (minimum of approximately 14 days 
[unless a screenfailed subject from AS0010 will be screened in AS0011] to ≤35 days), a 52 -week 
Treatment Period consisting of a 16 -week Double -Blind Treatment Period, a 36 -week 
Maintenance Period, and a Safety Follow -Up (SFU) Visit [ADDRESS_593079]  (IMP) ( ie, Week  48 for subjects who completed AS0011; for 
subjects not entering the extension study or who discontinue early, including those withdrawn 
from study treatment). The maximum study duration per subject will be 73  weeks.  
Approximately 300 subjects will be randomly assigned in a 2:1 ratio to the following treatment 
groups: bimekizumab 160mg sc Q4W (200 subjects) or placebo (100 subjects). Subjects 
receiving placebo during the Double -Blind Treatment Period will be re -allocated to 
bimekizumab treatment at Week [ADDRESS_593080] been completed. These 
subjects will receive bimekizumab 160mg sc at Week 1 6 and Q4W thereafter ( Section  7.2).  
A detailed schedule of study assessments is presented in Table  5-2 and a study schematic 
diagram is presented in Figure  5‒1. 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 18 of 187 Nonbiologic rescue therapy will be  at the Investigator’s discretion as add -on therapy to 
bimekizumab at any time from Week 20 or later. Details are provided in Table  7‒2. 
Subjects completing Week  52 who meet the eligibility criteria may be enrolled in an extension 
study to continue to receive bimekizumab treatment.  
2 INTRODUCTION  
2.1 Axial spondyloarthritis  
Spondyl oarthritis (SpA) is an umbrella term applied to a family of rheumatic diseases (including 
axial spondyloarthritis [axSpA], psoriatic arthritis [PsA], reactive arthritis, the arthritis of 
inflammatory bowel disease [IBD], and undifferentiated SpA) that have  features in common with 
each other and distinct from other inflammatory arthritides, particularly rheumatoid arthritis 
(RA).  
The ASAS working group established classification criteria to distinguish [ADDRESS_593081] categories of 
SpA: peripheral SpA and axSpA (Ru dwaleit et al, 2011; Rudwaleit, 2010; Rudwaleit et al, 
2009b). This division is based on the body part predominantly involved in the inflammatory 
process. Therefore, peripheral SpA includes diseases affecting mainly peripheral joints, such as 
reactive arth ritis and PsA, whereas axSpA comprises those diseases with mainly axial 
involvement (sacroiliac joints and spi[INVESTIGATOR_050]), including AS (also known as r -axSpA) diagnosed with 
definite radiographic changes of the sacroiliac joint and nr -axSpA.  
Patients with axSpA have inflammatory back pain. The disease typi[INVESTIGATOR_58888], then progresses to the spi[INVESTIGATOR_050]. In the sacroiliac joints and the spi[INVESTIGATOR_050], active 
inflammation results in erosions, sclerosis, and fatty lesions seen on magnetic resonance i maging 
(MRI). However, the most characteristic feature is new bone formation leading to ankylosis of 
the sacroiliac joints and syndesmophytes attached to the vertebral bodies. As a result of extended 
syndesmophyte formation, over time the spi[INVESTIGATOR_58889] (bamboo spi[INVESTIGATOR_050]). Objective 
signs of inflammation (such as enthesitis, dactylitis, peripheral arthritis, or uveitis), genetic 
features (such as the presence of human leukocyte antigen [HLA] B27), and laboratory 
parameters (such as elevated C -reactive p rotein [CRP]) may also be present (Braun, 2012; 
Rudwaleit et al, 2009a; Braun and Sieper, 2007). Disability in axSpA is related to both the 
degree of inflammatory activity, causing pain, stiffness, fatigue, and poor quality of sleep, and to 
the degree of b ony ankylosis, causing loss of spi[INVESTIGATOR_18171]. Patients with AS show 
radiographic progression of disease with x -ray identified sacroiliitis, while "bamboo spi[INVESTIGATOR_050]" may 
develop when the outer fibers of the fibrous ring of the intervertebral discs ossify, whi ch results 
in the formation of marginal syndesmophytes between adjoining vertebrae.  
2.1.1  axSpA epi[INVESTIGATOR_463118] a chronic inflammatory disease that impacts a substantial proportion of the 
population. Limited evidence exists regarding the global occurr ence of axSpA with a prevalence 
of 0.20 to 0.25% in Europe and North America, and a wider range in Asia (0.06 to 0.20%) 
(Stolwijk et al, 2016); however, recent data suggest that the prevalence is similar to that of RA in 
the US (axSpA: 0.7% to 1.4%; RA: 0. 5% to 1.0%) (Reveille et al, 2012; Myasoedova et al, 2010; 
Helmick et al, 2008). Axial SpA comprises those diseases with mainly axial involvement 
(sacroiliac joints and spi[INVESTIGATOR_050]), including AS and nr -axSpA.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593082] -line treatment and are effective for the 
symptoms (pain and stiffness) of axSpA (van der Heijde et al, 2017; Ward et al, 2015; 
Poddubnyy, 2013; Poddubnyy et al, 2012), but many patients lose or never have clinically 
meaningf ul response and structural damage often progresses despi[INVESTIGATOR_18186]. Conventional 
disease -modifying antirheumatic drugs (DMARDs, eg, methotrexate [MTX] and sulfasalazine 
[SSZ]) have no proven efficacy in axial disease, but may benefit patients with periph eral joint 
disease (Haibel et al, 2007; Braun et al, 2006; Haibel et al, 2005). Therefore, DMARDs are 
recommended only in patients with predominantly peripheral manifestations (Braun et al, 2011). 
Patients who are intolerant of or have inadequately respond ed to NSAIDs, or those in whom 
NSAIDs are contraindicated, have approved treatment options such as tumor necrosis factor 
alpha (TNFα) inhibitors (van der Heijde, 2017; Ward et al, 2015).  
Recently, the interleukin (IL) -17 cytokine family has been identifie d as a therapeutic target in 
axSpA and secukinumab, an IL -17A monoclonal antibody, has recently been approved as a 
treatment option in active AS.  
2.2 Bimekizumab  
Bimekizumab (UCB4940) is an engineered, humanized full -length monoclonal antibody of IgG1 
subclass  of approximately 150,000 Dalton, which is expressed in a genetically engineered 
Chinese Hamster Ovarian (CHO) cell line. Bimekizumab has high affinity for human IL -17A 
and human IL -17F and selectively and potently inhibits the activity of both isoforms in  vitro. 
Interleukin -17A and IL -17F are key proinflammatory cytokines believed to play important roles 
in autoimmune and inflammatory diseases. Therefore, bimekizumab permits an evaluation of the 
potential for additional efficacy, which may be conferred by [CONTACT_58945], in 
patients suffering from diseases in which both cytokines are active. Bimekizumab is being 
developed for the treatment of patients with inflammatory diseases such as PsA, psoriasis (PSO), 
axSpA and hidradenitis suppurat iva.  
2.2.1  Nonclinical  
There is increasing evidence of the role of IL -17F in various inflammatory diseases. 
Simultaneous inhibition of IL -17A and IL -17F has been shown to be more efficacious than 
inhibition of IL -17A alone in in vitro models. Intravenously or s c administered bimekizumab 
was well tolerated in repeat -dose toxicology studies in Cynomolgus monkeys with dosing up to 
200mg/kg/week for up to 26 weeks. The findings of note varied from study to study, but were all 
compatible with decreased muco -epi[INVESTIGATOR_463119] -17A and  F 
signaling. They consisted in diarrhea related to infectious enteritis, asymptomatic proliferation of 
a protozoan commonly found in the cynomolgus monkey, Balantidium coli , superficial 
dermatitis associate d with increased bacterial load on the skin (mainly Gram positive cocci, 
including Staphylococcus aureus ), and abscesses.  
Infection -related safety findings in a nonhuman primate can be highly variable from study to 
study and have limited ability to accura tely predict the incidence and type of infection that can be 
expected in humans, especially because nonhuman primates bear different commensal flora and 
show different sensitivity to different pathogens. Immunomodulators can increase the 
susceptibility of monkeys to potential pathogens that are endemic in nonhuman primate 
populations and usually remain clinically undetectable or are mild and self -limiting in 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 20 of 187 immunocompetent animals. Moreover, infections associated with the gastrointestinal (GI) tract 
that r esult in chronic enterocolitis are a persistent and widespread colony problem in nonhuman 
primates, often multifactorial in origin.  
The nonclinical studies have highlighted the already known risk of infection linked to decreased 
muco -epi[INVESTIGATOR_463120], but are unlikely to 
predict the risk of infection in humans based on dose and exposure for the aforementioned 
reasons . To date, similar findings have not been seen in studies in humans.  
Preliminary results from the embryofetal and postnatal study conducted in the Cynomolgus 
monkey indicate no effects of bimekizumab on the gestation, gestation duration, or the 
parturition of pregnant females. No bimekizumab -related effects were noted in infants at birth, 
during postnatal development, or on infant survival rate. Toxicokinetic data confirmed 
dose-related exposure of maternal animals during the pregnancy and the lactation phase, and of 
infants at birth and during the postnatal phase.  
Additional information on the  nonclinical data for bimekizumab is available in the current 
version of the Investigator’s Brochure (IB).  
2.2.2  Clinical  
[IP_ADDRESS]  Completed studies  
Twenty clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with 
mild-to-moderate plaque PSO, RA012 4 in 30 healthy volunteers, PA0007 in 53 subjects with 
PsA, UP0031 in 12 healthy volunteers, UP0033 in 189 healthy volunteers, UP0034 in 56 healthy 
volunteers, UP0042 in 48 Japanese and Caucasian healthy volunteers, UP0074 in 37 healthy 
volunteers, RA0123 in 159 subjects with moderate -to-severe RA, PS0010 in 250 subjects with 
moderate -to-severe chronic plaque PSO and the corresponding extension study (PS0011), 
PS0016 in 49 subjects with moderate -to-severe chronic plaque PSO and the corresponding 
extension s tudy (PS0018) , UC0011 in 23 subjects with moderate -to-severe active ulcerative 
colitis, HS0001 in 90 subjects with moderate to severe hidradenitis suppurativa, AS0008 in 
303 subjects with AS, PA0008 in 206  subjects with PsA, PS0008 in 478 subjects with mod erate 
to severe chronic plaque PSO, PS0009 in 567 subjects with moderate to severe chronic plaque 
PSO and PS0013 in 435 subjects with moderate to severe chronic plaque PSO.  
Information on the clinical data for bimekizumab from completed studies is availabl e in the 
current version of the IB.  
[IP_ADDRESS]  Ongoing studies  
Several additional studies of bimekizumab in subjects with axSpA are ongoing:  
• AS0009 is an open -label extension study for AS0008.  
• AS0013 is a Phase 2a Investigator - and subject -blind parallel -group study to evaluate the 
efficacy and safety of bimekizumab and certolizumab pegol (CZP) in subjects with active 
AS.  
• AS0010 is a Phase 3, double -blind, randomized, placebo -controlled study t o evaluate the 
efficacy and safety of bimekizumab in subjects with active nr -axSpA.  
• AS0014 is a Phase 3, open -label extension study for AS0010 and AS0011.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 21 of 187 Bimekizumab is also being evaluated in the treatment of other indications (eg, PsA, PSO, 
hidradenitis  suppurativa).  
Additional information on the ongoing studies for bimekizumab is available in the current 
version of the IB.  
3 STUDY OBJECTIVE(S)  
3.1 Primary objective  
The primary objective is to demonstrate the efficacy of bimekizumab administered sc Q4W 
compar ed to placebo in the treatment of subjects with active AS.  
3.2 Secondary objectives  
The secondary objectives of the study are as follows:  
• To assess the efficacy of bimekizumab compared to placebo  
• To assess the safety and tolerability of bimekizumab  
• To assess the impact of bimekizumab on patient -reported quality of life  
• To assess the impact of bimekizumab on spi[INVESTIGATOR_18171]  
• To assess the impact of bimekizumab on enthesitis and on peripheral arthritis  
3.3 Other objectives  
The other objectives are as follows:  
• To as sess the immunogenicity of bimekizumab  
• To assess the pharmacokinetics of bimekizumab  
• To assess the maintenance of efficacy of bimekizumab  
• To assess the relationship between exploratory biomarkers, drug treatment, and AS disease 
biology  
• To assess the impac t of bimekizumab on work productivity  
• To assess the impact of bimekizumab on inflammatory changes using MRI  
4 STUDY VARIABLES  
4.1 Primary variable  
4.1.1  Primary efficacy variable  
The primary efficacy variable for this study is:  
• ASAS40 response at Week  16.  
4.2 Secondary  variables  
4.2.1  Secondary efficacy variables  
The secondary efficacy variables for this study are as follows:  
• ASAS40 response at Week 16 in TNFα inhibitor -naïve subjects  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 22 of 187 • ASAS20 response at Week 16  
• Change from Baseline in BASDAI total score at Week 16  
• ASAS part ial remission (ASAS -PR) at Week 16  
• Ankylosing Spondylitis Disease Activity Score major improvement (ASDAS -MI) at 
Week  16  
• ASAS5/6 response at Week 16  
• Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week  16  
• Change from Basel ine in nocturnal spi[INVESTIGATOR_463121] (NRS) at Week 16  
• Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) total score at 
Week  16  
• Change from Baseline in the Short Form 36 -Item Health Survey (SF -36) physical component 
summary (PCS) score a t Week 16  
• Change from Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at 
Week 16  
• Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index 
in the subgroup of subjects with enthesitis at Baseline at Week  16 
• Enthesitis -free state based on the MASES Index in the subgroup of subjects with enthesitis at 
Baseline at Week 16  
4.2.2  Secondary safety variables  
Assessment time points for safety variables are specified in Table  5-2. Variables are as follows:  
• Incidence of treatment -emergent adverse events (TEAEs)  
• Incidence of treatment -emergent serious adverse events (SAEs)  
• TEAEs leading to withdrawal from IMP  
4.3 Other variables  
4.3.1  Other efficacy variables  
Other efficacy variables will be assessed as specified in Table  5-2. All time points not specified 
in Section  4.1.1  or Section  4.2.1  are exploratory:  
• ASAS40 response  
• Time to ASAS40 response  
• ASAS20 response  
• Time to ASAS20 response  
• ASAS5/6 response  
• ASAS -PR  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 23 of 187 • Change from Baseline in Ankylosing Spondylitis Disease Activity Score C -reactive protein 
(ASDAS -CRP)  
• ASDAS status (eg, inactive disease [ID], low disease [LD], high disease [HD], and very high 
disease [vHD])  
• ASDAS -MI  
• Change from Baseline in BASDAI total score  
• BASDAI50 response  
• Change from Baseline in BASFI  
• Change from Baseline in the MASES Index in the subgroup of subjects with enthesitis at 
Baseline  
• Enthesitis -free state based on the MASES in the subgroup of subjects with enthesitis at 
Baseline  
• Change from Baseline in BASMI  
• Change from Baseline in Physici an’s Global Assessment of Disease Activity (PhGADA)  
• Change from Baseline in Patient’s Global Assessment of Disease Activity (PGADA)  
• Change from Baseline in total and nocturnal spi[INVESTIGATOR_463121] (NRS)  
• Change from Baseline in the average score of Question s 5 and 6 of the BASDAI concerning 
morning stiffness  
• Change from Baseline in CRP  
• Responses to the European Qol -5 Dimensions 3 -Level (EQ -5D-3L)  
• Change from Baseline in EQ -5D-3L visual analog scale (VAS) scores  
• Change from Baseline in the EQ -5D utility s core  
• Change from Baseline in the SF -36 PCS score  
• Change from Baseline in the SF -36 mental component summary (MCS) score  
• Change from Baseline in sleep quality score (Medical Outcomes Study [MOS  12-item] scale)  
• Change from Baseline in Functional Assessment  of Chronic Illness Therapy 
(FACIT) -Fatigue subscale score  
• Change from Baseline in ASQoL total score  
• Change from Baseline in the Work Productivity and Activity Impairment 
Questionnaire - specific health problem (WPAI -SHP)  
• Change from Baseline in (44/44) t ender joint count (TJC) and swollen joint count (SJC)  
• Change from Baseline in Ankylosing Spondylitis spi[INVESTIGATOR_25342] -activity (ASspi[CONTACT_9268] -a) in the 
Berlin modification score  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 24 of 187 • Change from Baseline in sacroiliac joint Spondyloarthritis Research Consortium of Canada 
(SPARCC) score  
4.3.2  Other safety variables  
Other safety variables to be assessed as specified in Table  5-2 are as follows:  
• Change from Baseline in vital signs (blood pressure [BP], temperature, and pulse rate)  
• Standard 12 -lead electrocardiogram (ECG) results  
• Change from Baseline in clinical laboratory values (hematolog y, biochemistry, and 
urinalysis)  
• Change from Baseline in Patient Health Questionnaire -9 (PHQ -9) 
Physical examination findings considered clinically significant changes since the physical 
examination at the Screening Visit will be recorded as adverse events  (AEs). 
4.3.3  Pharmacokinetic variable  
The PK variable is the plasma concentration of bimekizumab.  
4.3.4  Pharmacogenomic variables  
Additional blood and stool samples will be collected from subjects who consent to participate in 
the substudy at specific time points sp ecified in Table  5-2. 
Genomic, genetic, epi[INVESTIGATOR_18193], proteins, and metabolite biomarkers may be measured to evaluate 
the relationship with response to tr eatment with bimekizumab, axSpA disease biology, bone 
metabolism, and inflammatory and immune response processes. The nature and format of these 
tentative substudy analyses will be determined at a later time.  
Additional candidate serum exploratory variabl es may include, but are not limited to the blood 
concentrations of cytokines and chemokines of relevance to the IL -17A/F signaling pathway and 
axSpA biology, and serum complement concentrations. Stool samples will be collected from 
subjects who consent to participate in the pharmacogenomics substudy at specific time points 
specified in Table  5-2. These samples may be used to assess biomarkers of gut infl ammation 
including but not limited to calprotectin and microbiome testing.  
4.3.[ADDRESS_593083] meet the following key inclusion criteria:  
• Adult subjects with active AS, determined by [CONTACT_58943] (x -ray) 
fulfilling the Modified [LOCATION_001] criteria for AS (1984) ( Section  19.2), including at least 
3 months of symptoms.  
• Age at symptom onset <45 years  
• Subject must have moderate -to-severe active disease as defined by [CONTACT_463172].  
− BASDAI ≥4 AND spi[INVESTIGATOR_18172] ≥4 on a 0 to 10 NRS (from BASDAI Item 2)  
Detailed eligibility criteria are presented in Section  6.1 and Section  6.2.  
The study will include the following 3 periods: a Screening Period (minimum of approximately 
14 days [unless a screenfailed subject from AS0010 will be  screened in AS0011] to ≤35 days), a 
Treatment Period (52  weeks) consisting of a 16 -week Double -Blind Treatment  Period and a 
36-week Maintenance Period, and a SFU Period (20 weeks after the final dose of IMP).  
Eligible subjects will be randomized 2:1 to receive 1 of 2 treatments (bimekizumab 
160mg  sc Q4W or placebo sc Q4W), and will remain on their allowable background medication. 
Details of the Treatment Period are provided in Section  5.1.[ADDRESS_593084] b een completed. These subjects will receive 
bimekizumab  160mg sc at Week 16 and 160mg sc Q4W thereafter. Starting at Week  20, 
nonbiologic rescue therapy for axial SpA may be adjusted or added, while continuing 
bimekizumab as outlined in Table  7‒2. 
Subjects completing Week [ADDRESS_593085] not to 
participate in the extension study at Week 52 will undergo a SFU Visit.  
Interim analyses of all available data (including efficacy, safety, and PK) will be conducted after 
the planned number of randomized subjects have completed [ADDRESS_593086] withdrawn from the IMP and/or study.  
A detailed schedule of study assessments is presented in Table  5-2 and a study schematic 
diagram is presented in Figure  5‒1.  
5.1.1  Screening Period/Baseline  
Assessmen ts of eligibility as described in Section  6 will be initiated during the Screening Period 
with a minimum duration of approximately 14 days (unless a screenfailed subject from AS0010 
will be screened in AS0011)  and a maximum duration of up to [ADDRESS_593087] an anterior posterior (AP) pelvis or sacroiliac joint x -ray (read centrally) to 
determine eligibility as per m NY criteria. Subjects who are mNY -negative may be eligible for 
Screening in AS0010, a double -blind, randomized, placebo -controlled Phase 3 study in subjects 
with active nr -axSpA. It is recommended to perform the sacroiliac joint x -ray prior to any other 
screening assessment to avoid repetition of screening assessments (applicable at sites 
participating in both Phase 3 studies).  
[IP_ADDRESS]  Within -study rescreening/retesting requirements  
Rules for rescreening or repetition of screening tests within the study are listed below:  
• Subjects who fail to meet the eligibility criteria for BASDAI, spi[INVESTIGATOR_18172], PHQ -9, eC -SSRS, 
or the TB questionnaire are not allowed  to be rescreened.  
The Medical Monitor must be contact[CONTACT_463173]/retesting in all other 
cases.  
• Subjects who initially fail to meet selected eligibility criteria (eg, documented completion of 
latent tuberculosis infection [LTBI] prophylactic therapy) may be rescreened.  
• Subjects for whom eligibility assessments could not be completed as planned (eg, for 
technical reasons) within the defined Screening Period of 35 days may be rescreened.  
• Subjects with individual laboratory screening tests for which the results are exclusionary, can 
be retested.  
Of note, repetition of laboratory screening tests within  the Screening Period is permitted for 
technical reasons (eg, frozen sample, expi[INVESTIGATOR_463122]) without contact[CONTACT_463174].  
[IP_ADDRESS]  Cross -study screening requirements  
Screening assessments for subjects previously screened for AS0010, who were not eligible for 
AS0010 based on mNY criteria and therefore entered AS0011 Screening for eligibility, must be 
repeated during the Screening Period unless defined in Table  5‒1. The Medical Monitor must be 
contact[CONTACT_463175].  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 27 of 187 Table  5‒1: Cross -study screening requirements  
Assessment  Screening requirements  
Cross -study screening is not permitted in the following cases:  
BASDAI and 
spi[INVESTIGATOR_463123] a subject not eligible for AS0010 who will be screened for AS0011, 
and who did not meet the related Inclusion Criteria in AS0010.  
PHQ -9, eC -SSRS, 
TB questionnaire 
(Q1)  Screening of a subject not eligible for AS0010 who will be screened for AS0011, 
and who did meet the related Exclusion Criteria in AS0010.  
Cross -study screening is permitted in the following cases:  
CRP  If a subject not eligible for AS0010 will be screened for AS0011, the Screening 
CRP testing must be repeated during Screening for AS0011 only if the result is 
older than 35 days at time of randomization at Baseline ( Section  12.6). 
All safety 
laboratory 
assessments  If a subject not eligible for AS0010 will be screened for AS0011, the Screening 
safety laboratory testing (hematology, biochemistry, urinaly sis, urine drug 
screen, pregnancy testing as applicable, HIV, Hepatitis B and C, and IGRA TB 
testing), and HLA -B27 testing must be repeated during Screening for AS0011 
only if the results are older than 35 days at time of randomization at Baseline 
(Section  12.6). 
Anterior posterior 
pelvis x -ray The following will be accepted to qualify subjects with AS for this study: 
Anterior posterior pelvis x -ray centrally read for AS0010 and determined to be 
modified [LOCATION_001] Criteria positive (+mNY); neither the x -ray nor the reading 
will be repeated ( Section  9.20). The central imaging reader needs to be informed 
by [CONTACT_463176]0010 to AS0011.  
AS=ankylosing spondylitis; BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; CRP=C -reactive 
protein; eC -SSRS=electronic Columbia -Suicide Severity Rating Scale; HIV=human immunodeficiency virus; 
HLA -B27=human leukocyte antigen B27; IGRA=Interferon -Gamma Release Assay; mNY=modified New 
York; PHQ -9=Patient Health Quest ionnaire 9; Q=question; TB=tuberculosis  
Assessments at the Screening Visit are presented in Table  5-2. 
5.1.2  Treatment Period  
[IP_ADDRESS]  Double -Blind Treatment  Period  
During the Double -Blind Treatment Period, subjects will be randomized in a 2:1 fashion 
(stratified by [CONTACT_463177]α inhibitor experience) to 1 of 2 treatment arms to receive 
blinded IMP regimens of bimekizumab 160mg sc Q4W or placebo sc Q4W. The en rollment of 
TNFα  inhibitor -experienced subjects will be limited to 30% of the total study population.  
Investigational medicinal product treatment details are provided in Section  7.2.  
Visit windows of ±[ADDRESS_593088] dose at all visits through Week 16. The visit 
window is relative to the Baseline Visit, not the previous study visit. The time between doses 
should be ≥25  days and ≤[ADDRESS_593089] be ensured 
that the time between these 2 visits does not exceed the allowed time between doses.  
Bimekizumab or placebo will be administered sc by [CONTACT_463178].  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 28 of 187 The Double -Blind Treatment  Period ends after Week 16 assessments. At Week 16, subjects will 
transition from the double -blind, placebo -controlled treatment into the 36 -week Maintenance 
Period with bimekizumab treatment, as discussed in Section  [IP_ADDRESS] . 
Subjects discontinuing IMP during the Double -Blind Treatment Period will be encouraged to 
return for all scheduled visits through Week 52 and the SFU Vi sit (20 weeks after the final dose 
of IMP), as applicable (Section  5.1.4 ). Subjects withdrawing from the study will have an 
ET Visit and a SFU  Visit  20 weeks after the final dose of IMP, as applicable.  
[IP_ADDRESS]  Maintenance Period  
The 36-week Maintenance Period starts with the Week 16 IMP administration. All  subjects will 
receive bimekizumab 160mg sc Q4W during the Maintenance Period.  
• Subjects who received bime kizumab 160mg sc Q4W during the 16 -week Double -Blind 
Treatment Period will continue to receive bimekizumab 160mg sc Q4W.  
• Subjects who received placebo during the 16 -week Double -Blind Treatment Period will be 
re-allocated to bimekizumab treatment. After the Week 16 assessments are performed, all 
subjects will receive bimekizumab 160mg sc Q4W.  
Bimekizumab will be administered by [CONTACT_463179], 
according to the site -specific blinding plan.  
Visit windows of ±4 days are allowed for all visits after Week 16. The time between doses 
during the Maintenance Period should be ≥24  days and ≤[ADDRESS_593090] be ensured that the time between these 2 visits does not exceed the 
allowed time between doses.  
All subjects will be eligible for nonbiologic rescue therapy from Week 20 onwards, as defined in 
Table  7‒2. 
Prior to completion of the Maintenance Period, Investigators should discuss treatment options 
with the subject. Subjects who complete AS0011 and meet the eligibility criteria may enroll in an 
extension study to continue to receive bimekizu mab.  
Subjects discontinuing IMP during the Maintenance Period after Week 16 will be encouraged to 
return for all scheduled visits through Week 52 and the SFU Visit (20 weeks after the final dose 
of IMP), as applicable. The SFU Visit is not required if the  Week 52 Visit is ≥20 weeks after the 
final dose of IMP ( Section  5.1.4 ). Subjects withdrawing from the study will have an ET Visit and 
a SFU Visit 2 0 weeks after the final dose of IMP.  
5.1.3  Early Termination Visit  
Subjects withdrawing consent and withdrawn early from the study will undergo the ET Visit 
assessments (see Section  8.5) and will enter the SFU Period.  
Subjects withdrawing from IMP who are not continuing for all scheduled visits through 
Week  52, will undergo the ET Visit, and will enter the SFU Period.  
5.1.4  Safety Follow -Up Visit  
All subjects who complete the study and do not enter the extension study will undergo the 
SFU Visit 20 weeks after their final dose of IMP (see Section  8.6). 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 29 of 187 Subjects withdrawing from the IMP during the study, will be encouraged by [CONTACT_463180] 52 and the SFU Visit (unless the Week 52 Visit 
occurs ≥20 weeks after the final dose of IMP).  
Subjects withd rawing from IMP who are not continuing for all scheduled visits, will undergo the 
ET Visit and the SFU Visit [ADDRESS_593091] up to 73 weeks, as follows:  
• Screening Period: minimum duration of approximately 14 days (unless a screenfailed subject 
from AS0010 will be screened in AS0011) to ≤35  days 
• 16-week Double -Blind Treatment Period  
• 36-week Maintenance Period  
• A SFU Visit for subjects who complete the study and who do not enter the extension study or 
who discontinue from the study early, including those withdrawn from IMP, will be 
conducted 2 0 weeks after the final dose of the IMP as applicable (ie, Week 48 for subjects 
who completed AS0011).  
The end of the study is defined as the date of the last visit of the last subject in the study.  
5.1.6  Planned number of subjects and site(s)  
Approximately 300 subjects will be randomly assigned in a 2:1 ratio to the following treatment 
groups: bimekizumab 160mg  sc Q4W (200 subjects) or placebo sc  Q4W (100 subjects). The 
planned number of study sites is approximately 95.  
Enrollment requirements  will be applied and controlled by [CONTACT_463181].  
The minimum proportion of TNFα inhibitor -naïve  subjects will be approximately 70% and the 
maximum proportion of subjects with p rior use of TNFα inhibitor will be approximately  30%.  
5.1.7  Anticipated regions an d countries  
This will be a multicenter, international study conducted in approximately 14 countries in the 
US, Eastern and Western Europe, and Asia . Enrollment will be competitive among study sites 
and may be capped in regions or at sites.  
5.2 Schedule of study assessments  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 30 of 187 Table  5-2: Schedule of study assessments  
Protocol activity  SC BL (D1)  Double -Blind Treatment  
Period (16 weeks)  Maintenance Period (36 weeks)  ET SFUb 
Weeka   [ADDRESS_593092] medical history 
and concomitant diseases  X Xc                  
Incl./excl. criteria  X X                  
Prior medication  X                   
Concomitant medication  X X X X X X X X X X X X X X X X X X X 
Adverse events  X X X X X X X X X X X X X X X X X X X 
eC-SSRSd X X   X X X X X X X X X X X X X X X 
PHQ -9 X X   X X X X X X X X X X X X X X X 
ASQoL   X   X X X X  X   X    X X  
BASDAI  X X X X X X X X  X   X     X X  
BASFI   X X X X X X X  X   X    X X  
SF-36 PCS and MCS   X    X  X  X   X    X X  
MOS Short Sleep Scale (12  items)   X    X  X  X   X    X X  
PGADA   X X X X X X X  X   X    X X  
Total and nocturnal spi[INVESTIGATOR_18172] 
(NRS)   X X X X X X X  X   X    X X  
Tuberculosis questionnaire  X X     X   X   X   X  X X 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 31 of 187 Table  5-2: Schedule of study assessments  
Protocol activity  SC BL (D1)  Double -Blind Treatment  
Period (16 weeks)  Maintenance Period (36 weeks)  ET SFUb 
Weeka   1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
Visita 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17   
FACIT -Fatigue subscale   X   X   X  X   X    X X  
EQ-5D-3L  X   X   X  X   X    X X  
WPAI -SHP  X      X  X   X    X X  
Vital signs (BP, pulse, 
temperature)e X X  X X X X X X X X X X X X X X X X 
Height and body weightf X X    X  X  X   X    X X X 
Physical examinationg X X    X  X  X   X    X X X 
TJC/SJC (44/44)   X    X  X  X       X   
MASES   X   X X  X  X       X X  
BASMI   X    X  X  X       X X  
PhGADA   X   X X  X  X   X    X X  
ECGh X       X  X       X X X 
Hematology/  
biochemistry  X X  X X X X X X X X X X X X X X X X 
Urinalysis  X       X     X    X X X 
Urine drug screen  X                   
CRP  X X  X X X X X  X   X    X X X 
Pregnancy testingi X X   X X X X X X X X X X X X X X X 
Hepatitis B and C testingj,k X                   
HIV testingj X                   
HLA -B27 analysis  X                   
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 32 of 187 Table  5-2: Schedule of study assessments  
Protocol activity  SC BL (D1)  Double -Blind Treatment  
Period (16 weeks)  Maintenance Period (36 weeks)  ET SFUb 
Weeka   1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
Visita 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17   
BKZ plasma concentrationj  X  X X X X X X X   X    X X X 
Anti-BKZ antibody detectionj  X   X X X X X X   X    X X X 
Serum and plasma samples for 
exploratory biomarkersj,l  X      X         X   
RNA blood samples for 
exploratory biomarkersj,l  X      X         X   
Blood sample for genetic/  
epi[INVESTIGATOR_463124],l  X      X         X   
Stool samplesl  X               X   
IGRA TB testj,m X              X     
Chest x -rayn X                   
Sacroiliac joint x -rayo X                   
Spi[INVESTIGATOR_050] x -rayp  X                  
Sacroiliac and spi[INVESTIGATOR_463125]  X      X         X   
Enter IXRSr X X X X X X X X X X X X X X X X X X X 
IMP administrations  X   X X X X X X X X X X X X    
AS=ankylosing spondylitis; ASQoL=Ankylosing Spondylitis Quality of Life; BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; BASFI=Bath 
Ankylosing Spondylitis Functional Index; BASMI=Bath Ankylosing Spondylitis Metrology Index; BL=Baseline; BKZ=bimekizumab; BP=blood pressure; 
CRP=C -reactive protein; D=day; EAM=extra -articular manifestation; eC -SSRS=electronic Columbia -Suicide Severity Scale; ECG=electrocardiogram; EQ -
5D-3L=EuroQol 5 Dimensions 3 Level; ET=Early Termination; excl. =excluding; FACIT=Functional Assessment of Chronic Illness Therapy; HIV=human 
immunodeficiency virus; HLA -B27=human leukocyte antigen B27; IGRA=interferon gamma release assay; IMP=investigational medicinal product; 
incl.=including; IXRS=interactive voice o r web response system; MASES=Maastricht Ankylosing Spondylitis Enthesitis; MCS=mental component score; 
MOS=Medical Outcomes Study; MRI=magnetic resonance imaging; NRS=numeric rating scale; mNY=modified [LOCATION_001]; PCS=physical com ponent score; 
PGADA=Patient’ s Global Assessment of Disease Activity; PhGADA=Physician’s Global Assessment of Disease Activity; PHQ -9=Patient’s Health 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 33 of 187 Table  5-2: Schedule of study assessments  
Protocol activity  SC BL (D1)  Double -Blind Treatment  
Period (16 weeks)  Maintenance Period (36 weeks)  ET SFUb 
Weeka   1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
Visita 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17   
Questionnaire 9; RNA=ribonucleic acid; SC=Screening; SF -36=Short Form -36 Health Survey; SFU=Safety Follow -Up; SJC=swollen joint count;  
TB=tuberculosis; TJC=tender joint count; WPAI -SHP=Work Productivity and Activity Impairment Questionnaire -specific health problem  
a Visit windows of ±3 days are allowed for all visits through Week 16. The visit window is relative to the Baseline Visit, not the previous week’s visit. During 
the Maintenance Period, visit windows of ±4 days are permitted for all visits after Week 16.  
b The SFU Visit occurs 20 weeks after the final dose for all subjects who complete the study and do not enter the extension s tudy or who discontinue early, 
including those withdrawn from study treatment. The visit window for the SFU Visit is -3/+[ADDRESS_593093] vital signs (pulse, BP, and temperature) prior to IMP administration and then at [ADDRESS_593094] of serum testing at Screening for all women of childbearing potential. A urine dipstick will be used for pr egnancy testing at all 
other visits ( Section  12.7.6 ). 
j At dosing visits, all blood samples are taken prior to dosing. Blood samples for bimekizumab and anti -bimekizumab antibody detection as well as 
pharmacogenetics/genomics will be processed as per instructions in the lab manual.  
k Subjects who have evidence of or test positive for hepatitis B or hepatitis C are excluded. Positive test criteria are define d in Section  6.2. 
l A separate Informed Consent Form will be required for subjects who decide to participate in the pharmacogenomic substudy. The  Informed Consent Form 
must be signed prior to collecting any samples for the substudy. Blood and/or stool samples are collec ted for exploratory purposes and participation in either 
blood or stool sampling (or both) is optional.  
m An IGRA TB test will be performed at the central laboratory. Details will be specified in the Laboratory Manual.  
n If a subject has had a recent x-ray of the chest within [ADDRESS_593095] x -ray. Any findings 
suggestive of active TB are exclusionary.  
o The following will be accepted to qualify AS subjects for this study: a) sacroiliac joint  x-ray centrally read for the Phase 3 study AS0010 determined to be 
modified [LOCATION_001] Criteria positive (+mNY); neither the reading nor the x -ray will be repeated; b) prior sacroiliac joint x -ray (performed at any time prior 
to the study) was submitted and  centrally read for the purposes of this study and determined to be modified [LOCATION_001] Criteria positive (+mNY). If the prior 
x-ray is not meeting central reading criteria for randomization, another x -ray may be performed if prior x -ray is more than 1 year old and if permitted by 
[CONTACT_13144], or c) if no prior x -ray is available, one must be performed at Screening.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 34 of 187 Table  5-2: Schedule of study assessments  
Protocol activity  SC BL (D1)  Double -Blind Treatment  
Period (16 weeks)  Maintenance Period (36 weeks)  ET SFUb 
Weeka   [ADDRESS_593096] dose of IMP. Th e sacroiliac joint and spi[INVESTIGATOR_463126]. Further sacroiliac joint and spi[INVESTIGATOR_463127] 16 and 52, within a 
window of ±5 days for all subjects participating in the substudy.  
r The IXRS is used to register subjects at Screening, randomize subjects at Baselin e/Day 1, rerandomize subjects at Week 16 and to register all visits.  
s At Week 16, the Maintenance Period  dosing will start, as detailed Section  [IP_ADDRESS] . At Week 52, IMP administration will only occur for subjects entering the 
extension study. Dosing details at Week 52 will be provided in the protocol of the extension study.  
 
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 35 of 187 5.3 Schematic diagram  
Figure  5‒1: Schematic diagram: study overview  
  
ASAS40= Assessment of SpondyloArthritis International Society 40% response criteria;  BKZ=bimekizumab; BL=Baseline; IMP=investigational medicinal 
product; Q4W=every 4 weeks; sc=subcutaneous; SFU=Safety Follow -Up; W=week  
a Subjects are eligible for nonbiologic rescue therapy starting at Week  [ADDRESS_593097] igator while continuing to receive BKZ. 
Treatment with non -BKZ biologics or prohibited treatment (see Section  7.8.2 ) will lead to BKZ discontinuation  (Table  7‒2).  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593098] received previous biologic treatment (eg, a TNFα inhibitor) as 
well as those who are biologic treatment -naïve. The primary efficacy outcome measures 
(ASAS40 response) and other efficacy asses sments included in this study are consistent with 
those used for other axSpA studies and are considered appropriate for establishing efficacy of 
bimekizumab. An initial double -blind treatment period of 16 weeks will be used to demonstrate 
the efficacy of b imekizumab over placebo. The study duration extends beyond the initial 
Double -Blind Treatment Period (ie, Maintenance Period up to 52 weeks) to collect data on the 
maintenance of efficacy of bimekizumab for exploratory analyses and to allow continued 
evalu ation of safety data.  
5.4.2  Dose selection  
A bimekizumab dose of 160mg  sc Q4W has been selected for AS0011.  
Bimekizumab doses of 16mg to 320mg Q4W were evaluated in a multicenter, Phase  2b, 
double -blind, placebo -controlled, randomized, parallel -group study in su bjects with active  AS 
(AS0008). Results from the Week [ADDRESS_593099] an acceptable safety profile and PK/PD modelling indicated a plateau in 
Week [ADDRESS_593100] be met:  
1a. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written 
Informed Cons ent form is signed and dated by [CONTACT_423].  
2a. Subject is considered reliable and capable of adhering to the protocol (eg, able to understand 
and complete diaries), visit schedule, or medication intake according to the judgment of the 
Investigator.  
3. Subject is male or female at least [ADDRESS_593101] has AS as per the Modified [LOCATION_001] (mNY) criteria (1984) including documented 
radiologic evidence (x -ray) based on central reading and at least 3 months of symptoms 
(Table  19‒2) with age at symptom onset <[ADDRESS_593102] has moderate -to-severe active disease as defined by [CONTACT_463182]:  
− BASDAI ≥4 AND spi[INVESTIGATOR_18172] ≥4 on a 0 to 10 NRS (from BASDAI Item 2)  
6a. Subjects had to have either failed to respond to [ADDRESS_593103] a history of intolerance to or a contraindication 
to NSAID therapy.  
7. Subjects who are regularly taking NSAIDs/COX -2 inhibitors or analgesics (including mild 
potency opi[INVESTIGATOR_2438]) are required to be on a stable dose for at least [ADDRESS_593104] be on an average daily dose of ≤10mg/day prednisone or 
equivalent for at least 14 days before Baseline.  
9. Subjects taking MTX (≤25mg/week) or LEF (≤20mg/day or an average of 20mg/day if not 
dosed daily) are allowed to continue their medication if started at least 12  weeks prior to 
Baseline, with a  stable dose and route of administration (MTX) for at least 8  weeks before 
randomization. It is strongly recommended that subjects taking MTX are also taking folic 
acid supplementation.  
10. Subjects taking SSZ up to 3g/day (or 4g/day if in accordance with loc al standard of care), 
HCQ up to 400mg/day (other anti -malarials may be used if in accordance with local standard 
of care), or apremilast (up to 60mg/day and dosed as per local label) are allowed to continue 
their medication if started at least [ADDRESS_593105] be:  
− Postmenopausal. Menopause is defined as 12 consecutive months of amenorrhea, for 
which there is no other obvious pathological or physiological cause.  
− Permanently sterilized (eg, tubal occlusion, hysterectomy, bilat eral salpi[INVESTIGATOR_1656]).  
− Or, if of childbearing potential (and engaged in sexual activity that could result in 
procreation), must be willing to use a highly effective method of contraception 
throughout the duration of the study until [ADDRESS_593106] at Visit 1 (Screening) and immediately prior to first dose.  
The following methods are considered highly effective when used consistently and correctly:  
− Combined (estrogen and progestogen) hormonal contrac eption associated with inhibition 
of ovulation (oral, intravaginal or transdermal)  
− Progestogen -only hormonal contraception associated with inhibition of ovulation (oral, 
injectable, implantable)  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 38 of 187 − Intrauterine device (IUD)  
− Intrauterine hormone -releasing syst em (IUS)  
− Vasectomized partner  
− Abstinence as a form of birth control is generally not allowed in the study unless 
abstinence is in accordance with a subject’s preferred and common lifestyle. Study 
personnel must confirm the continued use of abstinence is st ill in accordance with the 
subject’s lifestyle at regular intervals during the study  
6.2 Exclusion criteria  
Subjects are not permitted to enroll in the study if any of the following criteria are met:  
1. Female subject who is breastfeeding, pregnant, or plans to become pregnant during the study 
or within [ADDRESS_593107] 
1 dose of the IMP (including placebo).  
3a. Subject previously participated in ano ther study of a medication (systemic) under 
investigation within the [ADDRESS_593108] 5 half -lifes prior to the Baseline Visit, whichever 
is greater, or is currently participating in another study of a medication (systemic) under 
investigation, with th e exception of subjects who were screen failures in AS0010.  
4. Subject previously participated in another study of a medical device under investigation 
within the [ADDRESS_593109] has a known hypersensitivity to any excipi[INVESTIGATOR_58898].  
6. Subjects with a total ankylosis of the spi[INVESTIGATOR_050].  
7. Subjects with fibromyalgia or osteoarthritis symptoms that in the Investigator’s opi[INVESTIGATOR_463128].  
8. Subject had acute anterior uveitis within [ADDRESS_593110] received more than 1 TNFα inhibitor and/or more than 2 additional 
non-TNFα biological response modifiers, or any IL -17 bio logical response modifier at any 
time are excluded (please refer to Table  7‒2).  
10. Subject is taking or has taken prohibited medications as outlined in Table  7‒2 without 
meeting the mandatory washout period(s) relative to the Baseline visit.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593111] has an active infection or history of infections as follows:  
− Any active infection (except common cold) within 14 days prior to Baseline.  
− A serious infection, defined as requiri ng hospi[INVESTIGATOR_352156] -infectives within 
2 months prior to Baseline.  
− A history of opportunistic, recurrent or chronic infections that, in the opi[INVESTIGATOR_684], might cause this study to be detrimental to the subject. Opportunistic 
infecti ons are infections caused by [CONTACT_397144] (eg, Pneumocystis jirovicii, 
Cryptococcosis) or unusually severe infections caused by [CONTACT_352223] (eg, 
cytomegalovirus [CMV], herpes zoster).  
12. Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency 
virus (HIV) infection. Subjects who have evidence of, or tested positive for hepatitis B or 
hepatitis C are excluded.  
A positive test for the hepatitis B virus (HBV) is defined as:  
− Positive for hepatitis B surface antigen (HBsA g+); or,  
− Positive for anti -hepatitis B core antibody (HBcAb+)  
A positive test for the hepatitis C virus (HCV) is defined as:  
− Positive for hepatitis C antibody (anti -HCV Ab), and  
− Positive via a confirmatory test for HCV (for example, HCV polymerase chai n reaction).  
13. Subject has received any live (includes attenuated) vaccination within the 8 weeks prior to 
the Baseline Visit (eg, inactivated influenza and pneumococcal vaccines are allowed, but 
nasal influenza vaccination is not permitted) or has received Bacillus Calmette -Guerin 
vaccinations within [ADDRESS_593112] has known tuberculosis (TB) infection, at high risk of acquiring TB infection, or 
current or history of nontuberculous mycobacterium (NTMB) infection. A subject with latent 
tuberculosis (LTB) (a positive interferon -gammy release assay [IGRA] and diagnosis 
confirmed by [CONTACT_463183]) may be rescreened once and enrolled after receiving at least 
[ADDRESS_593113] injection (alanine aminotransferase 
[ALT]/aspartate aminotransferase [AST] remain ≤3 times upper limit of normal [ULN]).  
Subject has a past history of active TB involving any organ system, unless adequat ely treated 
according to World Health Organization (WHO)/Center for Disease Control and Prevention 
(CDC) therapeutic guidance and proven to be fully recovered upon consult with a TB 
specialist.  
Refer to Section  12.7.[ADDRESS_593114] has a diagnosis of inflammatory conditions other than AS, including but not limited 
to psoriatic arthritis, rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus, and 
reactive arthritis. Subjects with a diagnosis of Crohn’s disease, ulcer ative colitis, or other 
IBD are allowed as long as they have no active symptomatic disease at Screening or 
Baseline.  
18. Subject has had major surgery (including joint surgery) within the [ADDRESS_593115] has any systemic disease (ie, cardiovascular, neurological, renal, hepatic, metabolic, 
gastrointestinal, hematological, immunological, etc) considered by [CONTACT_352226], unstable or likely to prog ress to a clinically significant degree during the course 
of the study.  
20. Subject has had myocardial infarction or stroke within the [ADDRESS_593116] has laboratory abnormalities at Screening, including any of the following:  
a. ≥3.[ADDRESS_593117] of any of the following: ALT, AST, alkaline phosphatase (ALP); or >ULN 
total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome)  
b. White blood cell (WBC) count <3.00  x103/µL 
c. Absolute neutrophil count <1.5  x103/µL 
d. Absolute lymphocyte count <500  cells/µL  
e. Hemoglobin <8.5g/dL  
f. Creatinine >2mg/dL  
g. Any other laboratory abnormality, which, in the opi[INVESTIGATOR_689], will 
prevent the subject from completing the study or will interfere with the interpretation 
of the study results  
Individual screening tests for which the results are in error, borderline, or indeterminate for 
inclusion in the study, can be repeated once for confirmation during the Screening Period. 
Upon retesting, subjects whose results remain outside this threshold should not be 
randomized.  
22. Subject has any other condition, including medical or psychiatric, which, in the Investigator's 
judgment, would make the subject unsuitable for inclusion in the study.  
23. Presence of active suicidal ideation, or positive suicide behavior using  the “Screening” 
version of the electronic Columbia -Suicide Severity Rating Scale (eC -SSRS) with either of 
the following criteria:  
− History of a suicide attempt within the 5 years prior to the Screening Visit. Subjects with 
a history of a suicide attempt mo re than 5 years ago should be evaluated by a mental 
healthcare practitioner (HCP) before enrolling into the study.  
− Suicidal ideation in the past month prior to the Screening Visit as indicated by a positive 
response (“Yes”) to either Question 4 or Question  5 of the “Screening” version of the 
eC-SSRS  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593118] has moderately severe major depression or severe major depression, indicated by a 
score ≥[ADDRESS_593119] has a history of chronic alcohol or drug abuse within 6 months prior to Screening as 
evaluated by [CONTACT_352227], site interview, and/or results of the 
specified urine drug screen.  
26. Subject is a member of Investigator si te personnel directly affiliated with this study and/or 
their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, 
whether biological or legally adopted.  
27. Subject is a UCB employee or employee of third -party organizations involved in the study.  
6.[ADDRESS_593120] withdraws his/her consent.  
Subjects should be withdr awn from IMP and encouraged by [CONTACT_463184] 52, and the SFU Visit (if the Week 52 Visit is ≥20 weeks after the 
final dose of IMP, the SFU Visit is not required) if any of the following events occur:  
1. The S ponsor or a regulatory agency requests withdrawal of the subject.  
2. Subject develops an illness that in the opi[INVESTIGATOR_352158]/her 
continued participation if the risk of continuing IMP outweighs the potential benefit.  
3. Subje ct is noncompliant with the study procedures or medications in the opi[INVESTIGATOR_684].  
4. Subject uses prohibited concomitant medications as defined in this protocol ( Section  7.8.2 ), 
that may present a risk to the safety of the subject or the integrity of the study data, in the 
opi[INVESTIGATOR_3755]/or the Medical Monitor.  
5. Subject has a clinical laboratory value meeting any of the following criteria:  
a. Hepatotoxicity as described in Section  6.3.1 . 
b. A laboratory value meeting any of the following criteria:  
− Absolute neutrophil cou nt <1.0 x103/µL  
− Absolute lymphocyte count <200 cells/µL  
Subjects may remain on IMP if the result is transient. A retest is required within [ADDRESS_593121] (see Section  12.2 for more information regarding pregnancies).  
8. A subject considered as having either a susp ected new LTB infection or who develops active 
TB or NTMB infection during the study (including but not limited to, conversion 
demonstrated by [CONTACT_397145]) must be immediately discontinued from 
IMP, and an ET Visit must be scheduled as s oon as possible, but not later than the next 
regular visit.  
The subject must be permanently withdrawn if further examinations result in a diagnosis of 
active TB, or if the subject is diagnosed with latent TB infection (LTBI) with no initiation of 
prophylac tic treatment, prematurely discontinues prophylactic treatment, or, in the opi[INVESTIGATOR_352159], is noncompliant with prophylactic TB therapy.  
Confirmed active TB is an SAE and must be captured in the eCRF in the SAE Report Form 
section. As with all SAEs, periodic follow -up reports should be completed as per protocol 
requirements until such time as the TB infection resolves.  
Additional information on TB policies is provided in Section  12.7.[ADDRESS_593122]:  
− Be referred, as appropriate, to a healthcare professional treating IBD, such as a 
gastroenterologist  
− Discontinue I MP and be followed -up until resolution of active IBD symptoms  
If IBD flares increase in severity or frequency during the study, the Investigator should use 
clinical judgement in deciding whether the subject should continue on IMP and contact [CONTACT_463185]’s suitability for continued 
participation in the study.  
10. Subjects must be referred immediately to a mental healthcare professional and may be 
withdrawn from the study based upon the Investigator’s judgmen t of benefit/risk for:  
− Active suicidal ideation as indicated by a positive response (“Yes”) to Question 4 of the 
“Since Last Visit” version of the eC -SSRS  
− Moderately severe major depression as indicated by a PHQ -[ADDRESS_593123]’s source documentation.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593124] be 
withdrawn from the study in case of : 
− Active suicidal ideation as indicated by a positive response ("Yes") to Question 5 of the 
"Since Last Visit" version of the eC -SSRS.  
− Any suicidal behavior since last visit.  
− Severe major depression as indicated by a PHQ -9 score ≥20.  
The mental health consultation must be recorded in the subject’s source documentation.  
12. Any subject who develops a clinically important infection or recurrent infections not 
responsive to standard therapy during the study must discontinue IMP until resolution of the 
infectio n. The Investigator should use clinical judgement in deciding whether the subject 
should restart IMP and contact [CONTACT_463186]’s suitability for continued participation in the study.  
Investigators should  contact [CONTACT_1689], whenever possible, to discuss the withdrawal 
of a subject from IMP or from the study in advance.  
Subjects withdrawing from the study who are not continuing for all scheduled visits, will 
undergo the ET Visit and the SFU Visit [ADDRESS_593125] to follow -up, the Investigator should make an effort (at least 
[ADDRESS_593126]), and document his/her effort (date and 
summary of the p hone call and copy of the written message in the source documents), to 
complete the final evaluation. All results of these evaluations and observations, together with a 
narrative description of the reason(s) for removing the subject, must be recorded in th e source 
documents. The electronic Case Report Form (eCRF) must document the primary reason for 
withdrawal or discontinuation.  
Investigators should contact [CONTACT_1689], whenever possible, to discuss the withdrawal 
of a subject in advance.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 44 of 187 6.3.1  Potential  drug -induced liver injury IMP discontinuation criteria  
Subjects with potential drug -induced liver injury (PDILI) must be assessed to determine if IMP 
must be discontinued. In addition, all concomitant medications and herbal supplements that are 
not medica lly necessary should also be discontinued.  
The PDILI criteria below require immediate discontinuation of IMP for subjects with either of 
the following:  
• ALT or AST ≥8x ULN  
• ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN  
• Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
alternative cause), ra sh, or eosinophilia (ie, >5%).  
If a nondrug -related cause for the symptoms can be confirmed, these subjects may resume 
IMP administration after discussion with the responsible UCB physician, but only when the 
requirements for rechallenge with IMP as provi ded in ( Section  [IP_ADDRESS].1 ) are followed.  
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
Investigator.  
• Subjects with ALT or AST ≥5xULN and <8xULN, total bilirubin <2xULN, and no 
eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness).  
Evaluation of PDILI must be initiate d as described in Section  12.6.[ADDRESS_593127] reduced to <5xULN, the subject can 
continue with the study. However, if ALT or AST remains ≥5xULN and <8xULN after re -test, 
IMP should be temporarily withheld and subject should undergo a repeat test in [ADDRESS_593128] values remain ≥5xULN even after the second re -test, then the subj ect should be 
immediately discontinued from IMP and should be followed for possible PDILI.  
If subjects are unable to comply with the applicable monitoring schedule, IMP must be 
discontinued immediately.  
Investigators should attempt to obtain information o n subjects in the case of IMP discontinuation 
to complete the final evaluation. Subjects with PDILI should not be withdrawn from the study 
until investigation and monitoring are complete. All results of these evaluations and 
observations, as well as the re ason(s) for IMP discontinuation and subject withdrawal (if 
applicable), must be recorded in the source documents. The eCRF must document the primary 
reason for IMP discontinuation.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 45 of 187 7 STUDY TREATMENTS  
7.1 Description of investigational medicinal products  
The IMPs  used in this study are bimekizumab and placebo.  
•  
 
 
• Placebo will be supplied as 0.9% sodium chloride aqueous solution (physiological saline, 
preservative free) of pharmacopoeia (US Pharmacopoeia/European Pharmacopoeia) quality 
in a 1mL PFS for sc injection.  
Details of the IMPs and their specification will be provided in the IMP Handling Manual.  
7.2 Treatment(s) to be administered  
Unblinded study personnel will be responsible for recording the administration information on 
source documents, and administration of the IMP as sc injections. The unblinded personnel will 
not be involved in any other aspect of the study. During the Maintenance Period, bimekizumab 
will be administered by [CONTACT_250989], unless the site -specific blinding plan allows 
for the adm inistration by [CONTACT_127191].  
Suitable areas for sc injections are the lateral abdominal wall, upper arm, and upper outer thigh. 
Injection sites should be rotated and injections should not be given in areas where the skin is 
tender, bruised, red , or hard.  
An IMP Handling Manual will be provided to each site containing instructions regarding drug 
preparation and dosing.  
7.2.1  Double -Blind Treatment Period  
Subjects will be randomized 2:1 to receive 1 of 2 blinded treatment regimens during the 
Double -Blind Treatment Period. To keep the blinding, all subjects will receive administrations as 
per the dosing scheme shown in Table  7‒1.  
The IMP (bimekizumab and placebo) will be administered at the time points indicated in 
Table  5-2. The Double -Blind Treatment  Period ends with Week 16 as sessments and t he final 
dose in the Double -Blind Period will be administered at Week 12.  
During the  Double -Blind Treatment Period, bimekizumab or placebo will be administered by 
[CONTACT_463178].  
Table  7‒1: Overview on dosing during the Double -Blind Treatment  Period  
Treatment arm  Dosing  
BKZ 160mg sc Q4W  Subjects will receive 1 BKZ 160mg injection sc at Week 0 
(Baseline) followed by [CONTACT_463187] 160mg sc Q4W at Weeks 4, 8, and 12.  
PBO sc Q4W  Subjects will receive 1 PBO injection sc at Week  0 (Baseline) 
followed by [CONTACT_463188] Q4W at Weeks 4, 8, and 12.  
BKZ=bimekizumab; PBO=placebo; Q4W=every 4 weeks, sc=subcutaneous  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 46 of 187 7.2.2  Maintenance Period  
The 36-week Maintenance Period starts with the Week 16 IMP administration. All  subjects will 
receive bimekizumab 160mg sc Q4W during the Maintenance Period and will receive treatments 
as follows:  
• Subjects who received bimekizumab 160mg sc Q4W during the 16 -week Double -Blind 
Treatment Period will continue to receive bimekizumab 160mg sc Q4W.  
• Subjects who received placebo during the 16 -week Double -Blind Treatment Period will be 
re-allocated to bimek izumab treatment. After the Week 16 assessments are performed, all 
subjects will receive bimekizumab 160mg sc at the Week 16  Visit.  
During the Maintenance Period, all subjects will receive bimekizumab, and the responsibility for 
recording the administrati on information and the administration of the IMP can be switched to 
the blinded team only if the site -specific blinding plan defines a process of maintaining the blind 
of the documentation of IMP administration of the Double -Blind Treatment Period.  
7.3 Packag ing 
The IMPs are manufactured, packaged, and labeled according to Good Manufacturing Practice 
(GMP) guidelines and applicable laws or regulations. Investigational medicinal products will be 
suitably packaged in such a way as to protect the IMPs from deteri oration during transport and 
storage.  
7.4 Labeling  
Clinical drug supplies will be labeled in accordance with the current International Council for 
Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and Good Manufacturing 
Practice and will include any locally required statements. If necessary, labels will be translated 
into the local language.  
7.[ADDRESS_593129] be stored under refrigerated conditions (2ºC to 8ºC) 
protected from light. The IMP mu st not be frozen.  
The Investigator (or designee) is responsible for the safe and proper storage of IMP at the site. 
Investigational medicinal product stored by [CONTACT_58951] a secured area with 
limited access according to the storage co nditions mentioned on the label.  
Appropriate storage conditions must be ensured either by [CONTACT_261497] (eg, room, 
refrigeration unit) or by [CONTACT_37142] a temperature log in accordance with local requirements 
on a regular basis, showing act ual and minimum/maximum temperatures reached over the time 
interval.  
In case an out -of-range temperature is noted, it must be immediately reported as per instructions 
contained in the IMP Handling Manual.  
7.[ADDRESS_593130], damaged (due to breakage or wastage), not used, partially used, disposed of at th e 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593131] be made available throughout the study for UCB 
(or designee) to review.  
The packaging identifies each kit by a  unique number and by [CONTACT_463189]. Unblinded study staff 
will be responsible for preparation (eg, breaking tamper proof sticker on kit) of the clinical trial 
material, including recording the administration information in the source document during the 
Double-Blind Treatment Period. During the Maintenance Period, bimekizumab will be 
administered by [CONTACT_463190] -specific blinding plan allows the 
administration by [CONTACT_127191] ( Section  7.2.2 ). 
All IMP documentation of the Double -Blind Treatment Period (eg, shippi[INVESTIGATOR_18220], drug 
accountability logs, IXRS randomization materials) must be maintained and accessed by 
[CONTACT_58953], trained site personnel only. Designated, unblinded site personnel must be 
appropriately trained and licensed (per country guidelines) to administer injections. Each site 
will be required to have a written site -specific blinding plan in place sig ned by [CONTACT_737], 
which will detail the site’s steps for ensuring that the double -blind nature of the study is 
maintained from Week 0 to Week 16/ET, and for defining site -specific responsibilities of the 
blinded and unblinded team during the course of the study.  
The Investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of IMP until returned or destroyed.  
The Investigator may assign some of the Investigator’s duties for drug accountability at the study  
site to an appropriate pharmacist/designee.  
The Investigator must ensure that the IMP is used only in accordance with the protocol.  
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers)/partially u sed, unused, damaged, and/or expi[INVESTIGATOR_261466], regulations, and UCB SOPs or returned to UCB (or 
designee). Investigational medicinal product intended for the study cannot be used for an y other 
purpose than that described in this protocol.  
7.[ADDRESS_593132] be recorded on the Drug Accountability Form.  
7.8 Concomitant medications/treatments  
All concomitant medications, including over -the-counter products, herbal, traditional remedies, 
vitamin or minera l supplements, other dietary supplements, “nutraceuticals,” and hormones must 
be recorded in the subject’s source documentation (eg, clinical chart) and on the eCRF. This 
record should include the name [CONTACT_18467], the dose, the route and date(s) of admini stration, and 
the indication for use.  
Medications listed in Table  7‒2 are prohibited, restricted, or used as nonbiologic rescue therapy.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  48 of 187 Table  7‒2: Exclusionary, concomitant, and rescue medication  
Drug class/dose  Exclusion criteria  Study visits/during the 
study  Nonbiologic rescue ther apy as add -on therapy 
to bimekizumab from Week 20 or latera 
Analgesics  
• Acetaminophen/  
paracetamol  Any change in dose/dose 
regimen within 14  days 
prior to BL  Stable dose/regimen permitted  
Ad hoc/PRN/“as needed use” 
permitted, but:  
No ad hoc/PRN/“as needed use” 
in the 24h prior to any study visit  Ad hoc/PRN/“as needed use” permitted, but:  
No ad hoc/PRN/“as needed use” in the 24h prior to 
any study visit  
 
NSAID/COX -2 inhibitors  Any change in dose/dose 
regimen within 14  days 
prior to BL Stable dose/ regimen permitted  
No change until Week 20 Visit  Nonbiologic rescue therapy will be at the 
Investigator’s discretion with the following options for 
symptoms:  
• For subjects taking an NSAID/COX -2 inhibitor 
dosing can be optimized; a change can be made to 
a different NSAID/COX -2 inhibitor; changes 
from an NSAID to a COX -2 inhibitor or from a 
COX -2 inhibitor to an NSAID are also permitted 
up to the maximum approved or tolerated dose, 
whichever is lower. Only 1  NSAID/COX -2 
inhibitor may be taken at  a given time.  
• For subjects not taking NSAID/COX -2 inhibitors 
either 1  NSAID, or 1  COX -2 inhibitor can be 
initiated, up to the maximum approved or 
tolerated dose, whichever is lower. Only 
1 NSAID/COX -2 inhibitor may be taken at a 
given time.  
• For subjects w ho cannot take NSAIDs/COX -2 
inhibitors, topi[INVESTIGATOR_463129] a potential 
nonbiologic rescue therapy in regions where they 
are approved, up to the maximum approved or 
tolerated dose, whichever is lower.  
Mild potency opi[INVESTIGATOR_463130],:  
• Tramadol/any dose up to 
maximum approved dose  
• Codeine/o nly <90mg of 
codeine per dosage unit  Any change in dose/dose 
regimen within 14  days 
prior to BL  Dosing/ schedule should remain 
stable for the first 20 weeks of 
the study  Prohibited  for rescue therapy  
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  49 of 187 Table  7‒2: Exclusionary, concomitant, and rescue medication  
Drug class/dose  Exclusion criteria  Study visits/during the 
study  Nonbiologic rescue ther apy as add -on therapy 
to bimekizumab from Week 20 or latera 
Oral corticosteroids/average daily 
dose of ≤10mg/day prednisone or 
equivalent  Any change in dose/dose 
regimen within 14  days 
prior to BL  Permitted, but:  
• No steroid bursts/tapers  
• No increase in steroid 
dosing  
• No initiation of steroids 
until the Week 20 Visit  Prohibited  for rescue therapy  
Topi[INVESTIGATOR_463131]:  
• Intramuscular  
• Intravenous  
• Intra -articular  
• Bursal  
 Use within 28 days prior to 
BL Prohibited unless used as rescue 
therapy from Week 20 or later  Nonbiologic rescue therapy will be at the 
Investigator’s discretion with the following options for 
symptoms:  
• Sacroiliac joint steroid injection(s), either 
unilateral or bilateral.  
For non -axial symptoms:  
• One peripher al joint (or bursa) may be injected 
with a steroid at or after any visit where 
nonbiologic rescue therapy eligibility is assessed; 
however, the same joint may not be injected more 
than once during the study and should not be 
injected within 4  weeks of a sa croiliac joint 
injection(s).  
Intra -articular hyaluronic acid  Use within 8 weeks prior 
to the BL Visit or during 
the study  Prohibited  Not applicable  
Any established antidepressant 
regimen  Any change in dose/dose 
regimen within 8 weeks 
prior to BL  Permitted  Not applicable  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  50 of 187 Table  7‒2: Exclusionary, concomitant, and rescue medication  
Drug class/dose  Exclusion criteria  Study visits/during the 
study  Nonbiologic rescue ther apy as add -on therapy 
to bimekizumab from Week 20 or latera 
csARDs/formerly known as 
DMARDs     
• Azathioprine  
• Cyclosporine  
• Cyclophosphamide  
• Mycophenolic acid  
• Mycophenylate mofetil  
• Any other small molecule 
DMARDs  Use within 8  weeks prior 
to BL  Prohibited  Prohibited  for rescue  
• Methotrexate (MTX)  
 Use within 12 weeks prior 
to BL  unless Inclusion 
Criterion # 9 is met  Permitted  
MTX (≤25mg/week)  For non -axial symptoms:  
• MTX may be added or i ncreased to a maximum 
dose of 25mg/week, or the maximum tolerated 
dose, whichever is lower, in accordance with local 
standard of care. The route of administration may 
be changed from oral to sc or from sc to oral, at 
any visit at Week [ADDRESS_593133] rongly 
recommended that subjects taking MTX are also 
taking folic acid supplementation.  
• Leflunomide (LEF)  Use in the 6 months prior 
to the BL Visit (unless a 
cholestyramine washout 
has been performed; in 
which case, use up to 
28 days prior to the BL 
Visit  is acceptable) unless 
Inclusion Criterion # 9 is 
met Permitted  
LEF (≤20mg/day or an average 
of 20mg/day if not dosed daily)  For non -axial symptoms:  
• Leflunomide may be given at a maximum dose of 
20mg/day (or an average of 20mg/day if not 
dosed daily), or the maximum tolerated dose, 
whichever is lower.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  51 of 187 Table  7‒2: Exclusionary, concomitant, and rescue medication  
Drug class/dose  Exclusion criteria  Study visits/during the 
study  Nonbiologic rescue ther apy as add -on therapy 
to bimekizumab from Week 20 or latera 
• Hydroxychloroquine (HCQ) 
(and other anti -malarials)  
• Sulfasalazine (SSZ)  
• Apremilast  
 Use within 8 weeks prior 
to BL  unless Inclusion 
Criterion # 10 is met  Permitted  For non -axial symptoms:  
• HCQ may be added or increased to a maximum 
dose of 400mg/day or the maximum tolerated 
dose, whichever is lower. Other anti -malarials 
may be used in accordance with local standard of 
care.  
• SSZ may be added or increased up to a maximum 
dose of 3g/day (up to 4g/day if in accordance with 
local standard of care), or the maximum tolerated 
dose, whichever is lower.  
• Apremilast may be given at a maximum dose of 
60mg/day and dosed as per Investigator’s 
discretion or local label.  
Combination DMARDs are allowed except that LEF 
and MTX may not be given together.  
JAK inhibitors     
• Eg, tofacitinib  
• Upadacitinib  Use within 8 weeks prior 
to BL  Prohibited  Not applicable  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  52 of 187 Table  7‒2: Exclusionary, concomitant, and rescue medication  
Drug class/dose  Exclusion criteria  Study visits/during the 
study  Nonbiologic rescue ther apy as add -on therapy 
to bimekizumab from Week 20 or latera 
Biologic DMARDs     
TNFα inhibitors:  
• Infliximab (IFX)  
• Golimumab (GOL)  
• Certolizumab pegol (CZP)  
• Adalimumab (ADA)  
• Etanercept (ETN)  
• Biosimilar versions of any 
TNFα inhibitor  For IFX, ADA, GOL, and 
CZP, any use within the 
12 weeks prior to the BL 
Visit  
For ETN, use within the 
28 days prior to the BL 
Visit  
Any use of >1 TNFα in the 
history  
Subjects not meeting 
Inclusion Criterion # 11. Prohibited  Not applicable  
Other biologics:  
• Abatacept  Any use within 12 weeks 
prior to BL  Prohibited  Not applicable  
• Alefacept    
• Efalizumab    
• Guselkumab    
• Sarilumab    
• Sirukumab    
• Tocilizumab    
• Others in development 
targeting IL -6 or IL -6R   
• Ustekinumab  
 Any use within 24  weeks 
prior to BL  Prohibited  Not applicable  
• Tildrakizumab  Any use within 4  months 
prior to BL  Prohibited  Not applicable  
• Risankizumab  Any use within 5  months 
prior to BL  Prohibited  Not applicable  
• Briakinumab  
 Any use within 6  months 
prior to BL  Prohibited  Not applicable  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  53 of 187 Table  7‒2: Exclusionary, concomitant, and rescue medication  
Drug class/dose  Exclusion criteria  Study visits/during the 
study  Nonbiologic rescue ther apy as add -on therapy 
to bimekizumab from Week 20 or latera 
• Rituximab (incl. biosimilars), 
ocrelizumab  Any use within 12  months 
prior to BL  Prohibited  Not applicable  
Anti -IL-17 therapy:  
• Bimekizumab  
• Secukinumab  
• Ixekizumab  
• Brodalumab  
• Others in development  Any exposure history  Prohibited  Not applicable  
BL=Baseline; ADA=adalimumab; COX -2=cyclooxygenase 2; csARD=conventional synthetic antirheumatic drug; CZP=certolizumab pegol; 
DMARD=disease -modifying antirheumatic drug; ETN=etanercept; GOL=golimumab; h=hour; HCQ=hydroxychloroquine; IFX=infliximab; JAK=Janus 
kinase; LEF=leflunomide; IL=interleukin; MTX=methotrexate; NSAID=nonsteroidal anti -inflammatory dru g; PRN=as needed; sc=subcutaneous; 
SSZ=sulfasalazine; TNFα=tumor necrosis factor alpha  
a Note: any medication not listed here for rescue therapy must be approved by [CONTACT_463191]. 
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 54 of 187 7.8.1  Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])  
No medication increases or additions for AS are permitted until after the Week  20 Visit 
assessments. However, a decrease in dose or dosing frequency of  any agent is permitted for 
reasons of intolerance/AEs/side -effects at any time. Permitted nonbiologic rescue therapy is 
described in Table  7‒2. 
Whenever possible, physical therapy/physiotherapy/non -medication/complementary and 
alternative treatment(s) (including traditional Chinese medications) of AS should remain stable 
through the Week [ADDRESS_593134] completed the study 
treatment without ent ering the extension study and are in the SFU Period.  
7.8.2  Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014])  
Prohibited concomitant treatments are described in Table  7‒2. 
7.8.3  Nonbiologic rescue therapy  
Nonbiologic rescue therapy will be at the Investigator’s discretion as add -on therapy to 
bimekizumab at any time from Week 20 or later as described in Table  7‒2. 
7.8.4  Vaccines  
Administration of live (including attenuated) vaccines is not allowed during the conduct of the 
study and for [ADDRESS_593135] blinded and unblinded personnel.  
Bimekizumab and placebo injections will be administered at the investigational sites by 
[CONTACT_58953], dedicated study personnel according to the site -specific blinding plan ( Section  7.2). 
The unblinded personnel will not be involved in the study in any way other than assuring the 
medication is taken from the correct kit and prepa red according to the pharmacy manual 
instructions, and administering the drug to the subjects.  
A full blinding plan for the Week 24 interim statistical analysis will be written as described in 
Section  15.8.1 .  
7.9.1  Procedures for maintaining and breaking the treatment blind  
[IP_ADDRESS]  Maintenance of study treatment blind  
All subject treatment details will be allocated and maintained by [CONTACT_463192] (IXRS) system.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 55 of 187 [IP_ADDRESS]  Breaking the treatment blind in an emergency situation  
The integrity of this clinical study must be maintained by [CONTACT_58956]. In the 
event of an emergency for which the appropriate treatment for a subject cannot  be made without 
knowing the treatment assignment, it will be possible to determine to which treatment arm and 
dose the subject has been allocated by [CONTACT_58957]. All sites will be provided with 
details of how to contact [CONTACT_463193] g at the start of the study. The Medical 
Monitor or equivalent should be consulted prior to unblinding, whenever possible.  
The Clinical Project Manager (CPM) will be informed immediately via the IXRS when a code is 
broken, but will remain blinded to specif ic treatment information. Any unblinding of the IMP 
performed by [CONTACT_352239].  
7.10 Randomization and numbering of subjects  
An IXRS will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provided by [CONTACT_58973] (or 
designee). The randomization schedule will be produced by [CONTACT_395670]. The IXRS will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. Subjects treatment assignment will be stratified by [CONTACT_463177]α inhibitor 
exposure (yes/no). Enrollment of TNFα inhibitor -experienced subjects will be limited to 30% of 
the total study  population.  
At Screening, each subject will be assigned a [ADDRESS_593136] number 
and will be registered in IXRS.  
Eligible subjects will be randomized to treatment groups at the Baseline Visit (Day 1). To  
randomize a subject, unblinded study personnel will contact [CONTACT_463194]. The IXRS will automatically inform the unblinded study 
personnel of the subject’s randomization number and the treatment arm  assigned. At the end of 
the [ADDRESS_593137] numbers and kit numbers will be 
tracked via the IXRS.  
8 STUDY PROCEDURES BY [CONTACT_463195] ( Table  5-2) provides a general  overview of study assessments. A 
list of procedures to be completed at each visit is described below.  
Visit windows are ±3 days from Baseline (Day 1, first dose of IMP) at all visits through the 
Week  16 Visit and ±4 days from all visits thereafter. For t he SFU Visit (20 weeks after the final 
dose), the visit should occur no more than 3 days prior to the scheduled visit date and within 
7 days after the scheduled visit date ( -3 days/+7 days). The minimum amount of time between 
bimekizumab doses should be no  less than [ADDRESS_593138] withdrawal.  
8.1 Screening (Visit 1)  
The Screening Period will last for a minimum of approximately 14 days (unless a screenfailed 
subject fr om AS0010 will be screened in AS0011) and up to a maximum of 35 days.  
Prior to any study specific activities, subjects will be asked to read, sign, and date an Informed 
Consent Form (ICF) that has been approved by [CONTACT_58963]/IRB, and that compl ies 
with regulatory requirements. Subjects will be given adequate time to consider any information 
concerning the study given to them by [CONTACT_737] (or designee). As part of the informed 
consent procedure, subjects will be given the opportunity to as k the Investigator any questions 
regarding potential risks and benefits of participation in the study.  
Subjects will also be given the option to participate in the pharmacogenomic and/or MRI 
substudies. Subjects who decide to participate in the substudies will need to complete a separate 
ICF following the same procedure and given the same considerations as the main ICF. Their 
willingness to participate in the substudies will be independent from their consent to participate 
in the main study.  
Subjects who initially fail to meet selected eligibility criteria (including but not limited to 
documented completion of LTBI prophylactic therapy) or for whom eligibility assessments could 
not be completed as planned may be rescreened once after discussion with the Me dical Monitor.  
An overview on rescreening/retesting requirements is provided in Section  [IP_ADDRESS]  and 
Section  [IP_ADDRESS] . 
The following procedures or assessments will be performed at the Screening Visit:  
• Obtain written informed consent for the main study and for the MRI and/or the 
pharmacogenomic substud ies for participating subjects.  
• Collect demographic data including the lifestyle and infection history.  
• Collect AS history including extra -articular manifestations (EAMs).  
• Collect significant past medical history and concomitant diseases.  
• Assess that all inclusion and no exclusion criteria are met.  
• Record prior medications.  
• Record concomitant medications.  
• Record AEs.  
• Administer the eC -SSRS and the PHQ -9. 
• Administer the BASDAI.  
• Administer the TB questionnaire.  
• Measure BP, pulse, and temperature.  
• Measure hei ght and body weight.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 57 of 187 • Perform a physical examination, including an evaluation for signs and symptoms of active 
TB, and risk for exposure to TB.  
• Perform an ECG.  
• Collect blood samples for:  
− Hematology and biochemistry.  
− CRP.  
− Serum pregnancy test if the subject  is a woman of childbearing potential.  
− Hepatitis B and C tests.  
− HIV test.  
− HLA -B27 status.  
− IGRA TB test.  
• Collect urine samples for:  
− Urinalysis.  
− Urine drug screen.  
• Obtain a chest x -ray, unless one has been obtained within 3 months prior to the Screening 
Visit. Any findings suggestive of active TB are exclusionary.  
• Obtain an x -ray of the sacroiliac joint unless one has been obtained up to 6 months prior to 
Screening or as part of screening for AS0010 (see Section  9.20.1  for details).  
• Register the subject using the interactive voice or web response system (IXRS).  
8.2 Baseline (Visit 2, Day 1, first dose of IMP)  
The following procedures of assessments will be completed prior to administration of IMP:  
• Review significant past medical history and concomitant diseases to ensure there are no 
significant changes in medical history that would exclude the subject based on the exclusion 
criteria.  
• Confirm that the sub ject meets all inclusion and no exclusion criteria.  
• Record concomitant medications.  
• Record AEs.  
• Administer the eC -SSRS and the PHQ -9. 
• Administer the ASQoL.  
• Administer the BASDAI.  
• Administer the BASFI.  
• Administer the SF -36 questionnaire.  
• Administer the MOS Short Sleep Scale (12 items).  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 58 of 187 • Perform the PGADA.  
• Administer the total and nocturnal spi[INVESTIGATOR_18303].  
• Administer the TB questionnaire.  
• Administer the FACIT -Fatigue subscale.  
• Administer the EQ -5D-3L. 
• Administer the WPAI -SHP.  
• Measure BP, pulse, and temperatur e. 
• Measure body weight.  
• Perform a physical examination, including an evaluation for signs and symptoms of active 
TB, and risk for exposure to TB.  
• Perform the TJC and SJC assessment.  
• Determine the MASES.  
• Determine the BASMI.  
• Administer the PhGADA.  
• Collect blood samples for:  
− Hematology and biochemistry.  
− CRP.  
− Bimekizumab plasma concentrations and anti -bimekizumab antibody detection.  
• Perform a urine pregnancy test if the subject is a woman of childbearing potential.  
• For subjects consenting on a separate ICF for participation in the pharmacogenomic 
substudy:  
− Collect serum and plasma samples for exploratory biomarkers.  
− Collect ribonucleic acid (RNA) blood samples for exploratory biomarkers.  
− Collect blood samples for genetic/epi[INVESTIGATOR_58895].  
− Collect stool sa mples.  
• Obtain an x -ray of the spi[INVESTIGATOR_463132] 6 months prior to Screening 
(see Section  9.20.2  for details). The spi[INVESTIGATOR_050] x -ray must be performed prior to or no later than 
on the day of the second administration of IMP.  
• Obtain MRIs of the sacroiliac joint and the spi[INVESTIGATOR_463133] a separate ICF 
for participation in the MRI substudy prior to the first IMP administra tion (see Section  9.20.3  
for details).  
• Randomize the subject using the IXRS.  
• Administer IMP.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 59 of 187 The following procedures of assessments will be complet ed following administration of IMP:  
• Measure vital signs approximately 30 minutes and 1 hour after dosing.  
8.3 Double -Blind Treatment  Period  
8.3.1  Week 1 ( ±3 days) (Visit 3)  
• Record concomitant medications.  
• Record AEs.  
• Administer the BASDAI.  
• Administer the BASFI.  
• Perform the PGADA.  
• Administer the total and nocturnal spi[INVESTIGATOR_18303].  
• Record the visit in the IXRS.  
8.3.2  Week 2 ( ±3 days) (Visit 4)  
• Record concomitant medications.  
• Record AEs.  
• Administer the BASDAI.  
• Administer the BASFI.  
• Perform the PGADA.  
• Administer the total  and nocturnal spi[INVESTIGATOR_18303].  
• Measure BP, pulse, and temperature.  
• Collect blood samples for:  
− Hematology and biochemistry.  
− CRP.  
− Bimekizumab plasma concentrations.  
• Record the visit in the IXRS.  
8.3.3  Week 4 ( ±3 days) (Visit 5)  
• Record concomitant medications.  
• Record AEs.  
• Administer the eC -SSRS and the PHQ -9. 
• Administer the ASQoL.  
• Administer the BASDAI.  
• Administer the BASFI.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 60 of 187 • Perform the PGADA.  
• Administer the total and nocturnal spi[INVESTIGATOR_18303].  
• Administer the FACIT -Fatigue subscale.  
• Administer the EQ -5D-3L. 
• Meas ure BP, pulse, and temperature.  
• Determine the MASES.  
• Administer the PhGADA.  
• Collect blood samples for:  
− Hematology and biochemistry.  
− CRP.  
− Bimekizumab plasma concentrations and anti -bimekizumab antibody detection.  
• Perform a urine pregnancy test if the subject is a woman of childbearing potential.  
• Record the visit in the IXRS.  
• Administer IMP.  
8.3.4  Week 8 ( ±3 days) (Visit 6)  
• Record concomitant medications.  
• Record AEs.  
• Administer the eC -SSRS and the PHQ -9. 
• Administer the ASQoL.  
• Administer the BASDAI.  
• Administer the BASFI.  
• Administer the SF -36 questionnaire.  
• Administer the MOS Short Sleep Scale (12 items).  
• Perform the PGADA.  
• Administer the total and nocturnal spi[INVESTIGATOR_18303].  
• Measure BP, pulse, and temperature.  
• Measure body  weight.  
• Perform a physical examination, including an evaluation for signs and symptoms of active 
TB, and risk for exposure to TB.  
• Perform the TJC and SJC assessment.  
• Determine the MASES.  
• Determine the BASMI.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 61 of 187 • Administer the PhGADA.  
• Collect blood samples fo r: 
− Hematology and biochemistry.  
− CRP.  
− Bimekizumab plasma concentrations and anti -bimekizumab antibody detection.  
• Perform a urine pregnancy test if the subject is a woman of childbearing potential.  
• Record the visit in the IXRS.  
• Administer IMP.  
8.3.5  Week 12 ( ±3 days) (Visit 7)  
• Record concomitant medications.  
• Record AEs.  
• Administer the eC -SSRS and the PHQ -9. 
• Administer the ASQoL.  
• Administer the BASDAI.  
• Administer the BASFI.  
• Perform the PGADA.  
• Administer the total and nocturnal spi[INVESTIGATOR_18303].  
• Administer the TB questionnaire.  
• Measure BP, pulse, and temperature.  
• Collect blood samples for:  
− Hematology and biochemistry.  
− CRP.  
− Bimekizumab plasma concentrations and anti -bimekizumab antibody detection.  
• Perform a urine pregnancy test if the subject is a woman of childbear ing potential.  
• Record the visit in the IXRS.  
• Administer IMP.  
8.3.6  Week 16 ( ±3 days) (Visit 8)  
• Record concomitant medications.  
• Record AEs.  
• Administer the eC -SSRS and the PHQ -9. 
• Administer the ASQoL.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 62 of 187 • Administer the BASDAI.  
• Administer the BASFI.  
• Administer the SF -36 questionnaire.  
• Administer the MOS Short Sleep Scale (12 items).  
• Perform the PGADA.  
• Administer the total and nocturnal spi[INVESTIGATOR_18303].  
• Administer the FACIT -Fatigue subscale.  
• Administer the EQ -5D-3L. 
• Administer the WPAI -SHP.  
• Measure BP, pulse, and temperature.  
• Measure body weight.  
• Perform a physical examination, including an evaluation for signs and symptoms of active 
TB, and risk for exposure to TB.  
• Perform the TJC and SJC assessment.  
• Determine the MASES.  
• Determine the BASMI.  
• Administer the PhGADA.  
• Perform an ECG.  
• Collect blood samples for:  
− Hematology and biochemistry.  
− CRP.  
− Bimekizumab plasma concentrations and anti -bimekizumab antibody detection.  
• Collect urine samples for:  
− Urinalysis.  
− Urine pregnancy test if the subject is a woman of childbearing potential.  
• For subjects consenting on a separate ICF for participation in the pharmacogenomic 
substudy:  
− Collect serum and plasma samples for exploratory biomarkers.  
− Collect RNA blood samples f or exploratory biomarkers.  
− Collect blood samples for genetic/epi[INVESTIGATOR_58895].  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 63 of 187 • Obtain MRIs of the sacroiliac joint and the spi[INVESTIGATOR_463133] a separate ICF 
for participation  in the MRI substudy. Magnetic resonance imaging at Week 16 shoul d be 
performed within ±5 days (see Section  9.20.3  for details).  
• Record the visit in the IXRS.  
• Administer IMP.  
The following procedures of assessments  will be completed following administration of IMP:  
• Measure vital signs approximately 30 minutes and 1 hour after dosing.  
8.4 Maintenance Period  
8.4.1  Week 20 ( ±4 days) (Visit 9)  
• Record concomitant medications.  
• Record AEs.  
• Administer the eC -SSRS and the PHQ -9. 
• Measure BP, pulse, and temperature.  
• Collect blood samples for:  
− Hematology and biochemistry.  
− Bimekizumab plasma concentrations and anti -bimekizumab antibody detection.  
• Perform a urine pregnancy test if the subject is a woman of childbearing potential.  
• Reco rd the visit in the IXRS.  
• Administer IMP.  
8.4.2  Week 24 ( ±4 days) (Visit 10)  
• Record concomitant medications.  
• Record AEs.  
• Administer the eC -SSRS and the PHQ -9. 
• Administer the ASQoL.  
• Administer the BASDAI.  
• Administer the BASFI.  
• Administer the SF -36 questionnaire.  
• Administer the MOS Short Sleep Scale (12 items).  
• Perform the PGADA.  
• Administer the total and nocturnal spi[INVESTIGATOR_18303].  
• Administer the TB questionnaire.  
• Administer the FACIT -Fatigue subscale.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 64 of 187 • Administer the EQ -5D-3L. 
• Administer the WPAI -SHP.  
• Measure BP, pu lse, and temperature.  
• Measure body weight.  
• Perform a physical examination, including an evaluation for signs and symptoms of active 
TB, and risk for exposure to TB.  
• Perform the TJC and SJC assessment.  
• Determine the MASES.  
• Determine the BASMI.  
• Administer the PhGADA.  
• Perform an ECG.  
• Collect blood samples for:  
− Hematology and biochemistry.  
− CRP.  
− Bimekizumab plasma concentrations and anti -bimekizumab antibody detection.  
• Perform a urine pregnancy test if the subject is a woman of childbearing potential.  
• Record the visit in the IXRS.  
• Administer IMP.  
8.4.3  Week 28 (± 4 days) (Visit 11)  
• Record concomitant medications.  
• Record AEs.  
• Administer the eC -SSRS and the PHQ -9. 
• Measure BP, pulse, and temperature.  
• Collect blood samples for hematology and biochemistry.  
• Perform a urine pregnancy test if the subject is a woman of childbearing potential.  
• Record the visit in the IXRS.  
• Administer IMP.  
8.4.4  Week 32 (± 4 days) (Visit 12)  
• Record concomitant medications.  
• Record AEs.  
• Administer the eC -SSRS and the PHQ -9. 
• Measure BP, pu lse, and temperature.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 65 of 187 • Collect blood samples for hematology and biochemistry.  
• Perform a urine pregnancy test if the subject is a woman of childbearing potential.  
• Record the visit in the IXRS.  
• Administer IMP.  
8.4.5  Week 36 ( ±4 days) (Visit 13)  
• Record concomitant medications.  
• Record AEs.  
• Administer the eC -SSRS and the PHQ -9. 
• Administer the ASQoL.  
• Administer the BASDAI.  
• Administer the BASFI.  
• Administer the SF -36 questionnaire.  
• Administer the MOS Short Sleep Scale (12 items).  
• Perform the PGADA.  
• Administer the total a nd nocturnal spi[INVESTIGATOR_18303].  
• Administer the TB questionnaire.  
• Administer the FACIT -Fatigue subscale.  
• Administer the EQ -5D-3L. 
• Administer the WPAI -SHP.  
• Measure BP, pulse, and temperature.  
• Measure body weight.  
• Perform a physical examination, including an ev aluation for signs and symptoms of active 
TB, and risk for exposure to TB.  
• Administer the PhGADA.  
• Collect blood samples for:  
− Hematology and biochemistry.  
− CRP.  
− Bimekizumab plasma concentrations and anti -bimekizumab antibody detection.  
• Collect urine samples for: 
− Urinalysis.  
− Urine pregnancy test if the subject is a woman of childbearing potential.  
• Record the visit in the IXRS.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 66 of 187 • Administer IMP.  
8.4.6  Week 40 (± 4 days) (Visit 14)  
• Record concomitant medications.  
• Record AEs.  
• Administer the eC -SSRS and the PHQ -9. 
• Measure BP, pulse, and temperature.  
• Collect blood samples for hematology and biochemistry.  
• Perform a urine pregnancy test if the subject is a woman of childbearing potential.  
• Record the visit in the IXRS.  
• Administer IMP.  
8.4.7  Week  44 (± 4 days) (Visit 15)  
• Recor d concomitant medications.  
• Record AEs.  
• Administer the eC -SSRS and the PHQ -9. 
• Measure BP, pulse, and temperature.  
• Collect blood samples for:  
− Hematology and biochemistry.  
− IGRA TB test.  
• Perform a urine pregnancy test if the subject is a woman of childbearing potential.  
• Record the visit in the IXRS.  
• Administer IMP.  
8.4.8  Week 48 ( ±4 days) (Visit 16)  
• Record concomitant medications.  
• Record AEs.  
• Administer the eC -SSRS and the PHQ -9. 
• Administer the TB questionnaire.  
• Measure BP, pulse, and temperature.  
• Collect blood samp les for hematology and biochemistry.  
• Perform a urine pregnancy test if the subject is a woman of childbearing potential.  
• Record the visit in the IXRS.  
• Administer IMP.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 67 of 187 8.4.9  Week 52 ( ±4 days) (Visit 17)  
• Record concomitant medications.  
• Record AEs.  
• Administer the eC -SSRS and the PHQ -9. 
• Administer the ASQoL.  
• Administer the BASDAI.  
• Administer the BASFI.  
• Administer the SF -36 questionnaire.  
• Administer the MOS Short Sleep Scale (12 items).  
• Perform the PGADA.  
• Administer the total and nocturnal spi[INVESTIGATOR_18303].  
• Administer the FACIT -Fatigue subscale.  
• Administer the EQ -5D-3L. 
• Administer the WPAI -SHP.  
• Measure BP, pulse, and temperature.  
• Measure body weight.  
• Perform a physical examination, including an evaluation for signs and symptoms of active 
TB, and risk for  exposure to TB.  
• Perform the TJC and SJC assessment.  
• Determine the MASES.  
• Determine the BASMI.  
• Administer the PhGADA.  
• Perform an ECG.  
• Collect blood samples for:  
− Hematology and biochemistry.  
− CRP.  
− Bimekizumab plasma concentrations and anti -bimekizumab antibo dy detection.  
• Collect urine samples for:  
− Urinalysis.  
− Urine pregnancy test if the subject is a woman of childbearing potential.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 68 of 187 • For subjects consenting on a separate ICF for participation in the pharmacogenomic 
substudy:  
− Collect serum and plasma samples for exploratory biomarkers.  
− Collect RNA blood samples for exploratory biomarkers.  
− Collect blood samples for genetic/epi[INVESTIGATOR_58895].  
− Collect stool samples  
• Obtain MRIs of the sacroiliac joint and the spi[INVESTIGATOR_463133] a separate ICF 
for p articipation in the MRI substudy. Magnetic resonance imaging should be performed 
within ±5 days of the Week 52 Visit (see Section  9.20.3  for details).  
• Record the visit in the IXRS.  
8.5 Early Termination Visit (if applicable)  
• Record concomitant medications.  
• Record AEs.  
• Administer the eC -SSRS and the PHQ -9. 
• Administer the ASQoL.  
• Administer the BASDAI.  
• Administer the BASFI.  
• Administer the SF -36 questionnaire.  
• Administer the MOS Short Sleep Scale (12 items).  
• Perform the PGADA.  
• Administer the total and nocturnal spi[INVESTIGATOR_18303].  
• Administer the TB questionnaire.  
• Administer the FACIT -Fatigue subscale.  
• Administer the EQ -5D-3L. 
• Administer the WPAI -SHP.  
• Measure BP, pulse, and temperature.  
• Measure body weight.  
• Perform a physical examination, including an evaluation for signs and symptoms of active 
TB, and risk for exposure to TB.  
• Determine the MASES.  
• Determine the BASMI.  
• Administer the PhGADA.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 69 of 187 • Perform an ECG.  
• Collect blood samples for:  
− Hematology and biochemistry.  
− CRP.  
− Bimekizumab plasma concentrations and anti -bimekizumab antibody detection.  
• Collect urine samples for:  
− Urinalysis.  
− Urine pregnancy test if the subject is a woman of childbearing potential.  
• Record the visit in the IXRS.  
8.6 Safety Follow -Up Visit ( -3 days/+7 days)  
• Record concomitant medications.  
• Record AEs.  
• Administer the eC -SSRS and the PHQ -9. 
• Administer the TB questionnaire.  
• Measure BP, pulse, and temperature.  
• Measure body weight.  
• Perform a physical examination, including an evaluation for signs and symptoms of active 
TB, and risk for exposure to TB.  
• Perform an ECG.  
• Collect blood samples for:  
− Hematology and biochemistry.  
− CRP.  
− Bimekizumab plasma concentrations and anti -bimekizumab an tibody detection.  
• Collect samples for:  
− Urinalysis.  
− Urine pregnancy test if the subject is a woman of childbearing potential.  
• Record the visit in the IXRS.  
8.7 Unscheduled Visit  
At the Investigator’s discretion, an Unscheduled Visit may be completed at any time during the 
study but prior to the SFU Visit, if deemed necessary for the subject’s safety and well -being.  
If an Unscheduled Visit is conducted due to safety or efficacy re asons, an eC -SSRS assessment 
will be performed with the subject during the visit. If an Unscheduled Visit is conducted for 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 70 of 187 reasons other than safety or efficacy concerns (eg, repeated collection of a laboratory specimen 
due to collection or analysis issues ) an eC -SSRS will not be required at these visits.  
At this visit, assessments including, but not limited to the following may be performed, 
depending on the reason for the visit:  
• Record concomitant medication.  
• Record AEs.  
• Administer the eC -SSRS.  
• Measure B P, pulse, and temperature.  
• Physical examination.  
• Record 12 -lead ECG.  
• If indicated, obtain blood sample(s) for:  
− Standard safety laboratory tests (hematology, serum chemistry).  
− Bimekizumab plasma concentrations and anti -bimekizumab antibody detection.  
− An IG RA TB test.  
• Obtain urine sample for:  
− Urine pregnancy test.  
− Urinalysis.  
9 ASSESSMENT OF EFFICA CY 
9.1 ASAS20, 40, ASAS 5/[ADDRESS_593139] 20% and absolute improvement 
of at least [ADDRESS_593140] 3 of the 4 following domains:  
• PGADA (see Section  9.8) 
• Pain assessment (the total spi[INVESTIGATOR_18233]; see Section  9.9) 
• Physical function (measured by [CONTACT_18379], Section  9.5) 
• Inflammation (the mean of the BASDAI Questions 5 and 6, [see  Section  9.3] concerni ng 
morning stiffness intensity and duration)  
and absence of deterioration in the potential remaining domain (deterioration is defined as a 
relative worsening of at least 20% and an absolute worsening of at least 1 unit).  
The ASAS criteria for 40% improvement are defined as relative improvements of at least 40%, 
and absolute improvement of at least [ADDRESS_593141] 3 of the 4 domains and 
no worsening at all in the remaining domain.  
The ASAS 5/[ADDRESS_593142] 20%  improvement in 5 of 6 domains, including 
spi[INVESTIGATOR_18171] (lateral spi[INVESTIGATOR_18205]) and CRP as more objective measures (Brandt et al, 2004).  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 71 of 187 The ASAS -PR is defined as a score of ≤2  units on a 0 to 10 unit scale in all 4 domains listed 
above for ASAS20.  
The ASAS20, 40, ASAS 5/6 response, and ASAS -PR will be derived from assessments at the 
visits specified in Table  5-2.  
9.2 ASQoL  
The ASQoL, a validated disease -specific 18 -item questionnaire, has been developed specifically 
for measuring health -related quality of life (HRQoL) in subjects with AS (Doward et al, 2003). 
The ASQoL has been used and has shown to be responsive in axSpA (Barkham et al, 2009; 
Haibel et a l, 2008). Each statement on the ASQoL is given a score of 1  = Yes or 0 = No. A score 
of "1" is given where the item is affirmed, indicating adverse quality of life. All item scores are 
summed to total score ranging from [ADDRESS_593143] at the visits specified in Table  5-2. 
9.3 Inflammation – BASDAI (mean of Questions 5 and 6)  
Ques tion 5 of the BASDAI (described completely in Section  9.4) measures intensity of morning 
stiffness. The subject considers the previous week and responds to the question, “How would 
you describe the overall level of morning stiffness you have had from the time you wake up?” 
The response is indicated on a 10 -point NRS in which 0=None and 10=Very severe. Question  [ADDRESS_593144] considers the previous week 
and responds to the question, “How long does your morning stiffness last from the time you 
wake up? The respons e is indicated on a 10 -point NRS in which 0=0 hours, 5=1 hour, and 
10=[ADDRESS_593145]’s 
perspective is the BASDA I (Garrett et al, 1994). The BASDAI is a validated self -reported 
instrument which consists of six 10 -unit horizontal NRSs to measure severity of fatigue, spi[INVESTIGATOR_18238], enthesitis, and morning stiffness (both severity and 
duration, respectively) over the last week ( van Tubergen et al, 2015) . The final BASDAI score 
ranges from 0 to 10, with lower scores indicating lower disease activity.   
 
and the score is used as the “total back pain” factor in the calculation of ASDAS -CRP. 
 
 and the score is used as the “peripheral 
pain/swelling” factor in the calculation of ASDAS -CRP. Question [ADDRESS_593146] to describe his/her overall stiffness from the time of awakening in the past week, and the 
score is used as the “duration of morning stiffness” factor in the calculation of ASDAS -CRP.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 72 of 187 The BASDAI total score is calculated as follows:  
𝐵𝐴𝑆𝐷𝐴𝐼 =Q1+Q2+Q3+Q4+(𝑄5+𝑄6
2)
5      
Fatigue item of the BASDAI  
Fatigue, as a major symptom of AS, can effectively  be measured with single -item questions such 
as the BASDAI item (van Tubergen et al, 2002b). This item has shown moderate to good 
reliability and responsiveness (van Tubergen et al, 2002b). The same minimal clinically 
important difference (MCID) will be us ed for the fatigue item of the BASDAI as for the total 
BASDAI score, ie, a change of 1  unit on the NRS.  
The BASDAI will be assessed at the visits specified in Table  5-2.  
9.5 Physical function – BASFI  
The BASFI is a validated disease -specific instrument for assessing physical function (van der 
Heijde et al, 2005; Calin et al, 1994). The BASFI comprises [ADDRESS_593147] week. 
The NRS version will be used for the answering options of each item on a scale of 0  (“Easy”) 
to 10 (“Impossible”) (van Tubergen et al, 2015; van Tubergen et al, 2002a). The BASFI is the 
mean of the 10  scores such that the total score ranges from 0 to 10, with lower scores indi cating 
better physical function. The MCID used to interpret scores is 7mm on a 0 to 100mm VAS or 
17.5% of the Baseline score (Pavy et al, 2005); an MCID of [ADDRESS_593148] at the visits sp ecified in Table  5-2. 
9.6 SF-36 
The SF -36 (Version 2, standard recall) is a 36 -item generic HRQoL instrument that uses a recall 
period of 4 weeks. Items are  grouped into 8 domains as follows: Physical Functioning (10 items), 
Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), 
Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items). One addition al 
item asks respondents about health change (Health Transition) over the past year. The concepts 
represented by [CONTACT_18385], mental, and social aspects of HRQoL.  
In addition to domain scores, the Physical Component Summary and Men tal Component 
Summary scores are calculated from the 8 domains (excluding the Health Transition item). 
Component scores appreciate the impact of each domain on physical and mental health status 
(Maruish, 2011). The norm -based T -scores for the 2 SF -36 compo nent summary (PCS and MCS) 
and the [ADDRESS_593149] deviation (SD) of 10 
in the general US  population (Maruish, 2011). An individual respondent’s score that falls outside 
the T -score range of [ADDRESS_593150] at the visits specified in Table  5-2. 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 73 of 187 9.7 MOS -12 
The MOS Sleep Scale is a validated generic self -administered scale measuring specific aspects 
of sleep. The frequency with which each  problem has been experienced during the previous 
4 weeks is rated on a 5 -point scale ranging from “none of the time” to “all of the time,” except 
sleep quantity, which is reported in hours. All scores are transformed linearly to range from 
0 to 100, again  with the exception of the sleep quantity subscale, which is scored in hours. 
Higher scores indicate more of the attribute implied by [CONTACT_18381] (eg, more sleep 
disturbance, more adequate sleep, and greater sleep quantity). The psychometric properties of the 
MOS Sleep Scale have been found to be satisfactory by [CONTACT_58966] (Hays et al, 2005). 
The domains of interest for this study are the Sleep Disturbance and the Sleep Problems Index II 
domains.  
The MOS -[ADDRESS_593151] at the visits specified in Table  5-2. 
9.8 PGADA  
Subjects will score the global assessment of their disease activity in response to the question 
“How  active was your spondylitis on average during the last week?” using a NRS where 0 is 
“not active” and 10 is “very active” (van Tubergen et al, 2015).  
The PGADA will be assessed by [CONTACT_463196]  5-2.  
9.9 Total and nocturnal spi[INVESTIGATOR_463134] 2 separate questions: 1) total 
pain in the spi[INVESTIGATOR_18248] (ie, “How much pain of  your spi[INVESTIGATOR_463135]?”); 
and 2) pain in the spi[INVESTIGATOR_18249] (ie, “How much pain of your spi[INVESTIGATOR_18250]?”) (Sieper et al, 2009; van der Heijde et al, 2005; Committee for Proprietary 
Medicinal Pro duct [CPMP]/EWP/556/95, 2004). When responding to each question, the subject 
is to consider the average amount of pain in the preceding week.  
Total and nocturnal spi[INVESTIGATOR_463136]  5-2. 
9.[ADDRESS_593152] 7 days  (FACIT.org). The scale consists of 5 subscales 
(physical well -being, social/family well -being, emotional well -being, functional well -being, and 
fatigue). The fatigue subscale is the only one used in this study. It is composed of 13 items, all 
scored from 0 (Not at all) to 4 (Very much). The FACIT -Fatigue subscale score ranges from [ADDRESS_593153] (0) to the best (4) outcome.   
The FACIT -Fatigue subscale will be completed by [CONTACT_463196]  5-2. 
9.11 EQ-5D-3L 
The EQ -5D-3L is comprised of a 5 -item health status dimension and a VAS. The response to 
each of the 5 health status dimensions is divided into 3 levels (no problem, some or moderat e 
problems, or extreme problems) and is scored as 1, 2, and 3, respectively. The EQ -5D-3L VAS 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 74 of 187 records the respondent’s self -rated health status on a vertical 20cm scale, 0 to 100 graduated 
(0=worst imaginable health status, 100=best imaginable health statu s). 
The EQ -5D-3L will be assessed by [CONTACT_463196]  5-2. 
9.12 TJC and SJC (44/44)  
The following 44 joints are to be examined f or tenderness and swelling by [CONTACT_737], 
another delegated physician, or an appropriately qualified medical professional (based on local 
requirements) who has had documented training on how to perform these assessments correctly. 
Preferably the same  assessor should evaluate the subject at each arthritis assessment.  
• Upper body (4) – bilateral sternoclavicular, and acromioclavicular joints.  
• Upper extremity (26) – bilateral shoulders, elbows, wrists (includes radiocarpal, carpal and 
carpometacarpal bone s considered as a single unit), metacarpophalangeals (MCPs) I, II, III, 
IV, and V, and thumb interphalangeals (IPs), and proximal IPs (PI[INVESTIGATOR_18246]) II, III, IV, and V.  
• Lower extremity (14) – bilateral knees, ankles, and metatarsophalangeals (I, II, III, IV, 
and V). 
The assessment for tenderness and swelling is made on [ADDRESS_593154]. Artificial 
and ankylosed joints are excluded from swelling and tenderness assessments. The assessments 
per visit are described in the schedule of study assessments Table  5-2. 
Table  9‒1 summarizes the swelling and t enderness grading criteria.  
Table  9‒1: Tenderness and swelling grading  
Grade  Tenderness response (44)  Swelling response (44)  
[ADDRESS_593155]’s employment 
status, work absenteeism, work impairment while working (presenteeism), overall work, and 
daily activity impairment attr ibutable to a specific health problem (WPAI -SHP) (Reilly et al, 
1993). It has been used in several clinical studies of biologic therapy in subjects with plaque PSO 
(Kimball et al, 2012; Vender et al, 2012).  
Five out of [ADDRESS_593156] at the vi sits specified in Table  5-2. 
9.14 CRP  
Blood will be collected for measurement of CRP (ie, determination of hs -CRP) . After Baseline, 
the CRP data will not be  sent to the Investigator to protect the blinded nature of the treatment 
assignments and response.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593157] and 
Investigator and multiplied by a validated formula (van der Heijd e et al, 2009) as listed:  
• 0.121 x Total back pain (BASDAI Q2 result, Section  9.4) 
• 0.058 x Duration of morning stiffness (BASDAI Q6 result, Section  9.4) 
• 0.110 x PGADA ( Section  9.8) 
• 0.073 x Peripheral pain/swelling (BASDAI Q3 result, Section  9.4) 
• 0.579 x (natural logarithm of the CRP [mg/L] + 1)  
Back pain, PGADA, duration of morning sti ffness, peripheral pain/swelling, and fatigue are all 
assessed on a numerical scale (0 to 10  units) (Lukas et al, 2009). The results of these calculations 
are summed to calculate the ASDAS.  
The variables related to ASDAS disease activity are defined as fo llows:  
• ASDAS -Inactive Disease (ASDAS -ID): ASDAS <1.3  
• ASDAS -Low Disease activity (ASDAS -LD): ASDAS ≥1.3, <2.1  
• ASDAS -High Disease activity (ASDAS -HD): ASDAS ≥2.1, ≤3.5  
• ASDAS -very High Disease activity (ASDAS -vHD): ASDAS >3.5  
The variable related to ASDAS improvement is defined as follows:  
• ASDAS -MI: ASDAS reduction (improvement) of ≥2.0 relative to Baseline  
The ASDAS variables will be derived from assessments at the visits specified in Table  5-2. 
9.16 MASES  
Enthesitis is assessed with the MASES. The MASES is an index that measures the severity (ie, 
intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral 
costochondral  1, costochondral 7, anterior superior iliac spi[INVESTIGATOR_050], posterior iliac spi[INVESTIGATOR_050], iliac crest 
and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spi[INVESTIGATOR_58937]) (Heuft -Dorenbosch et al, 2003) each scored as [ADDRESS_593158] axial status: cervical 
rotation; tragus to wall distance; lateral spi[INVESTIGATOR_18205]; modified Schober test; intermalleolar 
distance. Each of the [ADDRESS_593159]’s limitation of movement due to their AS.  
The BASMI will be assessed at the visits specifi ed in Table  5-2. 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593160] to their AS signs and 
symptoms and functional capac ity using an NRS in which 0=very good, asymptomatic and no 
limitations of normal activities and 10=very poor, very severe symptoms which are intolerable 
and inability to carry out normal activities.  
This assessment by [CONTACT_463197].  
The PhGADA will be assessed at the visits specified in Table  5-2. 
9.[ADDRESS_593161] x -rays are discussed in Section  [IP_ADDRESS] . 
In addition to the analyses mentioned below, x -rays and MRI images may be evaluated using 
other reading criteria or methods.  
9.20.1  Sacroiliac joint x-ray (AP Pelvis Joint Film for modified [LOCATION_001] 
Criteria)  
The sacroiliac joint is assessed by [CONTACT_463198] x -ray that 
will be assessed by a central reading review during the Screening Period to evaluate for modified 
[LOCATION_001] Criteria status ( Table  19‒2) as described in Section  6.1. Sacroiliac joint changes will 
be scored according to the imaging specifications.  
The following will be accepted to qualify subjects with AS for this study:  
• Anterior posterior pelvis x -ray centrally read for one of the Phase 3 studies AS0010 or 
AS0011 and determined to be modified [LOCATION_001] Criteria positive (+mNY); neither the 
x-ray nor the reading will be repeated.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 77 of 187 • Prior sacroiliac joint or AP pelvis x -ray (performed at any time prior to the study) was 
submitted and centrally read for  the purposes of this study and determined to be modified 
[LOCATION_001] Criteria positive (+mNY). If the prior x -ray does not meet central reading criteria 
for randomization, another x -ray may be performed if the prior x -ray is more than 1 year old 
and if permi tted by [CONTACT_13144].  
• If no recent x -ray is available, one must be performed at Screening.  
9.20.[ADDRESS_593162] chronic bony changes (eg, sclerosis, erosions, bridging, and 
ankyloses), structural changes generally occur slowly and x -rays are insensitive; therefore, 
changes are difficult to detect in the relatively short duration  of a randomized clinical study. 
Unlike radiography, MRI can be used to visualize active inflammation in the sacroiliac joints and 
spi[INVESTIGATOR_463137]. Inflammation of the sacroiliac joints and spi[INVESTIGATOR_53553] a key 
feature of axSpA that is po tentially amenable to treatment with bimekizumab. If bimekizumab is 
effective, it is expected that reduction in inflammation in the sacroiliac joints and spi[INVESTIGATOR_463138] 52 -week Treatment Period of this study. Recently, a Danish study 
demonstrated significant changes in ASspi[CONTACT_9268] -a (Berlin modification) and 
SPARCC  MRI -assessed inflammation scores and in MRI -assessed erosion scores within 
12 weeks after initiation of adalimumab (see below for further description of these MRI scoring  
methods). The researchers concluded that MRI -assessed structural lesions change rapi[INVESTIGATOR_463139] -modifying treatment in clinical trials 
(Pedersen et al, 2016). In this study, MRI changes will be evaluated in the sacroiliac joint and 
spi[INVESTIGATOR_463140]. In addition, exploratory evaluation of other 
chronic MRI features, such as erosions and fatty lesions, will be performed as indicators of 
disease modification associated with structural disease progression (Baraliakos et al, 2014).  
Magnetic resonance imaging of the spi[INVESTIGATOR_463141]. If needed, the sacroiliac joint and spi[INVESTIGATOR_463142].  
A central reader will assess the Baseline MRIs to identify MRI -positive subjects as per the 
OMERACT criteria. Further MRIs of the spi[INVESTIGATOR_463143] -positive and 
MRI -negative subjects  will be performed at Week  16 and Week 52 within a window of ±[ADDRESS_593163]’s opportunity to participate in the 
main study.  
The following 2 diffe rent scoring systems will be utilized to determine changes from Screening 
(Lukas et al, 2007):  
SPARCC Sacroiliac Joint score  
This method is a scoring system for assessing the sacroiliac joint based on short -tau-inversion 
recovery (STIR) sequences. An abnor mal increased signal on the STIR sequence represents bone 
marrow edema. The sacroiliac joint is divided into 4 quadrants (upper iliac, lower iliac, upper 
sacral, and lower sacral). The presence of increased signal on STIR in each of these 4 quadrants 
is scored as either 0=normal signal or 1=increased signal. The maximum score for abnormal 
signal in the 2 sacroiliac joints of 1 coronal slice is therefore 8. Joints that include a lesion 
exhibiting intense signal are each given an additional score of 1 per sli ce (that demonstrate this 
feature). Each sacroiliac joint that includes a lesion demonstrating continuous increase signal of 
depth ≥1cm from the articular surface is also given an additional score of 1. The maximum score 
for a single coronal slice is 12. S coring is repeated in each of 6 consecutive coronal slices, so that 
the total sacroiliac joint SPARCC MRI score can range from 0 to 72.  
ASspi[CONTACT_9268] -a (Berlin modification) score (spi[INVESTIGATOR_050])  
This method is a scoring system with a concentration on STIR sequences wh ich quantifies 
changes in 23 disco -vertebral units (DVU) of the spi[INVESTIGATOR_050]. A DVU is defined as the region between 
[ADDRESS_593164]’s ability to 
participate in the main study.  
These analyses will enable evaluation of biomarkers relative to disease biology and progression, 
drug treatment and bone metabolism, and inflammatory and immune respons e processes. The 
nature and format of these tentative analyses will be determined at a later date.  
For individuals consenting to the genomics, genetics, and proteomics substudy, blood samples 
will be drawn for exploratory genetic/epi[INVESTIGATOR_18193], genomic, prote omic, metabolomics analysis, 
and for candidate biomarker analyses. Candidate biomarker evaluations may include, but are not 
limited to, IL -17A/IL -17F pathway signaling and axSpA biology (eg, IL -17A, IL -17F, IL -23, IL -
6, tumor necrosis factor, dendritic cel l-specific transmembrane protein, and circulating osteoclast 
precursors). These plasma samples may be used for additional analyses of other exploratory 
biomarkers.  
Collection of these samples will occur at the time points specified in the schedule of study  
assessments ( Table  5-2). At dosing visits, blood samples will be drawn prior to dosing, and will 
be drawn at the same time of the sampling for clinica l laboratory tests. The time and date of 
collection will be recorded in the eCRF. The samples will be stored at -80°C at the central 
biorepository for up to [ADDRESS_593165] ing. 
Blood and/or stool samples for pharmacogenomic and biomarker assessments are collected for 
exploratory purposes and participation in either blood or stool sampling (or both) is optional.  
Instructions pertaining to sample collection, processing, storage, labeling, and shippi[INVESTIGATOR_313530]. Detailed information on sample analysis will be 
provided in a bioanalytical report.  
[ADDRESS_593166] is 
dosed with IMP, the blood samples will be drawn prior to dosing. Samples should be drawn at 
the same time of the sampling for clinical laboratory tests. The time and date of collection will be 
recorded in the eCRF. Instructions pertaining to sample collection, processing, storage, labeling, 
and shippi[INVESTIGATOR_58911]. The pr esence of antibodies to 
bimekizumab will be determined using a validated bioanalytical method. Detailed information on 
sample analysis will be provided in a bioanalytical report.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 80 of 187 The presence of anti -bimekizumab antibodies will be determined using a tiered  approach of 
screening, confirmatory, and titer assays. Where applicable, a neutralizing -antibody assay will be 
performed.  
12 ASSESSMENT OF SAFETY  
12.1 Adverse events  
12.1.1  Definitions  
[IP_ADDRESS]  Adverse event  
An AE is any untoward medical occurrence in a patient or clinical inves tigation subject 
administered a pharmaceutical product that does not necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temp orally associated with the use of a 
medicinal (investigational) product, whether or not related to the medicinal (investigational) 
product.  
In order to ensure complete safety data collection, all AEs occurring during the study (ie,  after 
the signing of the  ICF), including any pretreatment and post -treatment periods required by [CONTACT_12695], must be reported in the eCRF even if no IMP was taken but specific study procedures 
were conducted. This includes all AEs not present prior to the initial visit and all AEs that 
recurred or worsened after the initial visit.  
Signs or symptoms of the condition/disease for which the IMP is being studied should be 
recorded as AEs only if their nature changes considerably or their frequency or intensity 
increases in a clinical ly significant manner as compared to the clinical profile known to the 
Investigator from the subject’s history or the Baseline Period.  
[IP_ADDRESS]  Serious adverse event  
Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
determin ed. An SAE must meet 1 or more of the following criteria:  
• Death  
• Life-threatening  
(Life -threatening does not include a reaction that might have caused death had it occurred in 
a more severe form.)  
• Significant or persistent disability/incapacity  
• Congenital a nomaly/birth defect (including that occurring in a fetus)  
• Important medical event that, based upon appropriate medical judgment, may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent 1 of the other 
outcomes liste d in the definition of serious  
(Important medical events may include, but are not limited to, potential Hy’s Law [see 
Section  [IP_ADDRESS] ], allergic br onchospasm requiring intensive treatment in an emergency room 
or at home, blood dyscrasias that do not result in inpatient hospi[INVESTIGATOR_059], or the 
development of drug dependency or drug abuse.)  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 81 of 187 • Initial inpatient hospi[INVESTIGATOR_463144]  
(A patient admitted to a hospi[INVESTIGATOR_307], even if he/she is released on the same day, meets the 
criteria for the initial inpatient hospi[INVESTIGATOR_059]. An emergency room visit that results in 
admission to the hospi[INVESTIGATOR_463145]. 
However, emergency room visits that do not result in admission to the hospi[INVESTIGATOR_352178], instead, should be evaluated for 1 of the other criteria in the 
definition of serious [eg,  life-threatening  adverse experience, important medical event].  
Hospi[INVESTIGATOR_58913] [eg,  preplanned 
surgery or elective surgery for a pre -existing condition that has not worsened or manifested 
in an unusual or uncharacteristic manner] do not qualify for reporting. For example, if a 
subject has a condition recorded on his/her medical history and later has a preplanned surgery 
for this condition, it is not appropriate to record the surgery or hospi[INVESTIGATOR_463146], 
since there is no AE upon which to assess the serious criteria. Please note that, if the 
pre-existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
this would then qualify as an AE and, if necessary, the seriousness o f the event would need to 
be determined.)  
[IP_ADDRESS].[ADDRESS_593167] does not chan ge the Investigator’s obligation to report all SAEs (including Anticipated 
SAEs) as detailed in Section  [IP_ADDRESS] . 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 82 of 187 Table  12‒1: Anticipated serious adverse events for the population of subjects 
with AS  
MedDRA system organ class  MedDRA preferred term  
Skin and subcutaneous tissue disorders  Psoriasis  
Eye disorders  Uveitis  
Musculoskeletal and connective tissue disorders  Dactylitis  
Tendonitis  
Atlantoaxial instability  
Gastrointestinal disorders  Colitis ulcerative  
Crohn's disease  
Cardiac disorders  Aortic valve incompetence  
Atrial tachycardia  
Atrioventricular block  
Bundle branch block  
Cardiomyopathy  
Vascular disorders  Aortitis  
Respi[INVESTIGATOR_696], thoracic and mediastinal disorders  Pulmonary fibrosis  
Nervous system disorders  Cauda equina syndrome  
Injury, poisoning and procedural complications  Spi[INVESTIGATOR_463147]=ankylosing spondylitis; MedDRA=Medical Dictionary for Regulatory Activities; SAE=serious adverse event  
Note: Exception: Listed events will not be regarded as anticipated SAEs if they are life threatening or if they 
result in the death of the study subject.  
[IP_ADDRESS]  Adverse e vents of special interest  
An AE of special interest (AESI) is any AE that a regulatory authority has mandated to be 
reported on an expedited basis, regardless of the seriousness, expectedness, or relatedness of the 
AE to the administration of a UCB product /compound.  
Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total bilirubin in 
the absence of ≥2xULN ALP, with no alternative explanation for the biochemical abnormality, 
must ALWAYS be reported to UCB as an AESI (ie, without waiting  for any additional etiologic 
investigations to have been concluded). Follow -up information should then be reported if an 
alternative etiology is identified during investigation and monitoring of the subject.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 83 of 187 [IP_ADDRESS]  Other safety topi[INVESTIGATOR_397119]-specified s afety topi[INVESTIGATOR_397120]: infections (serious, opportunistic, fungal, 
and TB), neutropenia, hypersensitivity, suicidal ideation and behavior, major cardiovascular 
events, liver function test changes/enzyme elevations, malignancies, and in flammatory bowel 
diseases (with gastroenterology referral, as appropriate).  
This is based on findings from the IMP clinical program to date, potential risks generally 
associated with biologic immunomodulators, or findings from other medicines with a relat ed 
mechanism of action. There are no specific AE reporting requirements for these topi[INVESTIGATOR_1102], however 
special monitoring, additional data collection activities, and/or enhanced signal detection 
activities (within UCB) are in place.  
12.1.[ADDRESS_593168] AEs. For example:  
“Did you notice anything unusual about your health (since your last visit)? ” 
In addition, the Investigator should review any self -assessment procedures (eg,  diary cards) 
employed in the study.  
[IP_ADDRESS]  Description of adverse events  
When recording an AE, the Investigator should use the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The eCRF 
and source documents should be consistent. Any discrepancies between the subject’s own words 
on his/her own records (eg,  diary card) and the corresponding medical terminology should be 
clarified in the source documentation.  
Details for completion of the Adverse Event eCRF (including judgment of relationship to IMP) 
are described in the eCRF Completion Guidelines.  
[IP_ADDRESS]  Rule for repetition of an adverse event  
An increase in the intensity of an AE should lead to the repetition of the AE being reported with:  
• The outcome date of the first AE that is not related to the natural course of the disease being 
the same as the start date of the repeated AE, and the outcome of “worsening”  
• The AE verbatim  term being the same for the first and repeated AE, so that the repeated AE 
can be easily identified as the worsening of the first one  
[IP_ADDRESS]  Additional procedures for reporting serious adverse events  
If an SAE is reported, UCB must be informed within [ADDRESS_593169] enter the information regarding the SAE into the appropriate 
eCRFs and transmit to UCB via the clinical database, even if the data are incomplete, or if it is 
obvious that more data will be ne eded in order to draw any conclusions. This information will be 
received by [CONTACT_463199]. Any ancillary documentation (eg, 
autopsy or other documentation) that is valid for the SAE can be sent to UCB using the contact 
[CONTACT_3031] (fax/email) for SAE reporting listed in the Serious Adverse Event Reporting section 
at the front of the protocol.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593170] and report to UCB (or its representative) any 
SAEs (even if the Investigator is certain that they are in no way associated with the IMP), up to  
[ADDRESS_593171] be reported to  UCB regardless of the 
time between the event and the end of the study.  
Upon receipt of the electronic transmission of the SAE, UCB will perform an assessment of 
expectedness of the reported SAE. The assessment of the expectedness of the SAE is based on 
the Investigator’s Brochure.  
12.1.[ADDRESS_593172]; further details regarding follow 
up of PDILI events is provided in Section  [IP_ADDRESS] .  
If an A E is ongoing at the end of the study for a subject, follow -up should be provided until 
resolution/stable level of sequelae is achieved, or until the Investigator no longer deems that it is 
clinically significant, or until the subject is lost to follow up. If no follow up is provided, the 
Investigator must provide a justification. The follow up will usually be continued for [ADDRESS_593173] has discontinued his/her IMP.  
Information on SAEs obtained after clinical database lock will be captured thro ugh the Patient 
Safety (PS) database without limitation of time.  
12.[ADDRESS_593174] immediately (within 24  hours) notify UCB’s PS department b y entering all 
pregnancy information into the eCRF. An automatic notification will be sent to UCB’s PS 
department. The subject should be permanently withdrawn from IMP as soon as pregnancy is 
known (by [CONTACT_18463]), and the following should be completed:  
• The subject should immediately stop the intake of the IMP.  
• The subject should return for an early ad -hoc study visit.  
• A Safety Follow -Up Visit should be scheduled [ADDRESS_593175] of information currently known about potential risks 
and about available treatment alternatives.  
The pregnancy will be documented in the eCRF. The progression of the pregnancy and the 
eventual birth (if applicable) must be followed up using the eCRF. The Investigator must inform 
the subject of information currently known about potential risks and about available tr eatment 
alternatives.  
The pregnancy will be documented on the Pregnancy Report and Outcome Form provided to the 
Investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
followed up using the Pregnancy Report and Outcome  Form in which the Investigator has to 
report on the health of the mother and of the child. Every reasonable attempt should be made to 
follow the health of the child for [ADDRESS_593176] to follow up and/or refuses to give information, written documentation of 
attempts to contact [CONTACT_463200]. 
UCB’s PS department is the primary contact [CONTACT_261545], eventual birth, and follow up.  
In cases where the partner of a male subject enrolled in a clinical study becomes pregnant, the 
Investi gator or designee is asked to contact [CONTACT_58972]/IEC and should 
be available in the Investigator site file. In case of questions about t he consent process, the 
Investigator may contact [CONTACT_58973]/contract research organization (CRO) contract monitor for the 
study. The Investigator will complete the information in the eCRF only after the partner has 
agreed that additional information can be ca ptured and has provided the signed Partner 
Pregnancy Consent Form. UCB’s PS department is also the primary contact [CONTACT_261510], eventual birth, and follow up.  
A pregnancy becomes an SAE in the following circumstances: miscarriage, elective abortion, 
medically indicated abortion (eg, when the pregnancy is endangering life or health of the woman, 
or when the fetus will be born with severe abnormalities), unintended pregnancy after hormonal 
contrac eptive failure (if the hormonal contraceptive was correctly used), ectopic pregnancy, fetal 
demise, or any congenital anomaly/birth defect of the baby. Those SAEs must be additionally 
reported using the eCRF.  
12.[ADDRESS_593177] should be considered as an SAE; such cases must be reported immediately, recorded in 
the AE module of the eCRF, and followed as any other SAE. Any orga nism, virus, or infectious 
particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infectious agent.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593178]  
Excessive dosing (beyond that prescr ibed in the protocol and including overdose) should be 
recorded in the eCRF. Any SAE or nonserious AE associated with excessive dosing must be 
followed as any other SAE or nonserious AE. These events are only considered AEs or SAEs if 
there are associated clinical signs and symptoms or if the act of taking the excess medicine itself 
is an AE or SAE (eg,  suicide attempt).  
12.[ADDRESS_593179] as early as possible any 
safety concern(s) r elated to the IMP so that Investigators, clinical study subjects, regulatory 
authorities, and IRBs/IECs will be informed appropriately and as early as possible.  
The Study Physician or medically qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.  
As appropriate for the stage of development and accumulated experience with the IMP, 
medically qualified personnel at UCB may identify additional safety measures (e g, AEs, vital 
signs, laboratory or ECG results) for which data will be periodically reviewed during the course 
of the study.  
In addition, an independent Data Monitoring Committee (DMC) will periodically review and 
monitor safety data from this study and ad vise UCB. Details are provided in the DMC Charter. 
Cardiovascular and Neuropsychiatric Adjudication Committees will also periodically review and 
monitor safety data from this study and advise UCB. Details are provided in the Adjudication 
Committee Charters . 
12.[ADDRESS_593180] of biochemistry, hematology, urinalysis, and pregnancy 
tests (serum or urine) ( Table  12‒2). A centralized laboratory will be used to supply all laboratory 
test supplies and analyze all blood and urine samples (except the urine pregnancy test). Any 
unscheduled laboratory testing sh ould also be collected using the central laboratory (with the 
exception of urgent safety laboratory measurements which should be performed locally and 
centrally simultaneously). Testing to exclude hepatitis B, hepatitis C, and HIV (see Exclusion 
Criterion #12, Section  6.2) will be performed at Scr eening in addition to those measurements 
listed in Table 12‒2 . A urine dipstick will be used for pregnancy testing . 
Rescreening and retesting rules are provided in Section  [IP_ADDRESS]  and Section  [IP_ADDRESS] . 
Specific details regarding the handling and processing of biochemistry and hematology samples 
are provided in the study laboratory manuals.  
For subjects consenting to the pharmacogenomic substudy, blood and/or stool samples will be 
collected at defined timepoints ( Table  5-2) and shipped and stored according to the laboratory 
manual.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 87 of 187 The following laboratory parameters will be measured:  
Table  12‒2: Laboratory measuremen ts 
Hematology  Biochemistry  Urinalysis  
Basophils  Calcium  pH 
Eosinophils  Chloride  Albumin (protein)  
Lymphocytes  Magnesium  Glucose  
Monocytes  Potassium  Blood  
Neutrophils  Sodium  Leukocyte esterase  
Hematocrit  Glucose  Nitrite  
Hemoglobin  BUN  Urine dipstick  for pregnancy 
testinga 
MCH  Creatinine  Urine drug screenc 
MCHC  AST   
MCV  ALT   
Platelet count  ALP   
RBC count  GGT   
WBC count  Total bilirubin   
 LDH   
 Total cholesterol   
 Serum pregnancy testinga  
 CRPb  
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; CRP=C -reactive protein; ET=Early Termination; GGT=gamma -glutamyltransferase; 
IMP=investigational medicinal product; LDH=lactate dehydrogenase; MCH=mean corpuscular hemoglobin; 
MCHC= mean corpuscular hemoglobin concentration; MCV=mean corpuscular volume; RBC=red blood cell; 
SFU=Safety Follow -Up; WBC=white blood cell  
a A serum pregnancy test will be performed at Screening for all women of childbearing potential. A urine 
pregnancy test ( urine dipstick analyzed locally) is also required at the Baseline Visit, Q4W from Week [ADDRESS_593181] be negative prior to administering IMP.  
b CRP will be tested at specified visits ( Table  5-2). 
c Urine drug screen will be performed at the Screening Visit.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593182] be reported as an AE and PDILI events meeting SAE criteria should be reported to the 
Sponsor within 24 hours of learning of their occurrence. Any PDILI event that meets the 
criterion for potential Hy’s Law must be reported within [ADDRESS_593183] (see Section  [IP_ADDRESS] ), and, if applicable, also reported as an SAE 
(see Section  [IP_ADDRESS] ).  
Evaluation of PDILI consists of the diagnostic tes ting and continued monitoring included in 
Table  12‒3) specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a  local hepatologist (if applicable; discussed in Section  [IP_ADDRESS] ). The local 
hepatologist is the expert usually consulted by [CONTACT_58979]. This would usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injur y/abnormality is confirmed (details in 
Section  [IP_ADDRESS] ).  
The results of all monitoring, including laboratory testing and other testing, should be made  
available to the study site and Sponsor.  
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but  
appropriate medical action must not be delayed waiting for the repeat result.  
If tests are done locally for more rapid results, a concurrent sample should also be sent to the 
central laboratory whenever possible. Medical care decisions are to be made initially using the 
most rapi[INVESTIGATOR_58916] a conservative approach must be taken if the results from the 
2 labor atory tests are significantly different. Data from the local and central laboratory are to be 
recorded on the applicable eCRF pages.  
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also b e discontinued. In these cases, the Investigator should also 
consider dose reduction for medically necessary concomitant medication and consider changing 
any medically required concomitant medication known to be hepatotoxic to a suitable 
alternative.  
When IMP is stopped due to PDILI (as described in Section 6.3.1 ), IMP must be discontinued 
unless a subsequent alternative diagnosis fully explains t he hepatic findings. If a subsequent 
alternative diagnosis fully explains the hepatic findings, and the requirements provided in 
Section  [IP_ADDRESS].1  are met, rechallenge with IMP may be appropriate.  
The approach to investigate PDILI is summarized in Table  12‒3. 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 89 of 187 Table  12‒3: Required investigations and follow -up for PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptomsa of 
hepatitis or 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
≥3xULN  ≥2xULN
b NA Hepatology consultc 
Medical Monitor must 
be notified within 
24 hours (eg,  by 
[CONTACT_58980]) and 
subject discussed with 
Medical Monitor ASAP.  Immediate IMP 
discontinuationd. 
 Essential: Must have 
repeat liver 
chemistry values and 
additional testing 
completed ASAP 
(see 
Section [IP_ADDRESS] ); 
recommended to 
occur at the site with 
HCP.  Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within baseline 
values.e ≥3xULN  NA Yes 
≥8xULN  NA NA   
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 90 of 187 Table  12‒3: Required investigations and follow -up for PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptomsa of 
hepatitis or 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
≥5xULN 
(and ≥2x 
baseline) 
and 
<8xULN  <2xULN  No Discussion with Medical 
Monitor required.  
Consider need for 
hepatology consult if 
there is no evidence of 
resolution (see  Follow 
up requirements).c Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section  [IP_ADDRESS] ). 
 
IMP discontinuation 
required i f any of the 
following occur:  
• Subject cannot 
comply with 
monitoring 
schedule.  
• Liver chemistry 
values continue 
to increase  
• Liver chemistry 
values remain 
≥5xULN (and 
≥2x baseline) 
after 4 weeks of 
monitoring 
without 
evidence of 
resolution  Essential: Every 
attempt must be 
made to have repeat 
liver chemistry 
values and 
additional testing 
completed within 
48 hours at the site 
with HCP (see 
Section  [IP_ADDRESS] ). Monitoring of liver chemistry 
values at least twice per week for 
2 weeks.e 
• Immediate IMP 
discontinuation required if 
liver chemistry values 
continue to increase.  
After 2 weeks of monitoring  
liver chemistry values:  
• ALT or AST remains 
≥5xULN <8xULN, IMP 
should be temporarily 
withheld and subject should 
undergo repeat test in [ADDRESS_593184] values <5xULN; 
continue to monitor at least 
twice per week until values 
normalize, s tabilize, or 
return to within baseline 
values.  
If ALT or AST remains 
≥5xULN after second re -
test, immediate IMP 
discontinuation required . 
Continue to monitor until values 
normalize, stabilize, or return to 
within baseline values.e 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 91 of 187 Table  12‒3: Required investigations and follow -up for PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptomsa of 
hepatitis or 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitio ner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug induced liver injury; ULN=upper limit of norma l 
a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia 
(>5%), rash, and fever (without clear alternative cause).  
b If the subject also has ≥2xULN ALP, the possibi lity of an indication of biliary obstruction should be discussed with the Medical Monitor.  
c Details provided in Section  [IP_ADDRESS] . The local hepatologist is the expert usually consulted by [CONTACT_58981]. This would usually be a hepatologist, but may be a gastroenterologist.  
d Details are provided in Section  [IP_ADDRESS] . 
e Unless an alternative monitoring schedule is agreed by [CONTACT_352315]. Determination of stabilization is at the discretion 
of the Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.  
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 92 of 187 [IP_ADDRESS]  Consultation with M edical Monitor and local hepatologist  
Potential drug -induced liver injury events require notification of the Medical Monitor within 
24 hours (eg, by [CONTACT_58980]), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject must also be discusse d with the local hepatologist. The 
local hepatologist is the expert usually consulted by [CONTACT_58979]. This would usually be a hepatologist, but may be a 
gastroenterologist. If determined  necessary, this discussion should be followed by a full 
hepatology assessment (see Section  [IP_ADDRESS] ) and SAE report (if applicable).  
[IP_ADDRESS]  Immediate acti on: determination of IMP discontinuation  
All PDILI events require immediate action, testing, and monitoring.  
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by [CONTACT_58984]) to 
immediate discontinuation (see Section  6.3.1  and Table  12‒3 for details).  
When IMP is discontinued, all concomitant m edications and herbal supplements that are not 
medically necessary should also be discontinued. The Investigator should also consider dose 
reduction for medically necessary concomitant medication and consider changing any medically 
required concomitant med ication known to be hepatotoxic to a suitable alternative.  
[IP_ADDRESS].1  IMP restart/rechallenge  
Subjects who are immediately discontinued from IMP due to having met certain criteria for 
PDILI (as described in Section  6.3.1  and Table  12‒3), but for whom an alternative diagnosis is 
confirmed, ie, drug -induced liver injury is excluded, can rarely restart IMP. Rechallenge with 
IMP can occur only if ALL of the following requirements are met at the time of the rechallenge:  
• The results of additional testing and monitoring described in Section  [IP_ADDRESS]  and 
Section  [IP_ADDRESS]  confirm a nondrug -related cause for  the abnormal hepatic laboratory 
parameters and any associated symptoms (ie, a subsequent alternative diagnosis fully 
explains the hepatic findings).  
• No alternative treatment options are available to the subject.  
• The subject has shown clear therapeutic be nefit from the IMP.  
• Subject’s ALT or AST elevations do not exceed ≥3xULN.  
• Subject’s total bilirubin is <1.5xULN.  
• Subject has no signs or symptoms of hypersensitivity.  
• The rechallenge is approved by [CONTACT_261513] a hepatologist. The 
hepatologist must be external to UCB. It is recommended that the hepatologist be a local 
hepatology expert or the hepatologist treating the subject.  
• Subject agrees to the investigator -recommended monitoring plan and understands their 
individual benefit risk f or restarting IMP and this is adequately documented.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 93 of 187 [IP_ADDRESS]  Testing: identification/exclusion of alternative etiology  
The measurements and additional information required for the assessment of PDILI events when 
there is a reasonable possibility  that they may hav e been caused by [CONTACT_67603]  12‒4 (laboratory measurements) and Table  12‒5 (additional information). Results of the 
laboratory measurements and information collected are to be submitted to the Sponsor on the 
corresponding eCRF. If the medical history of the subject indicates a requirement for other 
assessments not included below , these additional assessments should be completed and 
submitted, as applicable.  
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the central laboratory.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 94 of 187 The followi ng measurements are to be assessed:  
Table  12‒4: PDILI laboratory measurements  
Virology -
related  Hepatitis A IgM antibody  
HBsAg  
Hepatitis E IgM antibody  
HBcAb -IgM 
Hepatitis C RNA  
Cytomegalovirus IgM antibody  
Epstein -Barr viral capsid antigen IgM antibody (if unavailable, obtain heterophile 
antibody or monospot testing)  
Immunology  Anti-nuclear antibody (qualitative and quantitative)  
Anti-smooth muscle antibody  (qualitative and quantitative)  
Type 1 anti -liver kidney microsomal antibodies (qualitative and quantitative)  
Hematology  Eosinophil count  
Urinalysis  Urine drug screena 
Chemistry  Amylase  
 Sodium, potassium, chloride, glucose, BUN, creatinine  
 Total bilirubin, ALP, AST, ALT, GGT, total cholesterol, albumin  
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin  
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation   
Additional  Prothrombin time/INRb 
Serum pregnancy testc 
PK sample  
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; CPK=creatine phosphokinase; GGT=gamma -glutamyltransferase; HBcAb -IgM=hepatitis B core 
antibody -IgM; HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; 
LDH=lactate dehydrogenase; PDILI=potential drug -induced liver injury; PK=pharmacokinetic; RNA=ribonucleic 
acid; ULN=upper limit of normal  
a Tests in addition to the specified analytes may be performed based on the Investigator’s medical judgment and 
subject history.  
b Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis  symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).  
c For women of childbearing potential.  
Additional information to be collected is presented in Table  12‒5. 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 95 of 187 Table  12‒5: PDILI information to be collected  
New or updated information  
Concomitant prescription and over -the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.  
Pertinent medical history, including the following:  
• History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
liver disease”)  
• Adverse reactions to drugs  
• Allergies  
• Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha -1 antitrypsin 
deficiency)  
• Recent travel  
• Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by [CONTACT_5071], 
should not be used as an explanation for significant AST and/or ALT elevations.)  
The appearance or worsening of clinic al symptoms of hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)  
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function  
Alcohol and illicit drug use  
Results of liver imaging or liver biopsy, if done  
Results of any specialist or hepatology consult, if done  
Any postmortem/pathology reports  
ALT=alanine aminotransferase; AST=aspartate aminotransfer ase; PDILI=potential drug -induced liver injury  
[IP_ADDRESS]  Follow -up evaluation  
Potential drug -induced liver injury events require follow -up monitoring as described in 
Table  12‒3. Monitoring should continue until liver chemistry values normalize, stabilize, or 
return to Baseline. Determination of stabilization is at the discretion of the Investigator in 
consultation w ith the hepatologist (as applicable) and UCB responsible physician, as needed.  
12.7 Other safety measurements  
12.7.1  Vital signs  
The Investigator or designee should measure all vital signs (systolic and diastolic BP, 
temperature [oral, axillary, or otic], pulse rate) prior to dosing after the subject has been sitting 
for at least [ADDRESS_593185] should remain seated during the measurements. At 
Baseline/Day  [ADDRESS_593186] in kilograms at the time 
points listed in Table  5-2. The same scale should be utilized throughout the study where possible.  
12.7.3  Physical examination  
The physical examination should be conducted by [CONTACT_58986]  5-2 and will include general appearance ; ear, nose, and throat; eyes, hair, and 
skin; respi[INVESTIGATOR_696]; cardiovascular; GI; musculoskeletal; hepatic; neurological (including limb 
reflexes); and mental status. Findings considered clinically significant changes since the physical 
examination at the Sc reening Visit will be recorded as AEs.  
12.7.4  12-lead electrocardiogram  
The Investigator or designee will perform the ECG which will be read centrally at the time points 
listed in Table  5-2. Full details of ECG recording will be provided in the ECG Manual.  
12.7.5  Assessment and management of TB and TB risk factors  
All subjects will be assessed for TB at Screening and at the time points specified in the schedule 
of asse ssments ( Table  5-2) through physical examination for signs and symptoms of TB, chest 
x-ray (Section  [IP_ADDRESS] ), laboratory testing ( Section  [IP_ADDRESS] ), and TB questionnaire 
(Section  [IP_ADDRESS] ). 
At Screening, all subjects will have an IGRA test (QuantiFERON TB test is recommended), a 
chest x -ray (unless already performed within 3  months of Scre ening) and examination for signs 
and symptoms of TB. In addition, each subject will complete a TB questionnaire directed at 
potential exposure to TB and symptoms of TB.  
For the purposes of this study, TB definitions are as follows:  
a. Known TB infection:  
− Active TB infection or clinical signs and symptoms suspi[INVESTIGATOR_58917] (pulmonary or 
extra -pulmonary).  
− History of active TB infection involving any organ system or findings in other organ 
systems consistent with TB infection, unless adequately treated and prove n to be fully 
recovered upon consult with a TB specialist.  
− Any evidence by [CONTACT_58987]’s medical history.  
b. High risk of acquiring TB infection:  
− Known close exposure to another person with active TB infection within the 3 months 
prior to Screening.  
− Time spent in a healthcare delivery setting or institution where individuals infected with 
TB are housed and where the risk of transmission of infection i s high.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 97 of 187 c. Latent TB infection (unless appropriate prophylaxis is initiated at least 4 weeks prior to IMP 
dosing and continued to completion of prophylaxis):  
− The absence of signs, symptoms, or physical findings suggestive of TB infection with a 
positive IGRA test (or [ADDRESS_593187] results) and a chest x -ray (or other 
imaging) without evidence of TB infection. If the result of the IGRA test is 
indeterminate, the particular IGRA test previously performed may be repeated once; if 
positive or indetermi nate on retest, the subject may not be randomized to IMP without 
further evaluation by a TB specialist and discussion with the Study Physician, if LTB 
infection is identified. The retest must be done during the protocol -defined Screening 
window.  
− Note: If a vailable, respi[INVESTIGATOR_463148] (CDC diagnosis of LTB infection) http://www.cdc.gov/TB/topic 
/testing/default.htm).  
d. NTMB infection is defined as a clinical infection caused by [CONTACT_352263].  
e. Tuberculosis test conversion:  
− A positive IGRA result for the current test when previous IGRA test results were 
negative. All subjects with TB test conversion must immediately stop IMP ad ministration 
and be referred to a TB specialist for further evaluation. Confirmed TB  test conversions 
should be classified as due to LTBI, active  TB infection, or NTMB, and reported to the 
UCB PS function.  
Subject eligibility, retesting requirements, and t reatment requirements are shown in Figure  12‒1. 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 98 of 187 Figure  12‒1: Schematic diagram of TB test results and study eligibility  
 
CDC=Center for Disease Control; IGRA=interferon -gamma release assay; LTBI=latent tuberculosis infection; 
TB=tuberculosis; WHO=World Health Organization  
a IGRA retest must be done during the protocol -defined Screening window.  
b Subject has a past history of active TB involving any organ system unless adequately treated according to 
WHO/CDC therapeutic guidance and proven to be fully recovered upon consult with a TB specialist. Subjects who 
have recently (no more than 12 months prior to Screening) completed the full treatment course of prophylaxis for 
LTBI are allowed. Prophylaxis should be in accordance with WHO or CDC guidelines and TB specialist judgment 
based on the origin of infection.  
c Subjects with LTBI may enter the study only after they have completed at least 4 weeks of appropriate 
prophylactic therapy and thereafter, will continue and complete the entire regimen.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 99 of 187 Figure  12‒2: Schematic diagram of TB test results during the study  
 
ASAP=as soon as possible; IGRA=interferon -gamma release assay; IMP=investigational medicinal product; 
LTBI=latent tuberculosis infection; TB=tuberculosis  
a IGRA retest must be done ASAP and prior to the next IMP dose  
b Subjects with LTBI may continue the study only after they have completed at least 4 weeks of appropriate 
prophylactic therapy and thereafter, will continue and complete the entire regimen.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 100 of 187 [IP_ADDRESS]  Tube rculosis assessment by [CONTACT_397159], the TB assessment by [CONTACT_18406] (QuantiFERON TB test is 
recommended) will be performed as described in Table  5-[ADDRESS_593188] be reported as an AE and appropriately updated once 
the fina l diagnosis is known (eg, active TB, latent TB, or false positive TB test). UCB also 
recommends that a  TB specialist be consulted  where TB (latent or active) is suspected or if there 
are doubts regarding test results. If latent or active TB is identified, subject must undergo 
appropriate study -specified withdrawal procedures. For indeterminate test results, the retest 
during Screening must be done during the protocol -defined Screening window.  
[IP_ADDRESS]  Chest x -ray for tuberculosis  
A plain posteroanterior chest x -ray must be performed in the Screening Period unless one has 
been performed within [ADDRESS_593189] x -ray (or, if done, 
Computed Axial Tomography [CAT] of the chest) must be clear of signs of TB infection 
(previous or current) b efore first IMP administration. All chest imaging (particularly x -rays) 
should be available for review by [CONTACT_397160]. The chest 
x-ray reading should be repeated if the TB test was confirmed positive. If the second read of the 
pretreatment chest x -ray is confirmed to be clear, the subject may be included in the study 
[ADDRESS_593190] and/or pulmonary physician. Any new clinically significant findings post 
Baseline on chest x -ray must be documented in the source documents and the eCRF as an AE.  
[IP_ADDRESS]  Tuberculosis questionnaire  
The questionnaire “Evaluation of signs and symptoms of tuberculosis” should be used as a 
source docume nt. The questionnaire will be completed as described in Table  5-2. The 
questionnaire will assist with the identification of subjects who may require therapy for TB. A 
subject who answers “Yes” to the question  
 Screening 
is excluded. A “Yes” response to any of the other que stions within the questionnaire at Screening 
should trigger further careful assessment to determine if subject has LTB or active TB (see 
Exclusion Criterion # 14 in Section  6.2). A “Yes” response to any of the questions during the 
study should trigger further assessments to determine if the subjec t has either LTB or active TB 
infection.  
[IP_ADDRESS]  Tuberculosis management  
During the study, subjects who develop evidence of LTB infection or active TB must 
immediately stop further administration of IMP and will be referred to an appropriate TB 
specialist (pulmon ologist or infectious disease specialist) for further evaluation. Evidence of 
LTB infection is defined as subject’s IGRA test converts to positive or indeterminate (and 
confirmed indeterminate on repeat), or the subject’s questionnaire or history and physi cal 
indicates that TB infection or exposure may have occurred. Evidence of active TB includes, in 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593191] should be transferred to the care of his/her physician and managed according to the 
best available standard of care. Subjects identified as having converted to active TB during the 
study must be withdrawn and scheduled to return for the ET Visit  as soon as possible but no later 
than the next scheduled study visit and complete all ET Visit  assessments.  
The subject  should be encouraged to complete a SFU Visit  (20 weeks after the final dose of 
IMP).  
If infection with NTMB is identified during the stu dy, the same procedure as for active TB 
acquired during the study must be followed.  
12.7.[ADDRESS_593192] result should be obtained immediately 
prior to each administration of IMP and at all v isits specified in Table  5-2. Pregnancy tests 
should be administered to all female subjects of childbearing potential, regardless of their use of 
birth control.  
12.7.7  PHQ -9 
The PHQ -9 is a multipurpose instrument for screening, diagnosing, monitoring, and measuring 
the severity of depression. The PHQ -9 scores for depression range from 0 to 27 with higher 
scores indicating worse state. A score of 5  to 9 is consid ered to be minimal symptoms of 
depression. A score of 10 to 14 is considered minor depression, dysthymia, or mild major 
depression. A score of 15 to 19 is considered to indicate moderately severe major depression, 
and a score ≥[ADDRESS_593193] at the visits specified in Table  5-2.  
Refer to Section  6.3 for PHQ -9-related withdrawal criteria.  
12.7.8  Assessment of suicidal  ideation and behavior  
Suicidal ideation and behavior will be assessed by [CONTACT_352266] -SSRS; the questionnaire will be 
completed by [CONTACT_423]. This scale will be used to assess suicidal ideation and behavior that 
may occur during the study. The visits at  which the eC -SSRS assessments will be performed are 
specified in the schedule of study assessments ( Table  5-2). 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 102 of 187 The eC -SSRS is a standardized and valid ated instrument developed for the assessment of the 
severity and frequency of suicidal ideation and behavior (Posner et al, 2011; Mundt et al, 2010). 
Subjects respond to standardized clinical questions that are presented in a uniform fashion. The 
eC-SSRS d efines [ADDRESS_593194] demographic information for all subjects according to 
local rules and regulations. This  will include age, gender, race and ethnicity. Demographic 
information will be recorded in the eCRF.  
The Investigator or designee will obtain a complete history of lifestyle (alcohol or drug 
consumption within 6 months prior to Screening, nicotine consumpt ion at the time of screening) 
and infections (fungal skin infections within 12 months prior to Screening) as part of the 
screening assessment. Lifestyle and infection history will be recorded in the eCRF.  
13.2 Medical and ankylosing spondylitis history  
The Inve stigator or designee will obtain a complete medical history and a medical history related 
to AS (including EAMs, the date of diagnosis, and past treatments for AS, and ASAS 
classification criteria as referenced in Section  19.1) as part of the Screening assessment and 
include all clinically relevant past or coexisting medical conditions, responses to AS treatment as 
available, Baseline GI -related symptoms , and surgeries. Findings will be recorded in the eCRF.  
13.[ADDRESS_593195] to their health and safety. In this case, this action 
should be taken immediately, without prior notification of the regulatory authority,  IRB/IEC, or 
Sponsor.   
After implementation of such measure, the Investigator must notify the CPM of the Sp onsor 
within 24 hours and follow any local regulatory requirements.  
14.2 Monitoring  
UCB (or designee) will monitor the study to meet the CRO’s monitoring Standard Operating 
Procedures (SOPs), ICH -GCP guideline, and applicable regulatory requirements, and to ens ure 
that study initiation, conduct, and closure are adequate. Monitoring of the study may be 
delegated by [CONTACT_18410] a CRO or a contract monitor.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 103 of 187 The Investigator and his/her staff are expected to cooperate with UCB (or designee) and to be 
available during the  monitoring visits to answer questions sufficiently and to provide any 
missing information. The Investigator(s)/institution(s) will permit direct access to source 
data/documents for study -related monitoring, audits, IRB/IEC review, and regulatory 
inspectio n(s). 
The Investigator will allow UCB (or designee) to periodically review all CRFs and 
corresponding source documents (eg,  hospi[INVESTIGATOR_58921]). 
Monitoring visits will provide UCB (or designee) with the opportunity to evaluate the progress 
of the study, verify the accuracy and completeness of CRFs, ensure that all protocol 
requirements, applicable authorities’ regulations, and Investigator’s obligations are being 
fulfilled, and resolve any inconsistencies in the stud y records.  
14.2.[ADDRESS_593196] be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (ink, typi[INVESTIGATOR_007], printing, 
optical disc). They should not be o bscured by [CONTACT_18411] 
(such as removable self -stick notes). Photocopi[INVESTIGATOR_13265]/or printouts of eCRFs are not considered 
acceptable source documents. Source documents are original records in which raw data are first 
recorded . These may include hospi[INVESTIGATOR_307]/clinic/general practitioner records, charts, diaries, x -rays, 
laboratory results, printouts, pharmacy records, care records, ECG or other printouts, completed 
scales, quality of life questionnaires, or video, for example. Sourc e documents should be kept in 
a secure, limited access area.  
Electronic Patient -Reported Outcome (ePRO) measures (eg, ASQoL; BASDAI, BASFI, SF -36, 
MOS -12, PGADA, total and nocturnal spi[INVESTIGATOR_18172], FACIT -Fatigue, EQ -5D-3L, WPAI -SHP) will 
be completed by [CONTACT_463201].  
The data collection and database management system will be supplied by a vendor and will be 
compliant with the relevant regulations. The data collected on the ePROs will be uploaded to a 
central server databas e and will be sent electronically to UCB (or a designated CRO).  
Sponsor or designee will review to ensure that computerized source documents produced by [CONTACT_58991] (FDA) Part [ADDRESS_593197] be printed for review by [CONTACT_2037] (eg, ECG reports). Once printed, these copi[INVESTIGATOR_58923] a permanent part of the subjec t’s source 
documents. The Investigator will facilitate the process for enabling the monitor to compare the 
content of the printout and the data stored in the computer to ensure all data are consistent.  
Electronic data records must be saved and stored as in structed by [CONTACT_18338] (or designee).  
14.2.[ADDRESS_593198] to being accurate, complete, and verifiable from 
source documents (eg,  subject files, recordings from automated instruments, tracings [ECG], 
x-ray films, laboratory notes). All data reported on the eCRF should be supported by [CONTACT_58992], unless otherwise specified in Section  14.2.1 . 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 104 of 187 14.3 Data handling  
14.3.1  Case Report Form completion  
This study will use electronic data capture (EDC); the Investigator is responsible for prompt 
reporting of accurate, compl ete, and legible data in the eCRF and in all required reports.  
This study will also use an electronic device (Site Tablet) to capture patient reported outcomes.  
Serious AE reporting will be done using the eCRF in the appropriate SAE Report Form section 
and transmitted to Patient Safety (see Section  [IP_ADDRESS] ). The safety database and the clinical 
database will be reconciled during the study and discrep ancies will be corrected as needed.  
The Investigator should maintain a list of personnel authorized to enter data into the eCRF. 
Access to the EDC will be given after training has been received. A training certificate will be 
provided and filed.  
Detailed i nstructions on the use of the EDC will be provided in the eCRF Completion 
Guidelines.  
Corrections made after the Investigator’s review and approval (by [CONTACT_3553] a 
password/electronic signature) will be re -approved by [CONTACT_737]. Any change or correct ion 
to the eCRF after saving must be accompanied by a reason for the change.  
14.3.2  Database entry and reconciliation  
Case Report forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system (C DMS). Computerized data cleaning checks 
will be used in addition to manual review to check for discrepancies and to ensure consistency of 
the data. Case Report Form data are entered into the clinical database using independent, 
double -data entry, with the exception of comment fields, which are verified by a second person. 
The data are entered into the eCRFs once and are subsequently verified if the study is performed 
using electronic data capture.  
An electronic audit trail system will be maintained within t he CDMS to track all data changes in 
the database once the data have been saved initially into the system or electronically loaded. 
Regular backups of the electronic data will be performed.  
14.3.[ADDRESS_593199] Screening and Enrollment log/Subject Identification Code l ist 
The subject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
Log. 
The Investigator will keep a Subject Identification Code list. This list remains with the 
Investigator and is used for unambiguous identification of ea ch subject.  
The subject’s consent and enrollment in the study must be recorded in the subject’s medical 
record. These data should identify the study and document the dates of the subject’s 
participation.  
14.[ADDRESS_593200] to quality or quantity.  
If the study is prematurely terminated or suspended, UCB (or its representative) will inform the 
Investigators/institutions and the regulatory authority(ies) of the ter mination or suspension and 
the reason(s) for the termination or suspension, in accordance with applicable regulatory 
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the 
termination or suspension by [CONTACT_12942]/institution, as specified by [CONTACT_12926](s). In addition, arrangements will be made for the return of all 
unused IMP and other material in accordance with UCB procedures for the study.  
14.[ADDRESS_593201] elapsed since the 
formal discontinuation of clinical development of the IMP. These documents should be retained 
for a longer period, however, if required by [CONTACT_8146](s) or by [CONTACT_463202] B (CPMP/ICH/135/95, 2002 [Section  4.9.5]). The Investigator will contact 
[CONTACT_463203]. The Investigator will also notify UCB shoul d he/she 
relocate or move the study -related files to a location other than that specified in the Sponsor’s 
trial master file.  
14.[ADDRESS_593202] been protected, that enrolled subjects (ie,  signing consent and undergoing 
study procedure s) are appropriate for the study, and that all data relevant for the evaluation of the 
IMP have been processed and reported in compliance with the planned arrangements, the 
protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and applicable regulator y 
requirements.  
The Investigator will provide direct access to all study documents, source records, and source 
data. If an inspection by a regulatory authority is announced, the Investigator will immediately 
inform UCB (or designee).  
14.7 Good Clinical Practice  
Noncompliance with the protocol, ICH -GCP, or local regulatory requirements by [CONTACT_3786], institution, institution staff, or designees of the Sponsor will lead to prompt action 
by [CONTACT_18418]. Continued noncompliance may result in the t ermination of the 
site’s involvement in the study.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 106 of 187 15 STATISTICS  
A description of statistical methods follows and will be described in more detail in the Statistical 
Analysis Plan (SAP).  
15.1 Definition of analysis sets  
The following analysis sets were defined:  
• The Enrolled Set (ES) will consist of all subjects who have given informed consent.  
• The Randomized Set (RS) will consist of all randomized subjects.  
• The Safety Set (SS) will consist of all randomized subjects who received at least 1 dose of 
the IMP.  
• The Fu ll Analysis Set (FAS) will consist of all randomized subjects who received at least 
[ADDRESS_593203] a valid measurement of all components of the primary efficacy 
variable at Baseline.  
• The Per -Protocol Set (PPS) will consist of all subjects in th e RS who had no important 
protocol deviation affecting the primary efficacy variable. Important protocol deviations will 
be predefined and subjects with important protocol deviations will be evaluated during a data 
evaluation meeting prior to unblinding of  the data. Exclusions from the FAS will be 
considered important protocol deviations that also result in exclusion from the PPS.  
• The Pharmacokinetics Per -Protocol Set (PK -PPS) consists of all randomized subjects who 
received at least [ADDRESS_593204] the concentration.  
• The coronavirus disease 2019  (COVID -19) free set will consist of all subjects in the RS who 
had no COVID -[ADDRESS_593205] of number of available observations, arithmetic mean, 
SD, median, minimum, and maximum unless stated otherwise.  
All statistical tests will be performed 2 -sided at a 5% level of significance unless stated 
otherwise.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 107 of 187 15.3 Planned efficacy analyses  
15.3.1  Analysis of the primary and secondary efficacy variables  
A fixed sequence testing procedure will be applied for each of the primary and selected 
secondary variables. The testing procedure will control the family -wise type -I-error and will 
account for multiplicity. The  family -wise error will be set to α=0.05 (2 -sided).  
For the testing procedure, the hypotheses are mapped into a set ranging from H [ADDRESS_593206] based on a binary efficacy variable, the null hypothesis is that the conditional odds 
ratio is equal  to 1. 
H0: OR T1/T2 = 1 
The alternative hypothesis is that the conditional odds ratio is not equal to 1.  
HA: OR T1/T2 ≠ [ADDRESS_593207] on a continuous efficacy variable, the null hypothesis is that there is no difference 
between treatment groups.  
H0: T1 – T2 = 0 
The alternative hypothesis is that there is a difference between treatment groups.  
HA: T1 – T2 ≠ 0 
The treatment comparison for each of these hypotheses is between bimekizumab 160mg sc  Q4W 
and placebo. Point estimates and 95% confidence intervals  (CI) will be calculated.  
The testing starts with H 1. If H 1 can be rejected at α=0.05 (2 -sided), the corresponding α will be 
passed on to the next test in the sequence (ie, H 2) and testing will continue. The hierarchical 
testing will be stopped if a hypothesis cannot be rejected at α=0.05 (2 -sided).  
The sequential testing procedure of primary and secondary efficacy endpoints is shown in 
Figure  15‒1. 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 108 of 187 Figure  15‒1: Sequential testing procedure of primary/secondary efficacy 
endpoints  
 
ASAS40 (20)=Assessment of SpondyloArthritis International Society 40% (20%) response criteria; 
ASAS5/6=Assessment of SpondyloArthritis International Society 5 out of 6 response criteria; 
ASAS -PR=Assessment of SpondyloArthritis International Society partial remission; ASDAS -MI=Ankylosing 
Spondylitis Disease Activity Score major imp rovement; ASQoL=Ankylosing Spondylitis Quality of Life; 
BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; BASFI=Bath Ankylosing Spondylitis Functional 
Index; BASMI=Bath Ankylosing Spondylitis Metrology Index; BKZ=bimekizumab; CfB=change from Basel ine; 
H=hypothesis; PCS=physical component summary; SF -36=Short Form 36 -item Health Survey; TNF α=tumor 
necrosis factor alpha; W=Week  
[IP_ADDRESS]  Analysis of the primary efficacy variable  
The primary efficacy analysis will be performed based on the RS.  
The primary endp oint is the ASAS40 response at Week 16. The primary efficacy analysis will 
evaluate the composite estimand in the RS. The composite estimand combines the clinically 
meaningful improvement from Baseline based on the ASAS40 response and not discontinuing 
treatment early. In practice, this composite estimand is similar to non -responder imputation 
(NRI), referred to here as modified NRI.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593208] for the primary  efficacy analysis:  
1. Population = Subjects enrolled according to the protocol -specified inclusion/exclusion 
criteria and randomized to IMP.  
2. Subject -level outcome = ASAS40 at Week 16.  
3. Intercurrent event handling = An intercurrent event is defined as disconti nuation of study 
treatment prior to Week 16. A composite strategy will be implemented in which a positive 
clinical outcome is defined as achieving ASAS40 at Week  16 and not discontinuing study 
treatment through Week  16. 
4. Population -level summary measure = C onditional odds ratio comparing bimekizumab to 
placebo.  
Missing data at Week 16 that are not preceded by [CONTACT_463204], and any data after an 
intercurrent event will be imputed as non -responders.  
Any use of prohibited or rescue therapy through Week  16 would constitute an important protocol 
deviation which would be accounted for when the supportive analysis based on the PPS is 
performed  (see Section  [IP_ADDRESS].1 ). 
The statistical hypothesis for the ASAS40 response at Week  [ADDRESS_593209] of bimekizumab vs placebo on 
ASAS40  response. The model will include fixed effects for treatment. The suitability of 
including the stratification variables of prior TNFα inhibitor  exposure (yes/no) and region will be 
assessed, an d will be added to the model if appropriate. Comparisons will be made for 
bimekizumab vs placebo using the [ADDRESS_593210] at a significance level of α=0.05  (ie, H 1 in 
Figure  15‒1). The odds ratio versus placebo, p -value, and the 95% CI will be calculated.  
[IP_ADDRESS].1  Supportive analyses  
Supportive analyses for the primary efficacy variable will be conducted. The analyses will be 
repeated:  
1. Based on the PPS to evaluate the effect of important protocol deviations on the analysis.  
2. For all subjects in the FAS to evaluate the consistency between the RS and the more 
restrictive FAS. This analysis will only be performed if the number of subjects in RS and 
FAS are different.  
3. For all individual components of the ASAS40 response to explore the effect of the signs and 
symptoms of the individual components on the composite endpoint. Since all ASAS 
components are continuous variables (eg, chang e from Baseline in total spi[INVESTIGATOR_18172]), an 
analysis of covariance (ANCOVA) with treatment, region, and prior TNFα inhibitor 
exposure as fixed effects and the Baseline values as covariate will be used for the analysis.  
4. Using a modified composite estimand whe re intercurrent events are defined only as 
discontinuation due to adverse event or lack of efficacy.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 110 of 187 5. Using a treatment policy imputation.  
6. Using a tippi[INVESTIGATOR_18275].  
7. Using observed cases only (OC).  
8. Using the COVID -19-free set.  
Further specification of additional supportive analyses to evaluate varying assumptions related to 
the handling of missing data will also be performed and are described in Section  15.7. 
[IP_ADDRESS]  Analyses of the secondary efficacy variables  
The secondary efficacy variables will be analyzed for all subjects in the RS.  
Binary variables will be analyzed to evaluate the composite estimand in the RS, as done for the 
primary efficacy variabl e. The composite estimand combines (1) achieving the given binary 
response and (2) not discontinuing treatment prior to Week 16. The statistical hypothesis for the 
binary variables at Week 16 is that the conditional odds ratio for binary variables in the 
bimekizumab treatment group compared with the placebo treatment group is equal to 1.  
Continuous variables will be analyzed for treatment effects using a similar estimand approach as 
for the primary efficacy variable, except for the following:  
• Intercurrent e vent handling = An intercurrent event is defined as discontinuation of study 
treatment prior to Week 16. A hypothetical strategy for addressing intercurrent events will be 
implemented. This estimand targets the treatment difference in a scenario where with drawal 
from study treatment does not occur, such that outcomes for subjects without an intercurrent 
event are as observed, and outcomes for subjects with an intercurrent event are treated as 
though they had completed the randomized study treatment through Week 16. A multiple 
imputation strategy will be used to impute data following an intercurrent event.  
• Population -level summary measure = The difference in adjusted means between 
bimekizumab and placebo.  
Any missing data at Week 16 that is not preceded by [CONTACT_463205] (ie, discontinuation of 
study medication) will be imputed based on a predefined  multiple imputation (MI) model. The 
missing value will be replaced by a set of plausible values, where each value is a Bayesian draw 
from the conditional di stribution of the missing data given the observed data. Intermittent 
missing data will be imputed using the Markov -Chain Monte Carlo (MCMC) method, followed 
by [CONTACT_463206]. The statistical model for the comparison of 
bimek izumab and placebo will be an ANCOVA with treatment, region, and prior TNFα inhibitor 
exposure as fixed effects and the Baseline value as covariate. The statistical hypothesis for the 
continuous variables at Week 16 is that the treatment difference between  the bimekizumab 
treatment group and placebo is equal to 0.  
All secondary efficacy variables will also be summarized based on observed case data. Binary 
outcomes will also be summarized using the modified composite estimand.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 111 of 187 15.3.2  Analyses of other efficacy vari ables  
All other efficacy variables will be analyzed based on the RS.  
Binary variables will be summarized using frequency tables by [CONTACT_463207]. Generally, the 
estimand structure for binary other efficacy variables is as described below. Note that further 
details will be provided in the SAP.  
1. Population = Subjects meeting the protocol -specified inclusion/exclusion criteria.  
2. Subject -level outcome = The given variable and time point being summarized (eg, ASAS -PR 
at Week 24).  
3. Intercurrent event handling = An int ercurrent event is defined as discontinuation of study 
treatment prior to the time point being summarized. A composite strategy will be 
implemented in which a positive clinical outcome is defined as achieving the given variable 
at the specified time point and not discontinuing study treatment through that time point.  
4. Population -level summary measure = Unadjusted proportion of responders.  
Any missing data that are not preceded by [CONTACT_463208] a NRI as described for the primary and secondary efficacy variables.  
Continuous variables will be summarized using descriptive statistics by [CONTACT_463207]. Generally, the 
estimand structure for continuous other efficacy variables is as described below. Note that furth er 
details will be provided in the SAP.  
1. Population = Subjects meeting the protocol -specified inclusion/exclusion criteria.  
2. Subject -level outcome = The given variable and time point being summarized (eg, Change 
from Baseline in BASFI at Week 36).  
3. Intercurre nt event handling = An intercurrent event is defined as discontinuation of study 
treatment prior to the time point being summarized. A hypothetical strategy will be 
implemented in which outcomes for subjects without an intercurrent event are as observed at  
the given time point, and outcomes for subjects with an intercurrent event are treated as 
though they had completed the randomized study treatment through the time point being 
summarized. A multiple imputation strategy will be used to impute data followin g an 
intercurrent event.  
4. Population -level summary measure = Unadjusted mean.  
Any missing data that are not preceded by [CONTACT_463208] a predefined multiple imputation model as described for continuous sec ondary 
efficacy variables.  
In some cases, other efficacy variables may also be summarized based on observed case data (ie, 
subjects with missing data or who have prematurely discontinued study treatment are treated as 
missing).  
Time to ASAS20/[ADDRESS_593211] date when the response is achieved. Subjects who 
discontinue study t reatment prior to achieving a response will be censored at the date of study 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 112 of 187 treatment discontinuation. The median time to response, including the 2 -sided 95% CI, will be 
calculated for each treatment. Between -group differences will be analyzed with the lo g-rank 
statistic.  
15.3.3  Subgroup analyses  
Subgroup analyses using descriptive statistics will be performed on the primary efficacy 
variable. The following variables for subgroup analyses will be defined:  
• Age at Baseline (<45  years of age; ≥45 years of age)  
• Gend er (male; female)  
• Disease duration (<5 years; ≥5 years)  
• Region (eg, Asia, Eastern Europe, North America, Western Europe)  
• Body mass index at Baseline (<18.5kg/m2; 18.5kg/m2 to <25kg/m2; 25kg/m2 to <30kg/m2; 
≥30kg/m2) 
• Prior TNFα inhibitor exposure (yes; no)  
• CRP at Baseline (≤ULN; >ULN)  
• ASDAS status at Baseline (<1.3 [inactive disease]; 1.3 to ≤2.1 [low disease activity]; 
>2.1 to ≤3.5 [high disease activity]; >3.5 [very high disease activity])  
• HLA -B27 positivity (yes; no)  
• Anti-bimekizumab antibody status (posi tive, negative)  
15.4 Planned safety analyses  
15.4.1  Safety analyses  
Safety variables will be analyzed for all subjects in the SS.  
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA® 19.0). Adverse events with an onset date on or after the date of first IMP 
administration and up to [ADDRESS_593212] (most recent) dose of IMP will be defined as 
TEAEs. Treatment -emergent AEs will be summarized descriptively by [CONTACT_1570], primary 
system organ class, high level t erm, and preferred term. Additional tables will summarize TEAEs 
leading to withdrawal from IMP, TEAEs by [CONTACT_58998]. Treatment 
emergent AEs leading to withdrawal from both IMP or the study, serious TEAEs, TEAEs of 
special interest, T EAE of special monitoring, and deaths will be also be tabulated and listed.  
When analyzing categorical data, the number and percentage of subjects in each category will be 
presented by [CONTACT_1570]. In addition, shift tables may be used to evaluate the number and 
percentage of subjects having a different post -Baseline status when compared to their Baseline 
status.  
Laboratory values (including markedly abnormal values), urinary values, vital signs, ECGs, 
eC-SSRS, and extent of exposure will be presented d escriptively by [CONTACT_1570]. Definitions 
for markedly abnormal laboratory values will be provided in the SAP.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593213]. The criteria for identifying important protocol deviations will be defined 
within the appropriate protocol -specific document. Important protocol de viations will be 
reviewed as part of the ongoing data cleaning process and all important deviations will be 
identified and documented prior to unblinding to confirm exclusion from analysis sets.  
15.7 Handling of dropouts or missing data  
The primary analysis for  the primary variable will use a conservative approach to handling 
missing data that is similar to non -responder imputation. The sensitivity of results to the 
approach for handling missing data will be evaluated via supportive analyses using different 
missing data mechanisms.  
In instances where MI is used, the missing value is replaced by a set of plausible values, where 
each value is a Bayesian draw from the conditional distribution of the missing data given the 
observed data. Intermittent missing data wil l be imputed using the MCMC method, followed by 
[CONTACT_463209]. The planned multiple imputation procedures are based on 
an assumption of data missing at random (MAR).  
The following supportive analyses for the primary efficacy variable will be conducted:  
1. Multiple imputation as described above will be performed using the modified composite 
estimand as specified for the use with the secondary variables. The definition of an 
intercurrent event is changed from all treatment disconti nuation, to discontinuation of 
treatment due to AE or lack of efficacy.  
2. Tippi[INVESTIGATOR_463149]. These tippi[INVESTIGATOR_463150] α=0.05. Various delta adjustments will be made to the assumed 
responses on the monotone missing data in each treatment group independently with various 
degrees of plausibility. It will include scenarios where subjects who have missing  data and 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593214] (if possible). 
The plausibility of such required delta adjustment will then be assessed. Details will be 
provided in the Statistical Analysis Plan (SAP).  
3. The treatment policy strategy for addressing intercurrent events will be consid ered. This will 
be based on an analysis of all available data at Week [ADDRESS_593215] the primary outcome data for all subjects at Week 16, there 
may still be some subjects for whom Week 16 effic acy data cannot be obtained. In this case, 
missing data will be imputed using MI under the assumption of MAR. Results will be 
combined into a single inference using Rubin's rule. It should be noted that this measures 
something different from the primary an alysis and could be confounded by [CONTACT_463210]  [ADDRESS_593216] prematurely discontinued study treatment will be treated as missing.  
For the secon dary and other efficacy variables, the binary endpoints will be analyzed using 
modified NRI, MI, and OC , and the continuous endpoints will be analyzed using MI and OC.  
Additional details on these supportive analyses will be provided in the SAP.  
15.8 Planned int erim analysis and data monitoring  
15.8.1  Interim analyses  
Two interim analyses will be performed: one after the planned number of randomized subjects 
have completed the Double -Blind Treatment Period and the Week [ADDRESS_593217] (eg, stoppi[INVESTIGATOR_004], 
sample size re -estimation, or changes to eligibility criteria) are planned for this interim analysis.  
To ensure blinding of  Investigators and subjects, a statistical blinding plan will be written to 
evaluate the potential bias of the Maintenance Period, define blinded and unblinded teams, and 
describe the process of interim results generation and dissemination. The plan will b e finalized 
prior to the lock of the database at the Week [ADDRESS_593218] not be members of the 
study team at UCB or the conducting CRO. The duration of membership for the committees will 
be inclusive of planned analyses for AS0011.  
15.9 Determ ination of sample size  
Approximately 300 subjects will be randomly assigned in a 2:1 ratio to the following treatment 
groups: bimekizumab 160mg sc Q4W (200 subjects) or placebo sc Q4W (100 subjects).  
The primary efficacy analysis is based on the bimekizum ab dose versus placebo for 
ASAS40  response at Week  16.  
All sample size and power calculations were done at a significance level of 0.05.  
All sample size and power calculations were performed using the software nQuery Advisor® 7.0. 
15.9.1  Power calculation for pr imary endpoint  
The sample size assumptions for bimekizumab versus placebo are based on the ASAS40 
response data from the Phase  2b bimekizumab study in subjects with active AS (AS0008).  
An ASAS40 response at Week 16 of 40% can be assumed for the bimekizumab  treatment  group. 
This assumed treatment response is based on the bimekizumab 160mg dose results of AS0008 at 
Week 12 (46.7%). It was also assumed that the treatment response at Week 12 and Week  16 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 116 of 187 would be the same (ie, conservative assumption). In additi on, the observed ASAS40 response 
rates were adjusted to account for a higher number of subjects with prior TNFα inhibitor 
exposure and for a higher number of subjects with early withdrawal. Placebo ASAS40 response 
at Week 16 was assumed to be 15% and is mo re conservative than that of AS0008 at Week  12 
(ie, ASAS40 response=13.3%).  
The sample size for showing statistical superiority of bimekizumab versus placebo was 
calculated using a [ADDRESS_593219] with continuity correction (Fleiss et al,  
1980). With [ADDRESS_593220] for detecting statistical superiority of bimekizumab versus placebo based on 
ASAS40 response at Week 16 is powered with >99%.  
15.9.2  Power calculations fo r secondary endpoints in the hierarchical 
testing  
The assumptions for power calculations of the secondary endpoints are based on the Week  12 
results of AS0008, unless indicated otherwise. It was assumed that the treatment response at 
Week 12 and Week 16 wo uld be the same (ie, conservative assumption). In addition, the 
observed data were adjusted in the same way as the primary endpoint to account for a higher 
number of subjects with prior TNFα inhibitor exposure and for a higher number of subjects with 
early  withdrawal.  
All power calculations for binary endpoints were performed using a [ADDRESS_593221] with continuity correction (Fleiss et al, 1980). All power calculations for continuous 
endpoints were performed using a [ADDRESS_593222] (Moser et al, 1989) The 
power calculations provided below represent independent evaluations for each endpoint and do 
not account for multiplicity.  
For ASAS40 response of the TNFα inhibitor -naïve population at Week 16, an ASAS40 response 
of 48% for the bimekizumab group was assumed. Placebo ASAS40 response at Week 16 is 18%. 
It is also assumed that 70% of the subjects in each treatment group are TNFα inhibitor -naïve. 
With those assumptions, the endpoint is powered with >99% at the planned samp le size (ie, 
140 and 70 subjects in the bimekizumab and placebo group, respectively).  
For ASAS20 response at Week 16, an ASAS20 response of 70% for the bimekizumab group was 
assumed. Placebo ASAS20 response at Week 16 is 30%. With those assumptions, the en dpoint is 
powered with 99% at the planned sample size.  
For change from Baseline in BASDAI total score at Week 16, an adjusted between -treatment 
difference of - 1.38 with an SD=1.8 for bimekizumab and SD=1.4 for placebo was used. With 
those assumptions, the  endpoint is powered with >99% at the planned sample size.  
For ASAS -PR at Week 16, an ASAS -PR of 17% for the bimekizumab group was assumed. 
Placebo ASAS -PR at Week 16 was assumed to be 3.3%. With those assumptions, the endpoint is 
powered with 94% at the planned sample size.  
For ASDAS -MI at Week 16, the ASDAS -MI data of AS0008 at Week 12 and Week 16 were 
used and the placebo response was extrapolated to Week 16. The assumed ASDAS -MI are 
36.0% and 13.8% at Week 16 for the bimekizumab and placebo group, resp ectively. With those 
assumptions, the endpoint is powered with 98% at the planned sample size.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 117 of 187 For ASAS5/6 response at Week 16, an ASAS5/6 response of 44% for the bimekizumab group 
was assumed. Placebo ASAS -PR at Week 16 was assumed to be 5%. With those as sumptions, 
the endpoint is powered with >99% at the planned sample size.  
For change from Baseline in BASFI at Week 16, an adjusted between -treatment difference 
of - 2.35 with an SD=1.9 for bimekizumab and placebo was used. With those assumptions, the 
endpo int is powered with >99% at the planned sample size.  
For change from Baseline in nocturnal spi[INVESTIGATOR_463151] 16, the AS data from the 
certolizumab pegol study AS001 were used. An adjusted between -treatment difference of -1.88 
with an SD=2.9 for bim ekizumab and SD=2.4 for placebo was used. With those assumptions, the 
endpoint is powered with >99% at the planned sample size.  
For change from Baseline in ASQoL total score at Week 16, an adjusted between -treatment 
difference of - 2.39 with an SD=4.5 for bimekizumab and placebo was used. With those 
assumptions, the endpoint is powered with >99% at the planned sample size.  
For change from Baseline in SF -36 PCS score at Week 16, an adjusted between -treatment 
difference of 4.56 with an SD=8.1 for bimekizumab and SD=5.8 for placebo was used. With 
those assumptions, the endpoint is powered with >99% at the planned sample size.  
For change from Baseline in BASMI at Week 16, an adjusted between treatment difference 
of - 0.55 with an SD=0.8 for bimekizumab and SD=0. 7 for placebo was used. With those 
assumptions, the endpoint is powered with >99% at the planned sample size.  
[ADDRESS_593223]’s informed consent must be obtained and documented in accordance with local 
regulation s, ICH -GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.  
Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandable to the s ubject in both oral and written form by [CONTACT_737] (or 
designee). Each subject will have the opportunity to discuss the study and its alternatives with 
the Investigator.  
Prior to participation in the study, the Informed Consent Form should be signed and personally 
dated by [CONTACT_233791] 
(Investigator or designee). The subject must receive a copy of the signed and dated Informed 
Consent Form. As part of the consent process, each subject must  consent to direct access to 
his/her medical records for study -related monitoring, auditing, IRB/IEC review, and regulatory 
inspection.  
If the Informed Consent Form is amended during the study, the Investigator (or the Sponsor, if 
applicable) must follow a ll applicable regulatory requirements pertaining to the approval of the 
amended Informed Consent Form by [CONTACT_1201]/IEC and use of the amended form.  
All studies conducted at centers in the [LOCATION_002] must include the use of a Health Insurance 
Portability a nd Accountability Act Authorization Form.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593224] may withdraw his/her consent to participate in the study at any time. A subject is 
considered as enrolled in the study when he/she has signed the Informed Consent Form. A eCRF 
must not be started, nor m ay any study specific procedure be performed for a given subject, 
without having obtained his/her written consent to participate in the study.  
16.[ADDRESS_593225] with him/her at all times.  
16.3 Institut ional Review Boards and Independent Ethics 
Committees  
The study will be conducted under the auspi[INVESTIGATOR_18279]/IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical principles that have their origin in the Declaration 
of Helsink i. 
The Investigator/UCB will ensure that an appropriately constituted IRB/IEC that complies with 
the requirements of the current ICH -GCP version or applicable country -specific regulations will 
be responsible for the initial and continuing review and approv al of the clinical study. Prior to 
initiation of the study, the Investigator/UCB will forward copi[INVESTIGATOR_18280], Informed 
Consent Form, Investigator’s Brochure, Investigator’s curriculum vitae (if applicable), 
advertisement (if applicable), and all ot her subject -related documents to be used for the study to 
the IRB/IEC for its review and approval.  
Before initiating a study, the Investigator will have written and dated full approval from the 
responsible IRB/IEC for the protocol.  
The Investigator will al so promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to human subjects or others, and any protocol deviations, 
to eliminate immediate hazards to subjects.  
The Investigator will not make any changes in the s tudy or study conduct without IRB/IEC 
approval, except where necessary to eliminate apparent immediate hazards to the subjects. For 
minor changes to a previously approved protocol during the period covered by [CONTACT_18424], it may be possible for t he Investigator to obtain an expedited review by [CONTACT_1201]/IEC as 
allowed.  
As part of the IRB/IEC requirements for continuing review of approved studies, the Investigator 
will be responsible for submitting periodic progress reports to the IRB/IEC (based on I RB/IEC 
requirements), at intervals appropriate to the degree of subject risk involved, but no less than 
once per year. The Investigator should provide a final report to the IRB/IEC following study 
completion.  
UCB (or its representative) will communicate sa fety information to the appropriate regulatory 
authorities and all active Investigators in accordance with applicable regulatory requirements. 
The appropriate IRB/IEC will also be informed by [CONTACT_29539], as specified 
by [CONTACT_59002]. Where applicable, 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 119 of 187 Investigators are to provide the Sponsor (or its representative) with evidence of such IRB/IEC 
notification.  
16.[ADDRESS_593226] privacy  
UCB staff (or designee) will affirm and uphold the subject’s c onfidentiality. Throughout this 
study, all data forwarded to UCB (or designee) will be identified only by [CONTACT_18427].  
The Investigator agrees that representatives of UCB, its designee, representatives of the relevant 
IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of the 
subject’s primary medical records that directly concerns this study (including, but not limited to, 
laboratory test result reports, ECG reports, admission/discharge summaries for hospi[INVESTIGATOR_18281] a subject’s study participation, and autopsy reports for deaths 
occurring during the study).  
16.[ADDRESS_593227] 
be approved by [CONTACT_18338], the IRB/IEC, and the regulatory authorities (if required), prior to being 
implemented.  
17 FINANCE, INSURANCE, AND PUBLICATION  
Insurance coverage will be handled according to local requirements.  
Finance, insurance, and publication rights are addressed in the Investigator and/or CRO 
agreement s, as applicable.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 120 of 187 18 REFERENCES  
Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, et al. Which spi[INVESTIGATOR_463152] -TNF agents? A long -term observ ational study using MRI and conventional 
radiography. Ann Rheum Dis. 2014;73:1819 -25. 
Barkham N, Keen HI, Coates LC, O'Connor P, Hensor E, Fraser AD, et al. Clinical and imaging 
efficacy of infliximab in HLA –B27–Positive patients with magnetic resonance imaging –
determined early sacroiliitis. Arthritis Rheum. 2009;60:946 -54. 
Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and 
preselection of criteria for short term improvement after anti -TNFalpha treatment in ankylosing 
spondylitis. Ann Rheum Dis. 2004;63:1438 -44. 
Braun J. Axial spondyloarthritis: thoughts about nomenclature and treatment targets. Clin Exp 
Rheumatol. 2012;30:S132 -5. 
Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379 -90. 
Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos -Vargas R, Collantes -Estevez E, et al. 
2010 update of the ASAS/EULAR recommendations for the management of ankylosing 
spondylitis. Ann Rheum Dis. 2011;70:896 -904. 
Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Gras edyck K, et al. Efficacy of 
sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis 
and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis. 
2006;65:1147 -53. 
Calin A, Garrett S, Whi telock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to 
defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing 
Spondylitis Functional Index. J Rheumatol. 1994;2:[ADDRESS_593228] MG. Multiple i mputation and its application. Chichester: John Wiley 
& Sons Ltd; 2013.  
CPMP/EWP/556/95. Points to consider on the clinical investigation of medicinal products other 
than NSAIDS for the treatment of RA. June 2004.  
CPMP/ICH/135/95. Note for guidance on good  clinical practice. July 2002.  
Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of 
the ASQL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis. 
2003;62:20 -6. 
FACIT.org. https://www.facit.or g/measures/FACIT -F (Accessed on 03 February 2021).  
Fleiss JL, Tytun A, Ury HK. A simple approximation for calculating sample sizes for comparing 
independent proportions. Biometrics. 1980;36:343 -6. 
Food and Drug Administration. Guidance for Industry. Drug -induced liver injury: premarketing 
clinical evaluation. US Dept of Health and Human Services, Center for Drug Evaluation and 
Research, Center for Biologics Evaluation and Research, 07/2009.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593229] P, Calin A. A new approach to 
defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease 
Activity Index. J  Rheumatol. 1994;21:2286 -91. 
Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, et al. No efficacy of 
subcutaneous  methotrexate in active ankylosing spondylitis: a 16 -week open -label trial. Ann 
Rheum Dis. 2007;66:419 -21. 
Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active 
ankylosing spondylitis. Ann Rheum Dis. 2005;64:124 -6. 
Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al. Efficacy of 
adalimumab in the treatment of axial spondyloarthritis without radiographically defined 
sacroiliitis: results of a twelve -week randomized, double -blind, placebo -controlled trial by [CONTACT_18428] -label extension up to week fifty -two. Arthritis Rheum. 2008;58:[ADDRESS_593230], Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the Medical Outcomes 
study sleep measure. Sleep Med. 2005;6:41 -4. 
Helmick CG, Felson DT, Lawrenc e RC, Gabriel S, Hirsch R, Kwoh KC, et al. Estimates of the 
prevalence of arthritis and other rheumatic conditions in the [LOCATION_002]. Part I. Arthritis 
Rheum. 2008;58:15 -25. 
Heuft -Dorenbosch L, Spoorenberg A, van Tubergen A, Landewé R, van der Tempel H,  Mielants 
H, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis. 2003;62:127 -32. 
International Menopause Society. Cornwall, [LOCATION_006]: Menopause Terminology; c2015. 
http://www.imsociety.org/menopause_terminology.php. Accessed 25 Jan 2016.  
Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, et al. The effects of 
adalimumab treatment and psoriasis severity on self -reported work productivity and activity 
impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol. 
2012;66(2):e67 -e75. 
Lukas C, Braun J, van der Heijde D, Hermann K -G A, Rudwaleit M, Ostergaard M, et al. 
Scoring inflammatory activity of the spi[INVESTIGATOR_58930]: a multireader experiment. J of Rheum. 2007;34:862 -70.  
Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an 
ASAS -endorsed di sease activity score (ASDAS) in patients with ankylosing spondylitis. Ann 
Rheum Dis. 2009;68:18 -24. 
Mallinckrodt CH, Lin Q, Lipkovich I, Molenberghs G. A structured approach to choosing 
estimands and estimators in longitudinal clinical trials. Pharm Stat. 2012;11:456 -61. 
Mallinckrodt CH. Preventing and Treating Missing Data in Longitudinal Clinical Trials: A 
Practical Guide. [LOCATION_001], NY: Cambridge University Press; 2013.  
Maruish ME, editor. User’s manual for the SF -36v2 Health Survey. 3rd ed. Lincoln, RI:  
QualityMetric Incorporated; 2011.  
Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area 
and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis 
Severity Index (mNAPSI), Mander/Newc astle Enthesitis Index (MEI), Leeds Enthesitis Index 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 122 of 187 (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing 
Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic 
Arthritis, Dermatolog y Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), 
Functional Assessment of Chronic Illness Therapy -Fatigue (FACIT -F), Psoriatic Arthritis 
Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activit y 
in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). 
Arthritis Care Res 2011;[ADDRESS_593231] 11:S64 -85. 
Moser BK, Stevens GR, Watts CL. The Two -Sample T Test Versus Satterthwaite's Approximate 
F Test Article. Communication in Statistics -Theory and Methods.1989;18(11):[ADDRESS_593232] JH, Gelenberg AJ, Katzelnick DJ, Jefferson JW, Modell JG. Feasibility and 
Validation of a Computer -Automated Columbia -Suicide severity Rating Scale Using Interactive 
Voice Response Technol ogy. J Psychiatr Res. 2010;44(16):1224 -8. 
Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of 
rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955 -2007. Arthritis 
Rheum. 2010;62:1576 -82. 
Pavy S, Brophy S , Calin A. Establishment of the minimum clinically important difference for the 
bath ankylosing spondylitis indices: a prospective study. J Rheumatol. 2005;32:80 -5. 
Pedersen SJ, Poddubmyy D, Sorensen IJ, Loft A -G, Hindrup JS, Thamsborg G, et al. Course of 
Magnetic Resonance Imaging -Detected Inflammation and Structural Lesions in the Sacroiliac 
Joints of Patients in the Randomized, Double -Blind, Placebo -Controlled Danish Multicenter 
Study of Adalimumab in Spondyloarthritis, as Assessed by [CONTACT_463211]. Arthritis and Rheumatology. 2016;68:418 -29.  
Poddubnyy D. Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet 
Dis. 2013;5:[ADDRESS_593233] of 
non-steroidal anti -inflammatory drugs on radiographic spi[INVESTIGATOR_58932]: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 
2012;71:1616 -22. 
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The 
Columbia -Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From 
Three Multisite Studies With Adolescents and Adults. Am J Psychiatry. 2011;168(12):12 66-77. 
Reilly MC, Zbronzek AS, Dukes EM. The Validity and Reproducibility of a Work Productivity 
and Activitiy Impairment Instrument. Pharmacoeconomics. 1993:4(5):353 -65. 
Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondyloarthritis in the Unit ed States: 
estimates from a cross -sectional survey. Arthritis Care Res (Hoboken). 2012;64:905 -10. 
Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral 
spondyloarthritis. Curr Opin Rheumatol. 2010;22:375 -80. 
Rudwaleit M, Haibe l H, Baraliakos X, Listing J, Märker -Hermann E, Zeidler H, et al. The early 
disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception 
Cohort. Arthritis Rheum. 2009a;60:[ADDRESS_593234], et al. The 
Assessment of SpondyloArthritis International Society classification criteria for peripheral 
spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25 -31. 
Rudwaleit M, Landewé R, van der Heijde D,  Listing J, Brandt J, Braun J, et al. The development 
of Assessment of SpondyloArthritis international Society classification criteria for axial 
spondyloarthritis (part I): classification of paper patients by [CONTACT_18430][INVESTIGATOR_18287].  Ann Rheum Dis. 2009b;68:770 -6. 
Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos -Vargas R, et al. The Assessment 
of SpondyloArthritis International Society (ASAS) handbook: a guide to assess 
spondyloarthritis. Ann Rheum Dis. 2009;68(Supple 2) :ii1-44. 
Stolwijk C, van Onna M, Boonen A, van Tubergen A. Global Prevalence of Spondyloarthritis: A 
Systematic Review and Meta -Regression Analysis. Arthritis Care Res (Hoboken). 2016; 
68(9):[ADDRESS_593235] DE, Alten R, Bingham C, Yocum D, Sloan V, et al. Standardizing 
assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology 
Common Toxicity Criteria v.2.0. J Rheumatol. 2007;34:1401 -14. 
van der Heijde D, Dougados M, Davis J, Weisman MH, Maksymowych W, B raun J, et al. 
Assessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of 
America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis 
Rheum. 2005;52:386 -94. 
van der Heijde D, Ramiro S, Landew é R, Baraliakos X, van den Bosch F, Sepriano A, et al. 2016 
update of the ASAS -EULAR management recommendations for axial spondyloarthritis. Ann 
Rheum Dis. 2017;76(6):978 -91. 
van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, et al. Adali mumab 
effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: 
long-term results from the ATLAS trial. Ann Rheum Dis. 2009;68:922 -9. 
van Tubergen A, Black PM, Coteur G. Are patient -reported outcome instruments for ankylosing 
spondylitis fit -for-purpose for the axial spondyloarthritis patient? A Qualitative and 
Psychometric Analysis. Rheum. 2015;54:1842 -51. 
van Tubergen A, Debats I, Ryser L, Londoño J, Burgos -Vargas R, Cardiel MH, et al. Use of a 
numerical rating sca le as an answer modality in ankylosing spondylitis -specific questionnaires. 
Arthritis Rheum. 2002a;47:242 -8. 
van Tubergen A, Coenen J, Landewé R, Spoorenberg A, Chorus A, Boonen A, et al. Assessment 
of fatigue in patients with ankylosing spondylitis: a psy chometric analysis. Arthritis Rheum. 
2002b;47:8 -16. 
Vender R, Lynde C, Ho V, Chau D, Poulin -Costello M. Work productivity and healthcare 
resource utilization outcomes for patients on etanercept for moderate -to-severe plaque psoriasis: 
Results from a [ADDRESS_593236] Health 
Econ Health Policy. 2012:10(5):[ADDRESS_593237] MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, et al. American College of 
Rheumatology/Spondylitis Association of America/Spondy loarthritis Research and Treatment 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 124 of 187 Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and 
Nonradiographic Axial Spondyloarthritis. Arthritis Rheum. 2015;2016 Feb;68(2):282 -98. 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 125 of 187 19 APPENDICES  
19.1 ASAS classification criteria for axial SpA  
Table 19‒1: ASAS classification criteria for axial SpA (for subjects with 
chronic back pain of at least 3 months and age at onset <45 years)  
Imaging criteria  ASAS clinical  criteria for axial SpA  
Sacroiliitis (MRI or radiographsa) plus ≥1 SpA feature  HLA -B27 plus ≥2 other SpA features  
SpA featuresb  
Inflammatory back painc  Psoriasis  
Arthritis  Crohn’s disease/ulcerative colitis  
Enthesitis (heel)  HLA -B27 
Uveitis  Elevated CRP  
Dactylitis   
ASAS=Assessment of SpondyloArthritis International Society; axSpA=axial spondyloarthritis; CRP=C -reactive 
protein; HLA -B27=human leukocyte antigen B27; MRI=magnetic resonance imaging; NSAID=nonsteroidal 
anti-inflammatory drug; Sp A=spondyloarthritis  
a Active inflammatory lesions of sacroiliac joints with definite bone marrow oedema/osteitis suggestive of 
sacroiliitis associated with spondyloarthritis in MRI or radiographic sacroiliitis Grade 2 to 4 bilaterally or 
Grade  3 to 4 unilaterally according to modified NY criteria. For this study, only MRI will be permitted for 
study entry for the imaging criterion.  
b “Family history for SpA” and “Good response to NSAIDs” are excluded as SpA feature criteria.  
c Inflammatory back pain ac cording to ASAS criteria for axSpA defined as the presence of 4 out of 5 of the 
following parameters:  
1. age at onset <[ADDRESS_593238]  
5. pain at night (with improvement upon getting up)  
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 126 of 187 19.2 Modified [LOCATION_001] (mNY) Classification Criteria for AS  
Table  19‒2: Modified [LOCATION_001] (mNY) Classification Criteria for AS  
Diagnosis  
Clinical criteria:  
a. Low back pain and stiffness for more than [ADDRESS_593239] expansion relative to normal values correcte d for age and sex.  
Radiologic criterion:  
Sacroiliitis grade ≥[ADDRESS_593240] 1 clinical 
criterion  
AS=ankylosing spondylitis; mNY=modified [LOCATION_001] Criteria  
Note: A second grading of “probable ankylosing spondylitis” is part of the modified NY criteria, but it is not 
applicable for this study.  
 
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593241] on erosions and fatty 
lesions at Week 16. Additionally, including MRI -positive and MRI -negative subjects in the 
substudy was considered a more holistic strategy comparable to the a pproach used for other 
compounds. At the same time, the number of participating subjects will be expanded to include 
subjects in the substudy without restriction.  
Further key changes are summarized below. The amendment:  
• Clarifies that the minimum duration of the Screening Period of 14 days does not apply to 
screenfailed subjects from AS0010 who are screened for AS0011.  
• Changes the categorization of PHQ -9 from an other efficacy variable to an other safety 
variable for consistency within the program.  
• Clarifies that protected adults will not be enrolled in the study.  
• Clarifies that subjects with a diagnosis of PsA will be excluded from the study as per the 
revised Exclusion Criterion 17.  
• Adds new sections summarizing all within -study rescreening/retes ting and cross -study 
screening rules in one place and updates corresponding protocol sections.  
• Updates the IMP description for consistency within the program.  
• Updates for clarification and adds more detail to sections presenting exclusionary, 
concomitant, or rescue medication.  
− To clarify that permitted acetaminophen/paracetamol serve as examples for the larger 
group of analgesics and are permitted as rescue therapy except for 24  hours prior to any 
study visit.  
− To add that topi[INVESTIGATOR_12977].  
− To clarify that any change in dose/dose regimen of oral corticosteroids within 14 days 
prior to Baseline is exclusionary.  
− To clarify that apremilast used as a rescue medication can be dosed as per Investigator’s 
discretion or local label.  
− To clarify that the use of more than [ADDRESS_593242] not 
meeting the related Inclusion criterion is exclusionary.  
• Restructures sections related to exclusionary, concomitant medication, or rescue medication 
to allow a side by [CONTACT_463212].  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 128 of 187 • Clarifies that the 12 -item MOS Sleep Scale is rated using the 5 -point scale.  
• Removes the option for enrollment in a separate observational pregnancy follow -up study 
sponsored by [CONTACT_18338].  
• Updates statistical terminology and replaces “sensitivity analyses” with “supportive 
analyses”.  
• Increases the threshold for subgroup analyses by [CONTACT_463213] 2 to 5 years.  
• Updates the section detailing the status of bimekizumab studies.  
• Updates the list of references.  
• Updates instances of “AS” in the summary and introduction to clarify that “AS” is also 
known as “radiographic axSpA”.  
• Updates instances of “ASAS criteria” to “ASAS classification criteria” for consistency where 
applicable.  
In addition, a few minor updates including consistency changes for  PDILI -related text, contact 
[CONTACT_8972], the list of abbreviations, and minor formatting changes for the purpose of clarity have 
been made.  
Modifications and changes  
Global changes  
The following changes were made throughout the protocol:  
• All instances that re ferred to “legal representatives” were updated to remove this terminology 
from the entire protocol. Protected adults will not be enrolled in the study.  
• All instances that referred to a minimum of [ADDRESS_593243] been 
updated to clarif y that this requirement does not apply to screenfailed subjects from AS0010 
who are screened for AS0011. The minimum requirement is still applicable to all other 
subjects.  
• All instances of “sensitivity analysis” were replaced with “supportive analysis”. The revision 
corresponds to the structure of study estimands described in the ICH E9 (R1) Addendum.  
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 129 of 187 Specific changes  
Change #[ADDRESS_593244]  
Slough SL1 3WE  
UNITED KINGDOM  
 
Has been changed to:  
 
UCB BIOSCIENCES GmbH  
Alfred -Nobel -Straße [ADDRESS_593245]  
Raleigh,  NC [ZIP_CODE]  
UNITED STATES  
 
Has been changed to:  
 
UCB BIOSCIENCES Ltd.  
[ADDRESS_593246]  
Slough SL1 3WE  
UNITED KINGDOM  
 
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 130 of 187 Change #2  
Section 1, Summary, paragraph 1 sentence 1 and paragraph 7  
This is a multicenter, Phase  3, randomized, double -blind, placebo -controlled study to evaluate 
the efficacy and safety of bimekizumab in subjects with active ankylosing spondylitis (AS), a 
subtype of axial spondyloarthritis (axSpA) with radiographic evidence of disease.  
... 
The overa ll study design consists of a Screening Period (≥14 days to ≤35 days), a 16 -week 
Double -Blind Treatment Period, a 36 -week Maintenance Period, and a Safety Follow -Up (SFU) 
Visit [ADDRESS_593247]  (IMP ) .... 
Has been changed to:  
This is a multicenter, Phase 3, randomized, double -blind, placebo -controlled study to evaluate 
the efficacy and safety of bimekizumab in subjects with active ankylosing spondylitis (AS), a 
subtype of axial spondyloarthritis (axSpA) with radiographic evidence of disease (also known as 
radiographic axSpA [r -axSpA]).  
... 
The overall study design consists of a Screening Period (minimum of  approximately  14 days 
[unless a screenfailed subject from AS0010 will be screened in AS0011]  to ≤35  days), a 
52-week Treatment Period consisting of  a 16-week Double -Blind Treatment Period, a 36 -week 
Maintenance Period, and a Safety Follow -Up (SFU) Visit [ADDRESS_593248]  (IMP) ...  
 
Change #3  
Section 2.1, Axial spondyloarthritis, paragraph 2, sentence 3  
Therefore, peripheral SpA includes diseases affecting mainly peripheral joints, such as reactive 
arthritis and PsA, whereas axSpA comprises those diseases with mainly axial involvement 
(sacroiliac joint s and spi[INVESTIGATOR_050]), including AS diagnosed with definite radiographic changes of the 
sacroiliac joint and nr -axSpA.  
Has been changed to:  
Therefore, peripheral SpA includes diseases affecting mainly peripheral joints, such as reactive 
arthritis and PsA, whereas axSpA comprises those diseases with mainly axial involvement 
(sacroiliac joints and spi[INVESTIGATOR_050]), including AS ( also known as r -axSpA ) diagnosed with definite 
radiographic changes of the sacroiliac joint and nr -axSpA.  
 
Change #4  
Section [IP_ADDRESS], Completed studi es, paragraph [ADDRESS_593249] been completed: UP0008 in 39 subjects with 
mild-to-moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with 
PsA, UP0031 in 12 healthy volunteers, UP0042 in 48 Japanese and Caucasian healthy 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 131 of 187 volunteers, RA0123 in 159 subjects with moderate -to-severe RA, PS0010 in 250 subjects with 
moderate -to-severe chronic plaque PSO, PS0016 in 49 subjects with moderate -to-severe chronic 
plaque PSO, and UC0011 in 23 subjects with moderate -to-severe active ulcerative colitis.  
Has been changed to:  
Nine  Thirteen  clinical studies of bimekizumab have been  completed: UP0008 in 39 subjects 
with mild -to-moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects 
with PsA, UP0031 in 12 healthy volunteers, UP0042 in 48 Japanese and Caucasian healthy 
volunteers, RA0123 in 159 subjects with modera te-to-severe RA, PS0010 in 250 subjects with 
moderate -to-severe chronic plaque PSO and the corresponding extension study (PS0011),  
PS0016 in 49 subjects with moderate -to-severe chronic plaque PSO and the corresponding 
extension study (PS0018) , UC0011 in 23  subjects with moderate -to-severe active ulcerative 
colitis, AS0008 in 303 subjects with AS, and PA0008 in 206  subjects with PsA.  
 
Change #5  
Section [IP_ADDRESS], Ongoing studies  
The following bullet has been deleted:  
• AS0008 is a Phase 2b, double -blind, randomi zed, placebo -controlled, multiple -dose study to 
evaluate the efficacy and safety of bimekizumab in subjects with active AS.  
 
The following bullet has been added:  
• AS0010 is a Phase 3, double -blind, randomized, placebo -controlled study to evaluate 
the effic acy and safety of bimekizumab in subjects with active nr -axSpA.  
 
Change #6  
Section 4.3.1, Other efficacy variables  
The following variable has been removed:  
• Change from Baseline in Patient Health Questionnaire -9 (PHQ -9) 
 
Change #7  
Section 4.3.2, Other safety variables  
The following variable has been added:  
• Change from Baseline in Patient Health Questionnaire -9 (PHQ -9) 
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 132 of 187 Change #8  
Section 5.1, Study description, paragraph 3  
The study will include the following 3 periods: a Screening Period (≥14 days to ≤3 5 days), a 
Treatment Period (52 weeks) consisting of a 16 -week Double -Blind Treatment Period and a 36 -
week Maintenance Period, and a SFU Period (20 weeks after the final dose of IMP).  
Has been changed to:  
The study will include the following 3 periods: a Screening Period (minimum of approximately 
14 days [unless a screenfailed subject from AS0010 will be screened in AS0011]  to 
≤35 days), a Treatment Period (52  weeks) consisting of a 16 -week Double -Blind Treatment  
Period and a 36 -week Maintenance Period, and a SFU Period (20 weeks after the final dose of 
IMP).  
 
Change #9  
Section 5.1.1, Screening Period/Baseline, paragraph [ADDRESS_593250] sentence  
Assessments of eligibility as described in Section 6 will be initiated during the Screening Period 
with a minimum duration of 14 days and a maximum duration of up to 35 days.  
Has been changed to:  
Assessments of eligibility as described in Section  6 will be initiated during the Screening Period 
with a minimum duration of approximately  14 days (unless a screenfailed subject from 
AS0010 will be screened in AS0011)  and a maximum duration of up to 35 days.  
The following paragraph was added:  
All subjects will have an anterior posterior (AP) pelvis or sacroiliac joint x -ray (read 
centrally) to determine eligibility as per mNY criteria. Subjects who are mNY -negative 
may be eligible for Screening in AS0010, a double -blind, ra ndomized, placebo -controlled 
Phase 3 study in subjects with active nr -axSpA. It is recommended to perform the 
sacroiliac joint x -ray prior to any other screening assessment to avoid repetition of 
screening assessments (applicable at sites participating in both Phase 3 studies).  
 
Change #10  
Section 5.1.1, Screening Period/Baseline, last paragraph  
Screening assessments for subjects previously screened for AS0010, who were not eligible for 
AS0010 and therefore entered Screening again for eligibility during th e Screening Period of 
AS0011, must be repeated unless defined otherwise. These cross -study rescreening rules 
pertaining to laboratory testing are provided in Section 12.6 and imaging is described in 
Section  9.21. 
Has been deleted.  
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 133 of 187 Change #11  
Section 5.1.1 , Screening Period/Baseline  
The following sections have been added.  
[IP_ADDRESS] Within -study rescreening/retesting requirements  
Rules for rescreening or repetition of screening tests within the study are listed below:  
• Subjects who fail to meet the eligibility criteria for BASDAI, spi[INVESTIGATOR_18172], PHQ -9, eC -SSRS, 
or the TB questionnaire are not allowed  to be rescreened.  
The Medical Monitor must be contact[CONTACT_463173]/retesting in all other 
cases.  
• Subjects who initia lly fail to meet selected eligibility criteria (eg, documented completion of 
latent tuberculosis infection [LTBI] prophylactic therapy) may be rescreened.  
• Subjects for whom eligibility assessments could not be completed as planned (eg, for 
technical reason s) within the defined Screening Period of 35 days may be rescreened.  
• Subjects with individual laboratory screening tests for which the results are exclusionary, can 
be retested.  
Of note, repetition of laboratory screening tests within the Screening Perio d is permitted for 
technical reasons (eg, frozen sample, expi[INVESTIGATOR_463122]) without contact[CONTACT_463174].  
[IP_ADDRESS] Cross -study screening requirements  
Screening assessments for subjects previously screened for AS0010, who were not eligible for 
AS0010 based on mNY criteria and therefore entered AS0011 Screening for eligibility, must be 
repeated during the Screening Period unless defined in Table  5‒1. The Medical Monitor must be 
contact[CONTACT_463175].  
Table 5 -1: Cross -study screening requirements  
Assessmen t  Screening requirements  
Cross -study screening is not permitted in the following cases:  
BASDAI and 
spi[INVESTIGATOR_463123] a subject not eligible for AS0010 who will be screened for AS0011, 
and who did not meet the related Inclusion Criteria in AS0010.  
PHQ -9, eC -SSRS, 
TB questionnaire 
(Q1)  Screening of a subject not eligible for AS0010 who will be screened for AS0011, 
and who did not meet the related Exclusion Criteria in AS0010.  
Cross -study screening is permitted in the following cases:  
CRP  If a subject not eligible for AS0010 will be screened for AS0011, the Screening 
CRP testing must be repeated during Screening for AS0011 only if the result is 
older than 35 days at time of randomization at Baseline ( Section  12.6). 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 134 of 187 Table 5 -1: Cross -study screening requirements  
Assessmen t  Screening requirements  
Cross -study screening is not permitted in the following cases:  
All safety 
laboratory 
assessments  If a subject not eligible for AS0010 will be screened for AS0011, the Screening 
safety laboratory testing (hematology, biochemistry, urinalysis,  urine drug 
screen, pregnancy testing as applicable, HIV, Hepatitis B and C, and IGRA TB 
testing) and HLA -B27 testing must be repeated only during Screening for 
AS0011 if the results are older than 35 days at time of randomization at Baseline 
(Section  12.6). 
Anterior posterior 
pelvis x -ray The following will be accepted to qualify subjects with AS for this study: 
Anterior posterior pelvis x -ray centr ally read for AS0010 and determined to be 
modified [LOCATION_001] Criteria positive (+mNY); neither the x -ray nor the reading 
will be repeated ( Section  9.20). The central imaging reader needs to be informed 
by [CONTACT_463176]0010 to AS0011.  
AS=ankylosing spondylitis; BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; CRP=C -reactive 
protein; eC -SSRS=electronic Columbia -Suicide Severity Rating Scale; HIV=human immunodeficiency virus; 
HLA -B27=human leukocyte antigen B27; IGRA=Interferon -Gamma Release Assay; mNY=modified New 
York; PHQ -9=Patient Health Questionnaire 9; Q=question; TB=tuberculosis  
 
Change #12  
Section [IP_ADDRESS], Double -Blind Treatment Period, paragraph 3  
Visit windows of ±[ADDRESS_593251] dose at all visits through Week 16. The visit 
window is relative to the Baseline Visit, not the previous study visit. The time between doses 
should be ≥25  days and ≤31 days.  
Has been changed to:  
Visit windows of ±[ADDRESS_593252] dose at all visits through Week 16. The visit 
window is relative to the Baseline Visit, not the previous study visit. The time between doses 
should be ≥25  days and ≤[ADDRESS_593253] be 
ensured that the time between these 2 visits does not exceed  the allowed time between 
doses.  
 
Change #13  
Section [IP_ADDRESS], Maintenance Period, paragraph 3  
Visit windows of ±4 days are allowed for all visits after Week 16. The time betw een doses 
during the Maintenance Period should be ≥24  days and ≤32 days.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 135 of 187 Has been changed to:  
Visit windows of ±4 days are allowed for all visits after Week 16. The time between doses 
during the Maintenance Period should be ≥24  days and ≤[ADDRESS_593254] be ensured that the time between these 2 visits does not exceed  the 
allowed time between doses.  
 
Change #[ADDRESS_593255] been re -numbered and in -text references were updated.  
 
Change #[ADDRESS_593256], bullet #1  
• Screening Period: ≥14 days to ≤35 days  
Has been changed to:  
• Screening Period: minimum duration of a pproximately  14 days (unless a screenfailed 
subject from AS0010 will be screened in AS0011)  to ≤35 days  
 
Change #16  
Section 5.1.6, Planned number of subjects and site(s)  
Approximately 300 subjects will be randomly assigned in a 2:1 ratio to the following t reatment 
groups: bimekizumab 160mg  sc Q4W (200 subjects) or placebo sc  Q4W (100 subjects). The 
planned number of study sites is approximately 85.  
Has been changed to:  
Approximately 300 subjects will be randomly assigned in a 2:1 ratio to the following treatment 
groups: bimekizumab 160mg  sc Q4W (200 subjects) or placebo sc  Q4W (100 subjects). The 
planned number of study sites is approximately 85 95.  
 
Change #[ADDRESS_593257] dose of IMP. If 
preferred, the sacroiliac joint and spi[INVESTIGATOR_463153]. Further sacroiliac joint and sp ine MRIs will be performed at Weeks 16 and 52, within a 
window of ±5 days for sacroiliac joint MRI -positive subjects at Baseline participating in the 
substudy.  
Has been changed to:  
n If a subject has had a recent x -ray of the chest within [ADDRESS_593258] dose of IMP. If 
preferred , The sac roiliac joint and spi[INVESTIGATOR_463154]. Further sacroiliac joint and spi[INVESTIGATOR_463127] 16 
and 52, within a window of ±5 days for all subjects participating in the substudy.  
 
Chang e #[ADDRESS_593259] (IRB)/Independent Ethics Committee (IEC) approved written 
Informed Consent form is signed and dated by [CONTACT_29254].  
2. Subject/legal representative is consider ed reliable and capable of adhering to the protocol 
(eg, able to understand and complete diaries), visit schedule, or medication intake according 
to the judgment of the Investigator.  
Have been changed to:  
1a. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written 
Informed Consent form is signed and dated by [CONTACT_29254] . 
2a. Subject /legal representative  is considered reliable and capable of adhering to the  protocol 
(eg, able to understand and complete diaries), visit schedule, or medication intake according 
to the judgment of the Investigator.  
 
Change #19  
Section 6.2, Exclusion criteria #3 and #[ADDRESS_593260] previously participated in another study of a medication (systemic) under 
investigation within the [ADDRESS_593261] 5 half -lifes prior to the Screening Visit, 
whichever is greater, or is currently participating in another study of a medication (systemic) 
under investigation, with the exception of subjects who were screen failures in AS0010.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593262] has a diagnosis of inflammatory conditions other than AS, including but not limited 
to rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus, and reactive arthritis. 
Subjects with a diagnos is of Crohn’s disease, ulcerative colitis, or other IBD are allowed as 
long as they have no active symptomatic disease at Screening or Baseline.  
Has been changed to:  
3a. Subject previously participated in another study of a medication (systemic) under 
investigation within the [ADDRESS_593263] 5 half -lifes prior to the Screening  Baseline  Visit, 
whichever is greater, or is currently participating in another study of a medication (systemic) 
under investigation, with the exception of subjects who were scree n failures in AS0010.  
17a. Subject has a diagnosis of inflammatory conditions other than AS, including but not limited 
to psoriatic arthritis , rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus, and 
reactive arthritis. Subjects with a diagnosi s of Crohn’s disease, ulcerative colitis, or other 
IBD are allowed as long as they have no active symptomatic disease at Screening or 
Baseline.  
 
Change #20  
Section 6.3.1, Potential drug -induced liver injury IMP discontinuation criteria  
Subjects with potent ial drug -induced liver injury (PDILI) must be assessed to determine if IMP 
must be discontinued. In addition, all concomitant medications and herbal supplements that are 
not medically necessary should also be discontinued.  
The PDILI criteria below require  immediate and permanent discontinuation of IMP for subjects 
with either of the following:  
• ALT or AST ≥8x ULN  
• ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN  
The PDILI criterion below requires immediate discontinuation of IMP for:  
• Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without cle ar 
alternative cause), rash, or eosinophilia (ie, >5%).  
… 
Evaluation of PDILI must be initiated as described in Section  12.6.[ADDRESS_593264] reduced to <5xULN, the subject can 
continue with the study. However, if ALT or AST remains ≥5xULN and <8xULN after re -test, 
IMP should be temporarily withheld and subject should undergo a repeat te st in [ADDRESS_593265] values remain ≥5xULN even after the second re -test, then the subject should be 
permanently withdrawn from IMP and should be followed for possible PDILI.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 138 of 187 Has been changed to:  
Subjects with potential drug -induced liver injury (P DILI) must be assessed to determine if IMP 
must be discontinued. In addition, all concomitant medications and herbal supplements that are 
not medically necessary should also be discontinued.  
The PDILI criteria below require immediate and permanent  discont inuation of IMP for subjects 
with either of the following:  
• ALT or AST ≥8x ULN  
• ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN  
The PDILI criterion below requires immediate discontinuation of IMP for:  
• Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without cle ar 
alternative cause), rash, or eosinophilia (ie, >5%).  
… 
Evaluation of PDILI must be initiated as described in Section  12.6.[ADDRESS_593266] reduced to <5xULN, the subject can 
continue with the study. However, if ALT or AST remains ≥5xULN and <8xULN after re -test, 
IMP should be temporarily withheld and subject should undergo a repeat te st in [ADDRESS_593267] values remain ≥5xULN even after the second re -test, then the subject should be 
permanently withdrawn  immediately discontinued  from IMP and should be followed for 
possible PDILI.  
 
Change #[ADDRESS_593268] bullet  
•  
 
 
Has been changed to:  
•  
 
 
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 139 of 187 Change #22  
Section 7.8, Concomitant medications/treatments, paragraph 2  
The following sentence has been added.  
Medications listed in Table  7‒2 are prohibited, restri cted, or used as nonbiologic rescue 
therapy.  
 
Change #23  
Section 7.8, Concomitant medications/treatments, paragraph 2  
Table  7‒2 has been amended to include exclusionary and nonbiologic rescue therapy.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  140 of 187 Table 7 -2: Exclusionary, concomitant, and rescue medication  
Drug class/dose  Exclusion criteria  Study visits/during the 
study  Nonbiologic rescue therapy as add -on therapy 
to bimekizumab from Week 20 or latera 
Analgesics  
• Acetaminophen/  
paracetamol  Any change in dose/dose 
regimen within 14  days 
prior to BL  Stable dose/regimen permitted  
Ad hoc/PRN/“as needed use” 
permitted, but:  
No ad hoc/PRN/“as needed use” 
in the 24h prior to any study visit  Ad hoc/PRN/“as needed use” permitted, but:  
No ad hoc/PRN/“as needed use” in the 24h prior to 
any study visit  
 
NSAID/COX -2 inhibitors  Any change in dose/dose 
regimen within 14  days 
prior to BL Stable dose/ regimen permitted  
No change until Week 20 Visit  Nonbiologic rescue therapy will be at the 
Investigator’s discretion with the following options for 
symptoms:  
• For subjects taking an NSAID/COX -2 inhibitor 
dosing can be optimized; a change can be made to 
a different NSAID/COX -2 inhibitor; changes 
from an NSAID to a COX -2 inhibitor or from a 
COX -2 inhibitor to an NSAID are also permitted 
up to the maximum approved or tolerated dose, 
whichever is lower. Only 1  NSAID/COX -2 
inhibitor may be taken at  a given time.  
• For subjects not taking NSAID/COX -2 inhibitors 
either 1  NSAID, or 1  COX -2 inhibitor can be 
initiated, up to the maximum approved or 
tolerated dose, whichever is lower. Only 
1 NSAID/COX -2 inhibitor may be taken at a 
given time.  
• For subjects w ho cannot take NSAIDs/COX -2 
inhibitors, topi[INVESTIGATOR_463129] a potential 
nonbiologic rescue therapy in regions where they 
are approved, up to the maximum approved or 
tolerated dose, whichever is lower.  
Mild potency opi[INVESTIGATOR_463155]:  
• Tramadol/any  dose up to 
maximum approved dose  
• Codeine/o nly <90mg of 
codeine per dosage unit  Any change in dose/dose 
regimen within 14  days 
prior to BL  Dosing/schedule should remain 
stable for the first 20 weeks of 
the study  Prohibited  for rescue therapy  
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  141 of 187 Table 7 -2: Exclusionary, concomitant, and rescue medication  
Drug class/dose  Exclusion criteria  Study visits/during the 
study  Nonbiologic rescue therapy as add -on therapy 
to bimekizumab from Week 20 or latera 
Oral corticosteroids/average daily 
dose of ≤10mg/day prednisone or 
equivalent  Any change in dose/dose 
regimen within 14  days 
prior to BL  Permitted, but:  
• No steroid bursts/tapers  
• No increase in steroid 
dosing  
• No initiation of steroids 
until the Week 20 Visit  Prohibited  for rescue therapy  
Topi[INVESTIGATOR_463131]:  
• Intramuscular  
• Intravenous  
• Intra -articular  
• Bursal  
 Use within 28 days prior to 
BL Prohibited unless used as rescue 
therapy from Week 20 or later  Nonbiologic rescue therapy will be at the 
Investigator’s discretion with the following options for 
symptoms:  
• Sacroiliac joint steroid injection(s), either 
unilateral or bilateral.  
For non -axial symptoms:  
• One peripheral joint (or bursa) may be injected 
with a steroid at or after any visit where 
nonbiologic rescue therapy eligibility is assessed; 
however, the same joint may not be injected more 
than once during the study and should not be 
injected within 4  weeks of a sacroiliac joint 
injection(s).  
Intra -articular hyaluronic acid  Use within 8 weeks prior 
to the BL Visit or during 
the study  Prohibited  Not applicable  
Any established antidepressant 
regimen  Any change in dose/dose 
regimen within 8 weeks 
prior to BL  Permitted  Not applicable  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  142 of 187 Table 7 -2: Exclusionary, concomitant, and rescue medication  
Drug class/dose  Exclusion criteria  Study visits/during the 
study  Nonbiologic rescue therapy as add -on therapy 
to bimekizumab from Week 20 or latera 
csARDs/formerly known as 
DMARDs     
• Azathioprine  
• Cyclosporine  
• Cyclophosphamide  
• Mycophenolic acid  
• Mycophenylate mofetil  
• Any other small molecule 
DMARDs  Use within 8  weeks prior 
to BL  Prohibited  Prohibited  for rescue  
• Methotrexate (MTX)  
 Use within 12 weeks prior 
to BL  unless Inclusion 
Criterion #9  is met  Permitted  
MTX (≤25mg/week)  For non -axial symptoms:  
• MTX may be added or increased to a maximum 
dose of 25mg/week, or the maximum tolerated 
dose, whichever is lower, in accordance with local 
standard of care. The route o f administration may 
be changed from oral to sc or from sc to oral, at 
any visit at Week 20 or later. It is strongly 
recommended that subjects taking MTX are also 
taking folic acid supplementation.  
• Leflunomide (LEF)  Use in the 6 months prior 
to the BL Visit (unless a 
cholestyramine washout 
has been performed; in 
which case, use up to 
28 days prior to the BL 
Visit is acceptable) unless 
Inclusion Criterion 
Criterion #9  is met  Permitted  
LEF (≤20mg/day or an average 
of 20mg/day if not dosed daily)  For non -axial symptoms:  
• Leflunomide may be given at a maximum dose of 
20mg/day (or an average of 20mg/day if not 
dosed daily), or the maximum tolerated dose, 
whichever is lower.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  143 of 187 Table 7 -2: Exclusionary, concomitant, and rescue medication  
Drug class/dose  Exclusion criteria  Study visits/during the 
study  Nonbiologic rescue therapy as add -on therapy 
to bimekizumab from Week 20 or latera 
• Hydroxychloroquine (HCQ) 
(and other anti -malarials)  
• Sulfasalazine (SSZ)  
• Apremilast  
 Use within 8 weeks prior 
to BL  unless Inclusion 
Criterion #10  is met Permitted  For non -axial symptoms:  
• HCQ may be added or increased to a maximum 
dose of 400mg/day or the maximum tolerated 
dose, whichever is lower. Other anti -malarials 
may be used in accor dance with local standard of 
care.  
• SSZ may be added or increased up to a maximum 
dose of 3g/day (up to 4g/day if in accordance with 
local standard of care), or the maximum tolerated 
dose, whichever is lower.  
• Apremilast may be given at a maximum dose of 
60mg/day and dosed as per Investigator’s 
discretion or local label.  
Combination DMARDs are allowed except that LEF 
and MTX may not be given together.  
JAK inhibitors     
• Eg, tofacitinib  
• Upadacitinib  Use within 8 weeks prior 
to BL  Prohibited  Not applicable  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  144 of 187 Table 7 -2: Exclusionary, concomitant, and rescue medication  
Drug class/dose  Exclusion criteria  Study visits/during the 
study  Nonbiologic rescue therapy as add -on therapy 
to bimekizumab from Week 20 or latera 
Biologic DMARDs     
TNFα inhibitors:  
• Infliximab (IFX)  
• Golimumab (GOL)  
• Certolizumab pegol (CZP)  
• Adalimumab (ADA)  
• Etanercept (ETN)  
• Biosimilar versions of any 
TNFα inhibitor  For IFX, ADA, GOL, and 
CZP, any use within the 
12 weeks prior to the BL 
Visit  
For ETN, use within the 
28 days prior to the BL 
Visit  
Any use of >1 TNFα in the 
history  
Subjects not meeting 
Inclusion Criterion #11.  Prohibited  Not applicable  
Other biologics:  
• Abatacept  Any use within 12 weeks 
prior to BL  Prohibited  Not applicable  
• Alefacept    
• Efalizumab    
• Guselkumab    
• Sarilumab    
• Sirukumab    
• Tocilizumab    
• Others in development 
targeting IL -6 or IL -6R   
• Ustekinumab  
 Any use within 24  weeks 
prior to BL  Prohibited  Not applicable  
• Tildrakizumab  Any use within 4  months 
prior to BL  Prohibited  Not applicable  
• Risankizumab  Any use within 5  months 
prior to BL  Prohibited  Not applicable  
• Briakinumab  
 Any use within 6  months 
prior to BL  Prohibited  Not applicable  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  145 of 187 Table 7 -2: Exclusionary, concomitant, and rescue medication  
Drug class/dose  Exclusion criteria  Study visits/during the 
study  Nonbiologic rescue therapy as add -on therapy 
to bimekizumab from Week 20 or latera 
• Rituximab (incl. biosimilars), 
ocrelizumab  Any use within 12  months 
prior to BL Prohibited  Not applicable  
Anti -IL-17 therapy:  
• Bimekizumab  
• Secukinumab  
• Ixekizumab  
• Brodalumab  
• Others in development  Any exposure history  Prohibited  Not applicable  
BL=Baseline; ADA=adalimumab; COX -2=cyclooxygenase 2; csARD=conventional synthetic antirheumatic drug; CZP=certolizumab pegol; 
DMARD=disease -modifying antirheumatic drug; ETN=etanercept; GOL=golimumab; h=hour; HCQ=hydroxychloroquine; IFX=infliximab; JAK=Janus 
kinase; LEF=leflunomide; IL=interleukin; MTX=methotrexate; NSAID=nonsteroidal a nti-inflammatory drug; PRN=as needed; sc=subcutaneous; 
SSZ=sulfasalazine; TNFα=tumor necrosis factor alpha  
a Note: any medication not listed here for rescue therapy must be approved by [CONTACT_463191]. 
 
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 146 of 187 Change #24  
Section 7.8.1, Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])  
The following paragraphs have been moved to Table  7‒2. 
Subjects are allowed to use acetaminophen/paracetamol as needed except that PRN/as needed 
doses are not permitted within 24 hours before a study visit where efficacy assessments are 
performed . 
Mild potency opi[INVESTIGATOR_463156]/schedule should remain 
stable for the first 16 weeks of the study, but are not permitted as nonbiologic rescue therapy (see 
Section 5.1.3).  
No steroid bursts/tapers, increase in steroid d osing or initiation of steroids are permitted during 
the study.  
Subjects are permitted to decrease NSAID/COX -2 medications, analgesics (including opi[INVESTIGATOR_2438]), 
DMARD(s) and/or oral corticosteroids and/or alter their regimen only at/after the Week 20 Visit 
except for reasons of intolerance/AEs/side effects.  
Subjects who are receiving an established antidepressant regimen should be on a stable dose of 
the antidepressant for 8 weeks prior to Baseline.  
The following paragraph has been changed to:  
Whenever possible,  physical therapy/physiotherapy/non -medication/complementary and 
alternative treatment(s) (including traditional Chinese medications) of AS should remain stable 
through the Week 16 20 Visit.  
The following paragraph has been deleted:  
Subjects may be withdr awn from IMP at any time and continue treatment using other treatment 
options per the Investigator’s discretion, as described in the Withdrawal criteria Section 6.3.  
 
Change #25  
Section 7.8.2, Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014])  
Medications listed in Table 7‒2 are prohibited or restricted as follows:  
Has been changed to:  
Prohibited concomitant treatments are described in Table  7‒2. 
 
Change #26  
Section 7.8, Concomitant medications/treatments  
The following changes have been made and are included in Table  7‒2. 
• The dosing/schedule of mild potency opi[INVESTIGATOR_463157] 16 20 weeks 
of the study  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 147 of 187 • Any change in dose/dose regimen of oral corticosteroids within 14 days prior to BL is 
exclusionary.  
• Intramuscular, intravenous, intra -articular, and bursal corticosteroids use  is prohibited unless 
used as rescue therapy.  
• Any use of >1 TNFα in the history is exclusionary.  
• Subjects not meeting Inclusion Criterion # 11 are excluded.  
• Apremilast may be given at a maximum dose of 60mg/day and dosed as per Investigator’s 
discretion or local label.  
 
Change #27  
Section 7.8.2, Prohibited concomitant treatments (med ications and therapi[INVESTIGATOR_014]), Table 7 -2 
The outdated Table  7‒2 has been deleted . 
 
Change #28  
Section 7.8.3, Nonbiologic rescue therapy  
The section has been mov ed from Section 5.1.3 to Section 7.8. The following text has been 
added:  
Nonbiologic rescue therapy will be at the Investigator’s discretion as add -on therapy to 
bimekizumab at any time from Week 20 or later as described in Table  7‒2. 
 
Change #29  
Section 8, Study procedures by [CONTACT_765], paragraph 2  
Visit windows are ±3 days from Baseline (Day 1, first dose of IMP) at all visits through the 
Week  16 Visit and ±4 days from all visits thereafter. For the SFU Visit (20 weeks after the final 
dose), the visit should occur no more than 3 days prior to the sc heduled visit date and within 
7 days after the scheduled visit date ( -3 days/+7 days). The minimum amount of time between 
bimekizumab doses should be no less than 25  days and no more than 31  days from Baseline to 
Week 16 and 24 to 32  days thereafter.  
Has been changed to:  
Visit windows are ±3 days from Baseline (Day 1, first dose of IMP) at all visits through the 
Week  16 Visit and ±4 days from all visits thereafter. For the SFU Visit (20 weeks after the final 
dose), the visit should occur no more than 3 day s prior to the scheduled visit date and within 
7 days after the scheduled visit date ( -3 days/+7 days). The minimum amount of time between 
bimekizumab doses should be no less than [ADDRESS_593269] be 
ensured that the time between these 2 visits does not exceed  the allowed time between 
doses.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 148 of 187  
Change #30  
Section 8.1, Screening Visit (Visit 1), paragraph [ADDRESS_593270] for  a minimum of 14 days and up to a maximum of 35 days.  
Has been changed to:  
The Screening Period will last for a minimum of approximately  14 days ( unless a screenfailed 
subject from AS0010 will be screened in AS0011 ) and up to a maximum of 35 days.  
The following text has been added.  
An overview on rescreening/retesting requirements is provided in Section  [IP_ADDRESS]  and 
Section  [IP_ADDRESS] . 
 
Change #31  
Section 8.1, Screening Visit (Visit 1), bullet [ADDRESS_593271] and/or pulmonary physician and any 
significant finding is exclusionary. Any findings suggestive of active TB are exclusionary.  
Has been changed to:  
Obtain a chest x -ray, unless one has been obtained within [ADDRESS_593272] and/or pulmonary physician and any 
significant finding is exclusionary.  Any findings suggestive of acti ve TB are exclusionary.  
 
Change #32  
Section 9.7, MOS -12, paragraph 1, second sentence  
The frequency with which each problem has been experienced during the previous 4  weeks is 
rated on a 6 -point scale ranging from “none of the time” to “all of the time,” e xcept sleep 
quantity, which is reported in hours.  
Has been changed to:  
The frequency with which each problem has been experienced during the previous 4  weeks is 
rated on a 5-point scale ranging from “none of the time” to “all of the time,” except sleep 
quantity, which is reported in hours.  
 
Change #33  
Section 9.19, PHQ -9 
Has been moved from Section 9.19 to Section 12.7.7 without any content change.  
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 149 of 187 Change #34  
Section 9.19, Occurrence of extra -articular manifestations  
Information regarding dactylitis, PSO, uveitis, and IBD occurrences during the study will be 
captured as AEs. Enthesitis will be assessed regularly via the MASES performed at site visits as 
specified in Table  5-2.  
Has been changed to:  
Information regarding dactylitis, PSO, uveitis, and IBD occurrences  events during the study will 
be captured as AEs. Enthesitis will be assessed regularly via the MASES  performed at site visits 
as specified in Table  5-2.  
 
Change #35  
Section 9.20.1, Sacroiliac joint x -ray (AP Pelvis Joint Film for modified [LOCATION_001] Cr iteria, 
paragraph 2, bullet 1  
• Anterior posterior pelvis x -ray centrally read for one of the Phase 3 studies AS0010 or 
AS0011 and determined to be modified [LOCATION_001] Criteria positive (+mNY); neither the 
reading nor the x -ray will be repeated.  
Has been chang ed to:  
• Anterior posterior pelvis x -ray centrally read for one of the Phase 3 studies AS0010 or 
AS0011 and determined to be modified [LOCATION_001] Criteria positive (+mNY); neither the 
reading  x-ray nor the x-ray reading will be repeated.  
 
Change #[ADDRESS_593273] chronic bony changes (eg, sclerosis, erosions, bridging, and 
ankyloses), structural changes generally occur slowly and x -rays are insensitive; t herefore, 
changes are difficult to detect in the relatively short duration of a randomized clinical study. 
Unlike radiography, MRI can be used to visualize inflammation in the sacroiliac joints and spi[INVESTIGATOR_463158]. Inflammation of t he sacroiliac joints and spi[INVESTIGATOR_53553] a key feature of 
axSpA that is potentially amenable to treatment with bimekizumab. If bimekizumab is effective, 
it is expected that reduction in inflammation in the sacroiliac joints and spi[INVESTIGATOR_463159] 52 -week Treatment Period of this study. Recently, a Danish study 
demonstrated significant changes in in ASspi[CONTACT_9268] -a (Berlin modification) and SPARCC  MRI 
assessed inflammation scores and in SPARCC MRI -assessed erosion scores within 12 weeks 
after ini tiation of adalimumab (see below for further description of these MRI scoring methods). 
The researchers concluded that MRI -assessed structural lesions change rapi[INVESTIGATOR_463160] -modifying treatment in clinical tr ials (Pedersen et al, 
2016).  
... 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 150 of 187 Magnetic resonance imaging of the spi[INVESTIGATOR_58897] a substudy 
with approximately 15% of subjects at Baseline after confirmation of eligibility based on 
screening assessments and before the fi rst dose of IMP. If needed, the sacroiliac joint and spi[INVESTIGATOR_463161].  
... 
A central reader will assess the Baseline MRIs to identify MRI -positiv e subjects as per the 
OMERACT criteria. Further MRIs of the spi[INVESTIGATOR_463162] 16 
and Week 52 within a window of ±5 days only for those subjects who were MRI positive in the 
sacroiliac joint MRI at Baseline, and will be ce ntrally read.  
Has been changed to:  
While radiography can detect chronic bony changes (eg, sclerosis, erosions, bridging, and 
ankyloses), structural changes generally occur slowly and x -rays are insensitive; therefore, 
changes are difficult to detect in the  relatively short duration of a randomized clinical study. 
Unlike radiography, MRI can be used to visualize active  inflammation in the sacroiliac joints 
and spi[INVESTIGATOR_463137]. Inflammation of the sacroiliac joints and spi[INVESTIGATOR_53553] a key 
feature of axSpA that is potentially amenable to treatment with bimekizumab. If bimekizumab is 
effective, it is expected that reduction in inflammation in the sacroiliac joints and spi[INVESTIGATOR_463138] 52 -week Treatment Period of this study. Recently, a Danish study 
demonstrated significant changes in in ASspi[CONTACT_9268] -a (Berlin modification) and SPARCC  MRI 
assessed inflammation scores and in SPARCC  MRI-assessed erosion scores within 12 weeks 
after initiation of adalimumab (see below for furt her description of these MRI scoring methods). 
The researchers concluded that MRI -assessed structural lesions change rapi[INVESTIGATOR_463160] -modifying treatment in clinical trials (Pedersen et al, 
2016). In this stud y, MRI changes will be evaluated in the sacroiliac joint and spi[INVESTIGATOR_463163]. In addition, exploratory evaluation of 
other chronic MRI f eatures, such as erosions and fatty lesions, will be performed as 
indicators of disease modification associated with structural disease progression 
(Baraliakos et al, 2014).  
... 
Magnetic resonance imaging of the spi[INVESTIGATOR_463164]. If needed, the sacroiliac joint and spi[INVESTIGATOR_463165].  
A central reader will assess the Baseline MRIs to identify MRI -positive subjects as per the 
OMERACT criteria. Further MRIs of the spi[INVESTIGATOR_463143] -positive and 
MRI-negative subjects  will be performed at Week  16 and Week 52 within a window of ±[ADDRESS_593274]’s opportunity to part icipate 
in the main study.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 151 of 187 Change #37  
Section 10.2, Pharmacogenomic variables, paragraph 3, sentence 2  
...Candidate biomarker evaluations may include, but are not limited to, IL -17A/IL17 -F pathway 
signaling and AS biology (eg, IL -17A, IL -17F, IL -23, IL -6, tumor necrosis factor, dendritic cell -
specific transmembrane protein, and circulating osteoclast precur sors). ... 
Has been changed to:  
...Candidate biomarker evaluations may include, but are not limited to, IL -17A/IL -17F pathway 
signaling and AS axSpA  biology (eg, IL -17A, IL -17F, IL -23, IL -6, tumor necrosis factor, 
dendritic cell -specific transmembrane prot ein, and circulating osteoclast precursors). ... 
 
Change #[ADDRESS_593275] nor 
interfere with termination and follow -up procedures as described in protocol AS0011.  
This paragraph has been delet ed. 
 
Change #[ADDRESS_593276] of biochemistry, hematology, urinalysis, and pregnancy 
tests (serum or urine) ( Table  12‒2). A centralized laboratory will be used to supply all laboratory 
test supplies and analyze all blood and urine samples (except the urine pregnancy test). Any 
unscheduled laboratory testing should also be collected using the central laboratory (with the 
exception of urgent safety laboratory measurements which should be performed locally and 
centrally simultaneously). Testing to exclude hepatitis B, hepatitis C, and HIV (see Exclusion 
Criterion #12, Section  6.2) will be performed at Screening in addition to those measurements 
listed in Table 12‒2 . A urine dipstick will be used for pregnancy testing . Rescreening 
requirements pertaining to laboratory assessments are summarized below:  
• For CRP: If a subject will be rescreened for AS0011, the Screening CRP testing does not 
have to be repeated during Scree ning for AS0011 if the result is not older than [ADDRESS_593277] be repeated.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 152 of 187 • For all safety laboratory assessments: If a subject from AS0010 will be rescreened for 
AS0011, the Screening safety laborator y testing (hematology, biochemistry, urinalysis, urine 
drug screen, pregnancy testing as applicable, and IGRA TB testing) does not have to be 
repeated during Screening for AS0011 if the results are not older than [ADDRESS_593278] 
be repeated.  
Has been changed to:  
Clinical laboratory assessments consist of biochemistry, hematology, urinalysis, and pregnancy 
tests (serum or urine) ( Table  12‒2). A centralized laboratory will be used to supply all laboratory 
test supplies and analyze all blood and urine samples (except the urine pregnancy test). Any 
unscheduled laboratory testing should also be collected using the central laboratory (with the 
exception of urgent safety laboratory measurements which should be performed locally and 
centrally simultaneously). Testing to exclude hepatitis B, hepatitis C, and HIV (see Exclusion 
Criterion #12, Section  6.2) will be performed at Screening in addition to those measurements 
listed in Table 12‒2 . A urine dipstick will be used for pregnancy testing . Rescreening 
requirements pertaining to laboratory assessments are summarized below:  
Rescreening and retesting  rules are provided in Section  [IP_ADDRESS]  and Section  [IP_ADDRESS] . 
• For CRP: If a subject will be rescreened for AS0011, the Screenin g CRP testing does not 
have to be repeated during Screening for AS0011 if the result is not older than [ADDRESS_593279] be repeated.  
• For all safety laboratory assessments: If a subject from AS0010 will b e rescreened for 
AS0011, the Screening safety laboratory testing (hematology, biochemistry, urinalysis, urine 
drug screen, pregnancy testing as applicable, and IGRA TB testing) does not have to be 
repeated during Screening for AS0011 if the results are not  older than [ADDRESS_593280] 
be repeated.  
 
Change #[ADDRESS_593281] paragraph  
When IMP is stopped due to PDILI (as described in Section  6.3.1 ), IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings. If a 
subsequent a lternative diagnosis fully explains the hepatic findings, and the requirements 
provided in Section  [IP_ADDRESS].1  are met, rechallenge with IMP may be ap propriate.  
Has been changed to:  
When IMP is stopped due to PDILI (as described in Section  6.3.1 ), IMP must be permanently  
discontinued unless a sub sequent alternative diagnosis fully explains the hepatic findings. If a 
subsequent alternative diagnosis fully explains the hepatic findings, and the requirements 
provided in Section  [IP_ADDRESS].1  are met, rechallenge with IMP may be appropriate.  
 
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 153 of 187 Change #[ADDRESS_593282]  Total 
bilirubin  Symptomsa of 
hepatitis of 
hyper -
sensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
≥3xULN  ≥2xULNb NA Hepatology consultc 
Medical Monitor must 
be notified within 
24 hours (eg,  by 
[CONTACT_58980]) and 
subject discussed with 
Medical Monitor ASAP.  Immediate, 
permanent IMP 
discontinuation.  
 Essential: Must have 
repeat liver 
chemistry values and 
additional testing 
completed ASAP 
(see 
Section  [IP_ADDRESS]); 
recommended to 
occur at the site with 
HCP.  Monitoring o f liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within baseline 
values.d ≥3xULN  NA Yes 
≥8xULN  NA NA Need for hepatology 
consult to be discussed 
(required if ALT or AST 
≥8xULN)  
Medical Monitor must 
be notified within 
24 hours (eg,  by 
[CONTACT_58980]) and 
subject discussed with 
Medical Monitor ASAP.  Immediate, 
permanent IMP 
discontinuation  
 
≥5xULN 
(and ≥2x 
Baseline) 
and 
<8xULN  <2xULN  No Discussion with Medical 
Monitor required.  
Consider need for 
hepatology consult if 
there is no evidence of 
resolution (see Follow 
up requirements).c Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section  [IP_ADDRESS]).  
 
IMP discontinuation 
required if any of the 
following occur:  Essential: Every 
attempt must be 
made to have repeat 
liver chemistry 
values and 
additional testing 
completed within 
48 hours at the site 
with HCP (see 
Section  [IP_ADDRESS]).  Monitoring of liver chemistry 
values at least twice per week for 
2 weeks.d 
• Immediate IMP 
discontinuation required if 
liver chemistry values 
conti nue to increase.  
After 2 weeks of monitoring 
liver chemistry values:  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593283]  Total 
bilirubin  Symptomsa of 
hepatitis of 
hyper -
sensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
• Subject cannot 
comply with 
monitoring 
schedule.  
• Liver chemistry 
values continue 
to increase  
• Liver chemistry 
values remain 
≥5xULN (and 
≥2x baseline) 
after 4 weeks 
of monitoring 
without 
evidence of 
resolution  • ALT or AST remains 
≥5xULN <8xULN, IMP 
should be temporarily 
withheld and subject 
should undergo repeat test 
in [ADDRESS_593284] values <5xULN; 
continue to monitor at le ast 
twice per week until values 
normalize, stabilize, or 
return to within baseline 
values.  
If ALT or AST remains 
≥5xULN after second re -
test, immediate, permanent 
IMP discontinuation 
required.  
Continue to monitor until values 
normalize, stabilize, or retur n to 
within baseline values.d 
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page 155 of 187 Has been changed to:  
Laboratory value   Immediate  Follow up  
ALT or AST  Total 
bilirubin  Symptomsa of 
hepatitis or 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
≥3xULN  ≥2xULNb NA Hepatology consultc 
Medical Monitor must 
be notified within 
24 hours (eg,  by 
[CONTACT_58980]) and 
subject discussed with 
Medical Monitor ASAP.  
Need for hepatology 
consult to be discussed 
(required if ALT or AST 
≥8xULN).  
Medical Monitor must 
be notified within 
24 hours (eg,  by 
[CONTACT_58980]) and 
subject discussed with 
Medical Monitor ASAP.  Immediate permanent 
IMP discontinuation.d 
Immediate, permanent 
IMP discontinuation.  
 Essential: Must have 
repeat liver chemistry 
values and additional 
testing completed 
ASAP (see 
Section  [IP_ADDRESS] ); 
recommended to occur 
at the site with HCP.  Monitoring of liver 
chemistry values at least 
twice per week until values 
normalize, stabilize, or 
return to within baseline 
values.e ≥3xULN  NA Yes 
≥8xULN  NA NA 
≥5xULN (and 
≥2x baseline) 
and <8xULN  <2xULN  No Discussion with Medical 
Monitor required.  
Consider need for 
hepatology consult if 
there is no evidence of 
resolution (see Follow 
up requirements).c Further investigation – 
immediate IMP 
discontinuation not 
required  (see 
Section  [IP_ADDRESS] ). 
 
IMP discontinuation 
required if any of the 
following occur:  
 
• Subject cannot 
comply with 
monitoring schedule.  Essential: Every 
attempt must be made 
to have repeat liver 
chemistry values and 
additional testing 
completed within 
48 hours at the site 
with HCP (see 
Section  [IP_ADDRESS] ). Monitoring of liver 
chemistry values at least 
twice per week for 2 weeks.e 
• Immediate IMP 
discontinuation required 
if liver chemistry values 
continue to increase.  
After 2 weeks of monitoring 
liver chemistry values:  
• ALT or AST remains 
≥5xULN <8xULN, IMP 
should be temporarily 
withheld and subject 
should undergo repeat 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593285]  Total 
bilirubin  Symptomsa of 
hepatitis or 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
• Liver chemistry 
values continue to 
increase.  
• Liver chemistry 
values remain 
≥5xULN (and 
≥2x baseline) after [ADDRESS_593286] values 
<5xULN; continue to 
monitor at least twice 
per week until values 
normalize, stabilize, or 
return to within baseline 
values.  
 
If ALT or AST remains 
≥5xULN after second 
re-test, immediate,  
permanent  IMP 
discontinuation 
required.  
Continue to monitor until 
values normalize, stabilize, 
or return to within baseline 
values.e 
 
 
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  157 of 187 Change #42  
Section 12.6.1, Evaluation of PDILI, Table 12 -3, footnotes  
The following footnote has been added:  
d Details are provided in Section  [IP_ADDRESS] . 
Subsequent footnotes have been adjusted accordingly.  
 
Change #43  
Section [IP_ADDRESS], Immediate action: determination of IMP discontinuation, paragraph 2  
All PDILI events require immediate acti on, testing, and monitoring.  
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by [CONTACT_58984]) to 
immediate and permanent discontinuation (see  Section  6.3.1  and Table  12‒3 for details).  
Has been changed to:  
All PDILI events require immediate action, testing, and monitoring.  
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by [CONTACT_58984]) to 
immediate and permanent  discontinuation (see Section  6.3.1  and Table  12‒3 for detai ls). 
 
Change #44  
Section [IP_ADDRESS].1, IMP restart/rechallenge, paragraph 1  
Subjects who are immediately discontinued from IMP due to having met certain criteria for 
PDILI (as described in Section  6.3.1  and Table  12‒3), but for whom an alternative diagnosis is 
confirmed, ie, drug -induced liver injury is excluded, can rarely restart IMP. Rechallenge with 
IMP can occur only if ALL of the following requirements are met:  
Has been changed to:  
Subjects who are immediately discontinued from IMP due to having met certain criteria for 
PDILI (as de scribed in Section  6.3.1  and Table  12‒3), but for whom an alternative diagnosis is 
confirmed, ie, drug -induced liver injury is excluded, can rarely restart IMP. Rechallenge with 
IMP can occur only if ALL of the following requirements are met at the time of the 
rechallenge:  
 
Change #45  
Section 1 2.7.7, PHQ -9 
The following text was moved to Section 12.7.7.  
The PHQ -9 is a multipurpose instrument for screening, diagnosing, monitoring, and measuring 
the severity of depression. The PHQ -9 scores for depression range from 0 to 27 with higher 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  158 of 187 scores indic ating worse state. A score of 5  to 9 is considered to be minimal symptoms of 
depression. A score of 10 to 14 is considered minor depression, dysthymia, or mild major 
depression. A score of 15 to 19 is considered to indicate moderately severe major depressi on, 
and a score ≥[ADDRESS_593287] at the visits specified in Table  5-2.  
Refer to Section  6.3 for PHQ -9-related withdrawal criteria.  
 
Change #46  
Section 13.2, Medical and ankylosing spondylitis history  
The Investigator or designee will obtain a complete medical history and a medical history related 
to AS (including EAMs, the date of diagnosis, and past treatments for AS as part of the 
Screening assessment and include all clinically relevant past or coexisting medical condit ions, 
responses to AS treatment as available, Baseline GI -related symptoms, and surgeries. Findings 
will be recorded in the eCRF.  
Has been changed to:  
The Investigator or designee will obtain a complete medical history and a medical history related 
to AS (including EAMs, the date of diagnosis, and past treatments for AS, and ASAS 
classification criteria as referenced in Section  19.1) as part of the Scre ening assessment and 
include all clinically relevant past or coexisting medical conditions, responses to AS treatment as 
available, Baseline GI -related symptoms, and surgeries. Findings will be recorded in the eCRF.  
 
Change #47  
Section 15.3.1, Figure 15 -1, Sequential testing procedure of primary/secondary efficacy 
endpoints  
The time point (Week  16) was added to hypothesis #9 in the sequential testing procedure.  
 
Change #48  
Section 15.3.3, Subgroup analyses, bullet #3  
Subgroup analyses using descriptive statistics will be performed on the primary efficacy 
variable. The following variables for subgroup analyses will be defined:  
• ... 
• Disease duration (<2 years; ≥2 years)  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  159 of 187 Has been changed to:  
Subgroup analyses using descr iptive statistics will be performed on the primary efficacy 
variable. The following variables for subgroup analyses will be defined:  
• ... 
• Disease duration (< 5 years; ≥ 5 years)  
 
Change #[ADDRESS_593288], or his/her legal representative, and by [CONTACT_16994] (Investigator or designee). The subject or his/her legal 
represen tative must receive a copy of the signed and dated Informed Consent Form. As part of 
the consent process, each subject must consent to direct access to his/her medical records for 
study -related monitoring, auditing, IRB/IEC review, and regulatory inspectio n. 
Has been changed to:  
Prior to participation in the study, the Informed Consent Form should be signed and personally 
dated by [CONTACT_423] , or his/her legal representative , and by [CONTACT_16994] (Investigator or designee). The subject or his/her legal 
representative  must receive a copy of the signed and dated Informed Consent Form. As part of 
the consent process, each subject must consent to direct access to his/her medical records for 
study -related monitoring, au diting, IRB/IEC review, and regulatory inspection.  
 
Change #[ADDRESS_593289] with him/her at all times.  
Has been changed to:  
Upon signing the Informed  Consent Form, the subject or legal representative  will be provided 
with a subject identification card in the language of the subject. The Investigator will fill in the 
subject identifying information and medical emergency contact [CONTACT_3031]. The Investig ator 
will instruct the subject to keep the card with him/her at all times.  
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  160 of 187 Change #51  
Section 18, References  
The following reference has been added:  
Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, et al. Which spi[INVESTIGATOR_463166] -TNF agents? A long -term observational study using MRI and conventional 
radiography. Ann Rheum Dis. 2014;73:1819 -25. 
The following reference has been deleted:  
Sieper J, Poddubnyy D. Axial spondyloarthritis.Lancet. 2017;1;390([ZIP_CODE]):73 -84. 
 
Change #52  
Section 19.1, ASAS Classification Criteria for axial SpA  
The following table has been added:  
Table 19 -1: ASAS classification criteria for axial SpA (for subjects with chr onic 
back pain of at least 3 months and age at onset <45 years)  
Imaging criteria  ASAS clinical criteria for axial SpA  
Sacroiliitis (MRI or radiographsa) plus ≥1 SpA feature  HLA -B27 plus ≥2 other SpA features  
SpA featuresb  
Inflammatory back painc  Psoriasis  
Arthritis  Crohn’s disease/ulcerative colitis  
Enthesitis (heel)  HLA -B27 
Uveitis  Elevated CRP  
Dactylitis   
ASAS=Assessment of SpondyloArthritis International Society; axSpA=axial spondyloarthritis; CRP=C -reactive 
protein; HLA -B27=human leukocyte antigen B27; MRI=magnetic resonance imaging; NSAID=nonsteroidal 
anti-inflammatory drug; SpA=spondyloarthritis  
a Active inflammatory lesions of sacroiliac joints with definite bone marrow oedema/osteitis suggestive of 
sacroiliitis associated with spondyloarthritis in MRI or radiographic sacroiliitis Grade 2 to 4 bilaterally or 
Grade  3 to 4 unilaterally according to modified NY criteria. For this study, only MRI will be permitted for 
study entry for the imaging criterion.  
b “Family history for SpA” and “Good response to NSAIDs” are excluded as SpA feature criteria.  
c Inflammatory back pain according to ASAS criteria for axSpA defined as the presence of 4 out of 5 of the 
following parameters:  
1. age at onset <[ADDRESS_593290]  
5. pain at night (with improvement upon getting up)  
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  161 of 187 19.4 Protocol Amendment 2  
Rationale for the amendment  
The purpose of this protocol amendment is an update of Inclusion criterion #[ADDRESS_593291] the 
treatment guideli nes for axSpA, as presented in the recent EULAR/ASAS and ACR/SPARTAN 
guidelines. The List of Abbreviations has been updated accordingly. In addition, a minor update 
for consistency has been made.  
 
Modifications and changes  
Global changes  
No global changes have been made.  
 
Specific changes  
Change #1  
Section 6.1, Inclusion criterion #[ADDRESS_593292] 1 of the following:  
− Inadequate response to NSAID therapy, or  
− Intolerance to administration of at least 1 NSAID, or  
− Contraindication(s) to NSAID therapy  
Inadequate response to an NSAID is defined as lack of response for at least [ADDRESS_593293] 4 weeks total duration.  
Has been changed to:  
6a. Subjects had to have either failed to respond to [ADDRESS_593294] a history of intolerance to or a 
contraindicatio n to NSAID therapy.  
Change #2  
Section 9.15, ASDAS  
The variables related to ASDAS improvement are defined as follows:  
• ASDAS -CII: ASDAS reduction (improvement) of ≥1.1 relative to Baseline  
• ASDAS -MI: ASDAS reduction (improvement) of ≥2.0 relative to Baseline  
The ASDAS variables will be derived from assessments at the visits specified in Table  5‒2. 
 
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  162 of 187 Has been changed to:  
The variable related to ASDAS improvement is defined as follows:  
• ASDAS -MI: ASDAS reduction (improvement) of ≥2.0 relative to Baseline  
The ASDA S variables will be derived from assessments at the visits specified in Table  5‒2. 
 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  163 of 187 19.5 Protocol Amendment 3  
Rationale for the amendment  
The purpose of this amendment is to change the sponsor company name [CONTACT_18904] “UCB Biopharma 
SPRL” to “UCB Biopharma SRL” since the name [CONTACT_463223] “société à responsabilité limitée” abbreviated “SRL”.  
In addition, a minor correction has been made.  
Modifications and changes  
Global changes  
No global changes have been made.  
Specific  changes  
Change #[ADDRESS_593295] information  
Sponsor  
UCB Biopharma SPRL  
Allée de la Recherche 60  
1070 Brussels  
BELGIUM  
Has been changed to:  
Sponsor  
UCB Biopharma SRL  
Allée de la Recherche [ADDRESS_593296] of the pandemic. In addition, other previously planned supportive analyses defined in the 
SAP were added for completeness.  
Further key changes are summarized below.  
• The introduction in  Section  [ADDRESS_593297] status.  
• For some secondary and other endpoints in Section  4.2.1  and Section  4.3.1  (BASDAI, 
nocturnal spi[INVESTIGATOR_18172], ASQoL, SF -36, MOS12 -item scale, a nd FACIT -Fatigue), wording 
changes have been implemented for consistency with the user manuals and to reflect precise 
description of the PRO tool and scoring (change in terminology but no change in the 
method). Similarly, corresponding small changes in Section [ADDRESS_593298] been 
made f or clarity and consistency with the revised description of the assessments.  
• The definition of the secondary safety variables related to SAEs and AEs leading to 
withdrawal was changed to clarify these variables are related to treatment -emergent events. 
This definition is consistent with the SAP and common practice . 
• Interim analyses as described in Section  5.[ADDRESS_593299] been updated to clarify 
that interim analyses will include data from the planned number of randomized study 
participants who completed t he corresponding treatment period. In Section  15.8.1 , the 
amendment clarifies that additional interim analyses or data cuts for regulatory purposes are 
permitted.  
• A typographical error in Table  5‒1 showing cross -study screening requirements for the 
PHQ -9, eC -SSRS, and the TB questionnaire (Q1) relat ed criterion has been corrected.  
• In line with the Exclusion Criterion [ADDRESS_593300] biologic therapi[INVESTIGATOR_014], including other anti -IL17s.  
• In Table  7‒2, the section providing details for mild potency opi[INVESTIGATOR_463167].  
• Section  7.8.[ADDRESS_593301] 28 days of the final IMP dose.  
• Throughout the protocol, vital sign assessments  reported as pulse and blood pressure 
measurements were replaced with “vital sign” measurements for internal consistency. This 
update does not reflect a procedural change.  
• The description of the ASQoL assessment in Section  9.2 has been amended with details 
regarding scoring.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  165 of 187 • Language describing the BASFI component of the ASAS response has been updated for 
clarity to specifically mention “physical functi on” as opposed to “function”. The header for 
Section  9.5 was updated accordingly.  
• The presentation of the SF -36 assessment in Section  9.6 has been corrected to ensure 
consistency with the user manual and the author’s recommendation (Maruish, 2011). 
Subsequently, wording changes for consistency thr oughout the protocol, mainly in 
Section  4.2.[ADDRESS_593302] been made.  
• The presentation of the FACIT -Fatigue subscale in Section  9.10 has been corrected to ensure 
consistency with the user manual (FACIT.org). Subsequently, wording changes for 
consistency throughout the protocol, mainly in Section  4.3.[ADDRESS_593303] been made.  
• The proposed SPARCC and ASspi[INVESTIGATOR_463168], respectively, are currently well accepted.  Methodology 
for scoring of MRI inflammation in the SIJ or spi[INVESTIGATOR_463169], and the additional methods 
to evaluate the MRI inflammati on data (for instance spi[INVESTIGATOR_463170]) may be considered.  
Based on this approach, Section  9.20.3  has been amended accordingly.  
• With progressive development of bimekizumab and based on the ongoing review of 
emerging safety data, depression has been removed as a safety topic of interest. Nevertheless, 
depression will continue to be monitored as a safety parameter by [CONTACT_127659]9 and will be 
captured via  routine AE reporting during the study. This update is considered a procedural 
change.  
• Action to be taken in the event that a subject reports a pregnancy as described in Section  12.2 
has been updated for consistency with protocols in other indications.  
• Action to be taken if a subject presents with a PDILI event as described in Section  12.6.1  has 
been updated for consistency with protocols in other indications.  
• Section  15.8.2  was amended to all ow other adjudication committees as necessary.  
• Study contact [CONTACT_463214].  
At the same time, a few updates including consistency changes within the bimekizumab 
program, minor corrections, the list of abbreviations, a  reference has been added for the 
FACIT -Fatigue, and minor formatting changes for the purpose of clarity have been made.  
 
Modifications and changes  
Global changes  
The following change was made throughout the protocol:  
• All instances that referred to “Administer the SF -36 PCS and MCS” have been corrected 
to “Administer the SF -36 questionnaire”.  
• All instances that referred to “FACIT -F” have been corrected to “FACIT -Fatigue”, all 
instances that referred to “Administer the FACIT -F” have been corrected to “Administer 
the FACIT -Fatigue subscale” and the definition of the abbreviation was updated 
accordingly.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  166 of 187 Specific changes  
Change #1  
Protocol/Amendment number details on the cover page  
Protocol Amendment 4.2 ([LOCATION_013])  
Has been changed to:  
Protocol Amendment 3.2 ([LOCATION_013])  
 
Change #[ADDRESS_593304] INFORMATION  
Sponsor Study Physician  
Name:   
[CONTACT_2761]:  UCB BIOSCIENCES GmbH  
Alfred -Nobel -Straße 10  
[ZIP_CODE] Monheim am Rhein  
GERMANY  
Phone:   
Has been changed to:  
Name:   
[CONTACT_2761]:  UCB BIOSCIENCES GmbH  
Alfred -Nobel -Straße 10  
[ZIP_CODE] Monheim am Rhein  
GERMANY  
Phone:   
 
Change #3  
Section  2.2, Bimekizumab, paragraph 1, sentence 5  
Bimekizumab is being developed for the treatment of  patients with inflammatory diseases such 
as PsA, psoriasis (PSO), and axSpA.  
Has been changed to:  
Bimekizumab is being developed for the treatment of patients with inflammatory diseases such 
as PsA, psoriasis (PSO), and axSpA and hidradenitis suppurativa . 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  167 of 187  
Change #4  
Section [IP_ADDRESS], Completed studies, paragraph [ADDRESS_593305] been completed: UP0008 in 39 subjects with mild 
to moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA, 
UP0031 in 12 healthy volunteers, UP0042 in 48 Japanese and Caucasian healthy volunteers, 
RA0123 in 159 subjects with moderate -to-severe RA, PS0010 in 250 subjects with moderate -to-
severe chronic plaque PSO and the corresponding extension study (PS0011), PS0016 in 49 
subjects with moderate -to-severe chronic plaque PSO and the corresponding extension study 
(PS0018), UC0011 in 23 subjects with moderate -to severe active ulcerative colitis, AS0008 in 
303 subjects with AS, and PA0008 in 206 subjects with PsA.  
Has been changed  to: 
Thirteen  Twenty  clinical studies of bimekizumab have been completed: UP0008 in 39 subjects 
with mild to moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects 
with PsA, UP0031 in 12 healthy volunteers, UP0033 in 189 healthy volunt eers, UP0034 in 
56 healthy volunteers, UP0042 in 48 Japanese and Caucasian healthy volunteers, UP0074 in 
37 healthy volunteers,  RA0123 in 159 subjects with moderate -to-severe RA, PS0010 in 250 
subjects with moderate -to-severe chronic plaque PSO and the cor responding extension study 
(PS0011), PS0016 in 49 subjects with moderate -to-severe chronic plaque PSO and the 
corresponding extension study (PS0018), UC0011 in 23 subjects with moderate -to severe active 
ulcerative colitis, HS0001 in 90 subjects with modera te to severe hidradenitis suppurativa,  
AS0008 in 303 subjects with AS, and PA0008 in 206 subjects with PsA , PS0008 in 478 subjects 
with moderate to severe chronic plaque PSO, PS0009 in 567 subjects with moderate to 
severe chronic plaque PSO and PS0013 in 4 35 subjects with moderate to severe chronic 
plaque PSO . 
 
Change #5  
Section [IP_ADDRESS], Ongoing studies, paragraph 1  
Several additional studies of bimekizumab in subjects with AS are ongoing:  
Has been changed to:  
Several additional studies of bimekizumab in subjects with AS axSpA  are ongoing:  
In addition, t he following bullet has been added:  
• AS0014 is a Phase 3, open -label extension study for AS0010 and AS0011.  
 
Change #6  
Section 4.2, Secondary variables  
Section 4.2.1, Secondary efficacy variables  
• … 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  168 of 187 • Change from Baseline in BASDAI at Week 16  
• … 
• Change from Baseline in nocturnal spi[INVESTIGATOR_18172] (NRS) at Week 16  
• Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week  16  
• Change from Baseline in the Short Form 36 -Item Health Survey (SF -36) physical component 
summary (PCS) at Week 16  
• … 
Section 4.2.2, Secondary safety variables  
… 
• Incidence of serious adverse events (SAEs)  
• Adverse events (AEs) leading to withdrawal from IMP  
Has been changed to:  
Section 4.2.1, Secondary efficacy variables  
• … 
• Change from Baseline in BASDAI total score  at Week 16  
• … 
• Change from Baseline in nocturnal spi[INVESTIGATOR_463121]  (NRS) at Week 16  
• Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) total score  at 
Week  16  
• Change from Baseline in the Short Form 36 -Item Health Survey (SF -36) physical component 
summary (PCS) score  at Week 16  
• … 
Section 4.2.2, Secondary safety variables  
… 
• Incidence of treatment -emergent  serious adverse events (SA Es) 
• Adverse events (AEs)  TEAEs  leading to withdrawal from IMP  
 
Change #7  
Section  4.3.1, Other efficacy variables  
• … 
• Change from Baseline in BASDAI  
• … 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  169 of 187 • Change from Baseline in total and nocturnal spi[INVESTIGATOR_18172] (NRS)  
• Change from Baseline in the average of Questions 5 and 6 of the BASDAI concerning 
morning stiffness  
• … 
• Change from Baseline in the SF -36 PCS  
• Change from Baseline in the SF -36 mental component summary (MCS)  
• Change from Baseline in sleep quality (Medical O utcomes Study [MOS  12-item] scale)  
• Change from Baseline in Functional Assessment of Chronic Illness Therapy -Fatigue 
(FACIT -F)  
• Change from Baseline in ASQoL  
• … 
Has been changed to:  
• … 
• Change from Baseline in BASDAI total score   
• … 
• Change from Baseline in to tal and nocturnal spi[INVESTIGATOR_463121]  (NRS)  
• Change from Baseline in the average score  of Questions 5 and 6 of the BASDAI concerning 
morning stiffness  
• … 
• Change from Baseline in the SF -36 PCS score  
• Change from Baseline in the SF -36 mental component summary ( MCS) score  
• Change from Baseline in sleep quality score  (Medical Outcomes Study [MOS  12-item] 
scale)  
• Change from Baseline in Functional Assessment of Chronic Illness Therapy -Fatigue  
(FACIT -F)-Fatigue subscale  score  
• Change from Baseline in ASQoL total score   
• … 
 
Change #8  
Section  5.1, Study description, paragraph 6, sentence 1  
Interim analyses of all available data (including efficacy, safety, and PK) will be conducted after 
all randomized subjects have completed [ADDRESS_593306] wit hdrawn 
from IMP or the study.  
Has been changed to:  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  170 of 187 Interim analyses of all available data (including efficacy, safety, and PK) will be conducted after 
all the planned number of randomized subjects have completed [ADDRESS_593307] withdrawn from IMP or the study.  
 
Change #9  
Section [IP_ADDRESS] Cross -study screening requirements  
Table 5 -1: Cross -study screening requirements, fourth row, second column  
Table 5 -1: Cross -study screening requirements  
Assessment  Screening requirements  
… 
PHQ -9, eC -SSRS, 
TB questionnaire 
(Q1)  Screening of a subject not eligible for AS0010 who will be screened for AS0011, 
and who did not meet the related Exclusion Criteria in AS0010.  
… 
Has been changed to:  
Table 5 -1: Cross -study screening requirements  
Assessment  Screening requirements  
… 
PHQ -9, eC -SSRS, 
TB questionnaire 
(Q1)  Screening of a subject not eligible for AS0010 who will be screened for AS0011, 
and who did not meet the related Exclusion Criteria in AS0010.  
… 
 
Change #10  
Section 5.2, Schedule of study assessments  
Table 5‒2: Schedule of study assessments, 22nd row, first column  
Protocol activity  
… 
• FACIT -F 
… 
Has been changed to:  
Protocol activity  
… 
• FACIT -F-Fatigue subscale  
… 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  171 of 187  
Change #11  
Section 6.3, Withdrawal criteria  
The following bullet has been added:  
12.  Any subject who develops a clinically important infection or recurrent infections not 
responsive to standard therapy during the study must discontinue IMP until resolution of the 
infection. The Investigator should use clinical judgement in deciding whether the subject 
should restart IMP and contact [CONTACT_463186]’s suitability for continued participation in the study.  
 
Change #12  
Section 7.8, Concomitant medications/treatments  
Table 7‒2: Exclusionary, concomitant, and rescue medication , fourth row, first column  
Drug class/dose  
… 
Mild potency opi[INVESTIGATOR_463155]:  
• Tramadol/any dose up to 
maximum approved dose  
• Codeine/o nly <90mg of 
codeine per dosage unit  
… 
Has been changed to:  
Drug class/dose  
… 
Mild potency opi[INVESTIGATOR_463130],: 
• Tramadol/any dose up to 
maximum approved dose  
• Codeine/o nly <90mg of 
codeine per dosage unit  
… 
 
Change #13  
Section 7.8.1, Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])  
The following text has been added:  
Subjects are allowed to use any other medications, including biologics, after at least [ADDRESS_593308] completed the study 
treatment without entering the extension study and are in the SFU Period.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  172 of 187  
Change #14  
Section  8.2, Basel ine (Visit 2, Day 1, first dose of IMP), last bullet  
and  
 Section 8.3.6, Week 16 (±3 days) (Visit 8), last bullet  
• Measure BP and pulse approximately 30 minutes and 1 hour after dosing.  
Has been changed to:  
• Measure BP and pulse  vital signs  approximately 30 minutes and 1 hour after dosing.  
 
Change #15  
Section 9.1, ASAS20, 40, ASAS 5/[ADDRESS_593309] bullet point  
• Function section (represented by [CONTACT_18379], Section  9.5) 
Has been changed to:  
• Physical Function section  (represented  measured  by [CONTACT_18379], Section  9.5) 
 
Change #[ADDRESS_593310] paragraph  
The ASQoL, a validated disease -specific 18 -item questionnaire, has been developed specifically 
for measuring health -related quality of life (HRQoL) in subjects with AS (Doward et al, 2003). 
The ASQoL has been used and has shown to be responsive in axSpA (Barkham et al, 2009; 
Haibel et al, 2008). The ASQoL score ranges from 0 to 18 with a higher score indicating worse 
HRQoL.  
Has been changed to:  
The ASQoL, a validated disease -specific 18 -item questionnaire, has been developed specifically 
for measuring health -related quality of life (HRQoL) in subjects with AS (Doward et al, 2003). 
The ASQoL has been used and has shown t o be responsive in axSpA (Barkham et al, 2009; 
Haibel et al, 2008). The Each statement on the  ASQoL is given a  score ranges  of 1 = Yes or 0 
= No. A score of "1" is given where the item is affirmed, indicating adverse quality of life. 
All item scores are su mmed to total score ranging  from 0 to 18 with a higher score indicating 
worse HRQoL.  
 
Change #17  
Section 9.4, BASDAI, second paragraph  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  173 of 187 The BASDAI is calculated as follows:  
Has been changed to:  
The BASDAI total score  is calculated as follows:  
 
Change #18  
Section  9.5, Function – BASFI, heading  
Has been changed to:  
Section  9.5, Physical Ffunction – BASFI  
 
Change #19  
Section  9.6, SF -36, paragraphs 1 and 2  
The SF -36 (Version 2, standard recall) is a 36 -item generic HRQoL instrument that uses a recall 
period of 4 weeks. Items are grouped into 8 domains as follows: Physical Functioning (10 items), 
Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), 
Social Functioning (2 items), Role Emotional (3 items), Mental Health (5  items), and 1 item for 
perceived stability or change in health (Health Transition) during the last year. The concepts 
represented by [CONTACT_18385], mental, and social aspects of HRQoL.  
In addition to domain scores, the Physical Comp onent Summary and Mental Component 
Summary scores are calculated from the 8 domains (excluding the Health Transition item). 
Component scores appreciate the impact of each domain on physical and mental health status 
(Maruish, 2011). Each of the [ADDRESS_593311] deviation (SD) of 10 in the general 
US population.  
Has been c hanged to:  
The SF -36 (Version 2, standard recall) is a 36 -item generic HRQoL instrument that uses a recall 
period of 4 weeks. Items are grouped into 8 domains as follows: Physical Functioning (10 items), 
Role Physical (4 items), Bodily Pain (2 items), Gene ral Health (5 items), Vitality (4 items), 
Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items) , and 1  One 
additional  item for perceived stability or change in  asks respondents about  health change  
(Health Transition) during  over  the last past year. The concepts represented by [CONTACT_463215], mental, and social aspects of HRQoL.  
In addition to domain scores, the Physical Component Summary and Mental Component 
Summary scores are calculated from the 8 domains (ex cluding the Health Transition item). 
Component scores appreciate the impact of each domain on physical and mental health status 
(Maruish, 2011). Each of the 8 domain scores and the component summary scores range from 
0 to 100, with a higher score indicatin g a better health status.  The norm -based T -scores for the  
2 SF-36 component summary (PCS and MCS) and the [ADDRESS_593312] deviation (SD) of 10 in the general US  population (Maruish, 2011). 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  174 of 187 An individual res pondent’s score that falls outside the T -score range of 45 to 55 should be 
considered outside the average range for the US general population. When considering 
group -level data, a score below 47 should be considered indicative of impaired functioning 
withi n that health domain or dimension. Similar to individual respondent data, group 
mean scores of 47 or greater should be considered average or above average as compared 
to the general US population. Higher scores indicate a better health status.  
 
Change #[ADDRESS_593313] 7 days. The FACIT -F contains 13 questions with responses scored 
on a 5 -point Li kert scale from 0 (not at all) to 4 (very much). Scores range from 0 to 52 (Mease 
et al, 2011).  
The FACIT -F will be assessed by [CONTACT_463196]  5-2. 
Has been changed to:  
Section  9.10, FACIT -F-Fatigue subscale  
The FACIT -F is a self-administered quality of life questionnaire targeted to  40-item measure 
that assesses self -reported fatigue and its impact upon daily activities and function over  the 
management of chronic illness within the past 7 days (FACIT.org) . The scale consists of 
5 subscales (physical well -being, social/family well -being, emotional well -being, functional 
well-being, and fatigue). The fatigue subscale is the onl y one used in this study. The FACIT -
F contains  It is composed of  13 questions with responses  items, all  scored on a 5 -point Likert 
scale  from 0 ( nNot at all) to 4 ( vVery much). Scores range  The FACIT -Fatigue subscale score 
ranges  from 0 to 52 (Mease et al,  2011)  with [ADDRESS_593314] (0) to the best (4) outcome.  
The FACIT -F-Fatigue subs cale will be assessed  completed  by [CONTACT_463216]  5-2. 
 
Change #21  
Section [IP_ADDRESS] Other safety topi[INVESTIGATOR_23254], para graph [ADDRESS_593315] for the study are: infections (serious, opportunistic, fungal, 
and TB), neutropenia, hypersensitivity, suicidal ideation and behavior, depression, major 
cardiovascular events, liver function test changes/enzyme eleva tions, malignancies, and 
inflammatory bowel diseases (with gastroenterology referral, as appropriate).  
Has been changed to:  
Pre-specified safety topi[INVESTIGATOR_397120]: infections (serious, opportunistic, fungal, 
and TB), neutropenia, hypers ensitivity, suicidal ideation and behavior, depression,  major 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593316] changes/enzyme elevations, malignancies, and 
inflammatory bowel diseases (with gastroenterology referral, as appropriate).  
 
Change #[ADDRESS_593317] paragraph:  
Additional scoring systems of inflammation may be used as appropriate methodology becomes 
accepted.  
 
Change #[ADDRESS_593318] immediately notify UCB’s PS department by [CONTACT_463217]. An automatic notification will be sent to UCB’s PS department. The 
subject should be withdrawn from the study as soon as pregnancy is known (by [CONTACT_368790]), and the following should be completed:  
• The subject should return for the ET Visit.  
• The subject should immediately stop the intake of the IMP.  
• A Safety Follow -Up Visit should be scheduled [ADDRESS_593319] has discontinued 
her IMP.  
Has been changed to:  
If an Investigator is notified that a subject has become pregnant after the firs t intake of any IMP, 
the Investigator must immediately (within 24  hours)  notify UCB’s PS department by [CONTACT_463218]. An automatic notification will be sent to UCB’s PS 
department. The subject should be permanently  withdr awn from the study  IMP  as soon as 
pregnancy is known (by [CONTACT_18463]), and the following should be completed:  
• The subject should return for the ET Visit.  
• The subject should immediately stop the intake of the IMP.  
• The subject should return for an early ad -hoc study visit . 
• A Safety Follow -Up Visit should be scheduled [ADDRESS_593320] of information currently known about potential 
risks and about available treatment alternatives.  
 
Change #[ADDRESS_593321] be reported as an AE and reported to the study site and Sponsor within 24 hours of learning 
of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be 
reported as an AE of special interest (see Section  [IP_ADDRESS] ), and, if applicable, also reported as an 
SAE (see Section  [IP_ADDRESS] ). 
Has been changed to:  
The PDILI IMP discontinuation criteria for this study are provided in Section  6.3.[ADDRESS_593322] be reported as an AE and PDILI events meeting SAE criteria should be  reported to t he 
study site and  Sponsor within 24 hours of learning of their occurrence. Any PDILI event that 
meets the criterion for potential Hy’s Law must be reported within [ADDRESS_593323] (see Section  [IP_ADDRESS] ), and, if applicable, also reported 
as an SAE (see Section  [IP_ADDRESS] ).  
 
Change #25  
Section 12.7.1 Vital signs  
The Investigator or designee should measure all vital signs (systolic and diastolic BP, 
temperature [oral, axillary, or otic], pulse rate) prior to dosing after the subject has been sitti ng 
for at least [ADDRESS_593324] should remain seated during the measurements. At 
Baseline/Day  [ADDRESS_593325] pulse and BP prior to drug administration and then at 
approximately 30  minutes and 1 hour after dosing.  
Has been changed to:  
The Investigator or designee should measure all vital signs (systolic and diastolic BP, 
temperature [oral, axillary, or otic], pulse rate) prior to dosing after the subject has been sitting 
for at least [ADDRESS_593326] should remain seated durin g the measurements. At 
Baseline/Day  [ADDRESS_593327] pulse and BP  vital signs  prior to drug administration and 
then at approximately 30  minutes and 1 hour after dosing.  
 
Change #26  
Section 15.1, Definition of analysis sets, fifth bullet  
• The Per -Protocol Set (PPS) will consist of all subjects in the RS who had no important 
protocol deviation affecting the primary efficacy variable. Important protocol deviations will 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  177 of 187 be predefined and subjects with important protocol deviations will be eval uated during a data 
evaluation meeting prior to unblinding of the data.  
Has been changed to:  
• The Per -Protocol Set (PPS) will consist of all subjects in the RS who had no important 
protocol deviation affecting the primary efficacy variable. Important proto col deviations will 
be predefined and subjects with important protocol deviations will be evaluated during a data 
evaluation meeting prior to unblinding of the data. Exclusions from the FAS will be 
considered important protocol deviations that also result in exclusion from the PPS.  
In addition, t he following bullet has been added:  
The coronavirus disease 2019  (COVID -19) free set will consist of all subjects in the RS who had 
no COVID -[ADDRESS_593328] up to the primary efficacy endpoint. Further details will be def ined as part 
of the SAP.  
 
Change #27  
Section [IP_ADDRESS] Analysis of the primary efficacy variable, paragraph 2, bullet #1, bullet #3 
and paragraph 4  
… 
The primary endpoint is the ASAS40 response at Week 16. The primary efficacy analysis will 
evaluate the com posite estimand in the RS. The composite estimand combines the clinically 
meaningful improvement from Baseline based on the ASAS40 response and not discontinuing 
treatment early due to an AE or lack of efficacy.  
… 
1. Population = Subjects meeting the protocol -specified inclusion/exclusion criteria.  
… 
3. Intercurrent event handling = An intercurrent event is defined as discontinuation of study 
treatment due to an AE or lack of efficacy prior to Week 16. A composite strategy will be 
implemented in which a p ositive clinical outcome is defined as achieving ASAS40 at 
Week  16 and not discontinuing study treatment due to an AE or lack of efficacy through 
Week  16.  
… 
Any missing data at Week 16 that are not preceded by [CONTACT_463204] (ie, discontinuation 
of study medication due to an AE or lack of efficacy) will be imputed based on a predefined 
multiple imputation (MI) model.  In MI, the missing value is replaced by a set of plausible values, 
where each value is a Bayesian draw from the conditional distributi on of the missing data given 
the observed data. Intermittent missing data will be imputed using the Markov -Chain Monte 
Carlo (MCMC) method, followed by [CONTACT_463219].   
… 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  178 of 187 Has been changed to:  
… 
The primary endpoint is the ASA S40 response at Week 16. The primary efficacy analysis will 
evaluate the composite estimand in the RS. The composite estimand combines the clinically 
meaningful improvement from Baseline based on the ASAS40 response and not discontinuing 
treatment early due to an AE or lack of efficacy . In practice, this composite estimand is 
similar to non -responder imputation (NRI), referred to here as modified NRI.  
… 
1. Population = Subjects meeting  enrolled according to  the protocol -specified 
inclusion/exclusion criter ia and randomized to IMP . 
… 
3. Intercurrent event handling = An intercurrent event is defined as discontinuation of study 
treatment due to an AE or lack of efficacy  prior to Week 16. A composite strategy will be 
implemented in which a positive clinical outcome is defined as achieving ASAS40 at 
Week  16 and not discontinuing study treatment due to an AE or lack of efficacy  through 
Week  16. 
… 
Any m Missing data at Week 1 6 that are not preceded by [CONTACT_463204] , and any data 
after an intercurrent event will be imputed as non -responders  (ie, discontinuation of study 
medication due to an AE or lack of efficacy) will be imputed based on a predefined multiple 
imputatio n (MI) model.  In MI, the missing value is replaced by a set of plausible values, where 
each value is a Bayesian draw from the conditional distribution of the missing data given the 
observed data. Intermittent missing data will be imputed using the Markov -Chain Monte Carlo 
(MCMC) method, followed by [CONTACT_463219] .  
… 
 
Change #28  
Section [IP_ADDRESS].1 Supportive analyses  
Supportive analyses for the primary efficacy variable will be conducted:  
1. The analysis will be repeated based on the PPS to evaluate the effect of important protocol 
deviations on the analysis.  
2. The analyses will be repeated for all subjects in the FAS to evaluate the consistency between 
the RS and the more restrictive FAS. This  analysis will only be performed if the number of 
subjects in RS and FAS are different.  
3. The analyses will also be repeated for all individual components of the ASAS40 response to 
explore the effect of the signs and symptoms of the individual components on the composite 
endpoint. Since all ASAS components are continuous variables (eg, change from Baseline in 
total spi[INVESTIGATOR_18172]), an analysis of covariance (ANCOVA) with treatment, region, and prior 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  179 of 187 TNFα inhibitor exposure as fixed effects and the Baseline value s as covariate will be used for 
the analysis.  
Additional supportive analyses to evaluate varying assumptions related to the handling of 
missing data will also be performed and are described in Section  15.7. 
Has been changed to:  
Supportive analyses for the primary efficacy variable will be conducted . The analyses will be 
repeated : 
1. The analysis will be repeated b Based on the PPS to evaluate the effect of important protocol 
deviations on the analysis.  
2. The analyses will be repeated f For all subjects in the FAS to evaluate the consistency 
between the RS and the more restrictive FAS. This analysis will only be perform ed if the 
number of subjects in RS and FAS are different.  
3. The analyses will also be repeated f For all individual components of the ASAS40 response to 
explore the effect of the signs and symptoms of the individual components on the composite 
endpoint. Since  all ASAS components are continuous variables (eg, change from Baseline in 
total spi[INVESTIGATOR_18172]), an analysis of covariance (ANCOVA) with treatment, region, and prior 
TNFα inhibitor exposure as fixed effects and the Baseline values as covariate will be used f or 
the analysis.  
4. Using a modified composite estimand where intercurrent events are defined only as 
discontinuation due to adverse event or lack of efficacy.  
5. Using a treatment policy imputation.  
6. Using a tippi[INVESTIGATOR_18275].  
7. Using observed cases only (OC).  
8. Using the COVID -19-free set.  
Further specification of  Aadditional supportive analyses to evaluate varying assumptions 
related to the handling of missing data will also be performed and are described in Section  15.7. 
 
Change #29  
Section [IP_ADDRESS] Analyses of the secondary efficacy variables, paragraph 2, first bullet point 
and paragraphs 4 and 5  
… 
Binary variables will be analyzed to evaluate the composite estimand in the RS as done for the 
primary efficacy variable. The composite estimand combines (1) achieving the given binary 
response and (2) not discontinuing prior to Week 16 due to an AE or lack of efficacy. The 
statistical hypothesis for the binary variables at Week 16 is that the conditional odds ratio for 
binary variables in the bimekizumab treatment group compared with the placebo treatment group 
is equal to 1.  
… 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  180 of 187 • Intercurrent event handling = An intercurrent event is defined as discontinuat ion of study 
treatment due to an AE or lack of efficacy prior to Week 16. A hypothetical strategy for 
addressing intercurrent events will be implemented. This estimand targets the treatment 
difference in a scenario where withdrawal from study treatment due  to an AE or lack of 
efficacy does not occur, such that outcomes for subjects without an intercurrent event are as 
observed, and outcomes for subjects with an intercurrent event are treated as though they had 
completed the randomized study treatment throug h Week 16. A multiple imputation strategy 
will be used to impute data following an intercurrent event.  
… 
Any missing data at Week 16 that is not preceded by [CONTACT_463204] (ie, discontinuation of 
study medication due to an AE or lack of efficacy) will be imputed based on a predefined  MI 
model. The missing value will be replaced by a set of plausible va lues, where each value is a 
Bayesian draw from the conditional distribution of the missing data given the observed data. 
Intermittent missing data will be imputed using the MCMC method, followed by [CONTACT_463220]. The statist ical model for the comparison of bimekizumab 
and placebo will be an ANCOVA with treatment, region, and prior TNFα inhibitor exposure as 
fixed effects and the Baseline value as covariate. The statistical hypothesis for the continuous 
variables at Week 16 is  that the treatment difference between the bimekizumab treatment group 
and placebo is equal to 0.  
All secondary efficacy variables will also be summarized based on observed case data.  
 
Has been changed to:  
… 
Binary variables will be analyzed to evaluate th e composite estimand in the RS , as done for the 
primary efficacy variable. The composite estimand combines (1) achieving the given binary 
response and (2) not discontinuing treatment  prior to Week 16 due to an AE or lack of efficacy . 
The statistical hypoth esis for the binary variables at Week 16 is that the conditional odds ratio for 
binary variables in the bimekizumab treatment group compared with the placebo treatment group 
is equal to 1.  
… 
• Intercurrent event handling = An intercurrent event is defined as  discontinuation of study 
treatment due to an AE or lack of efficacy  prior to Week 16. A hypothetical strategy for 
addressing intercurrent events will be implemented. This estimand targets the treatment 
difference in a scenario where withdrawal from study treatment due to an AE or lack of 
efficacy does not occur, such that outcomes for subjects without an intercurrent event are as 
observed, and outcomes for subjects with an intercurrent event are treated as though they had 
completed the randomized study tre atment through Week 16. A multiple imputation strategy 
will be used to impute data following an intercurrent event.  
… 
Any missing data at Week 16 that is not preceded by [CONTACT_463204] (ie, discontinuation of 
study medication due to an AE or lack of  efficacy ) will be imputed based on a 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  181 of 187 predefined  multiple imputation ( MI) model. The missing value will be replaced by a set of 
plausible values, where each value is a Bayesian draw from the conditional distribution of the 
missing data given the observed d ata. Intermittent missing data will be imputed using the 
Markov -Chain Monte Carlo ( MCMC ) method, followed by [CONTACT_463221]. The statistical model for the comparison of bimekizumab and placebo will be an 
ANCOVA with treatment , region, and prior TNFα inhibitor exposure as fixed effects and the 
Baseline value as covariate. The statistical hypothesis for the continuous variables at Week 16 is 
that the treatment difference between the bimekizumab treatment group and placebo is equ al to 
0. 
All secondary efficacy variables will also be summarized based on observed case data. Binary 
outcomes will also be summarized using the modified composite estimand.  
 
Change #30  
Section 15.3.2 Analyses of other efficacy variables, bullet #3, paragraph 3 and the second 
bullet #3  
… 
3. Intercurrent event handling = An intercurrent event is defined as discontinuation of study 
treatment due to adverse event or lack of efficacy prior to the time point being summarized. A 
composite strategy will be i mplemented in which a positive clinical outcome is defined as 
achieving the given variable at the specified time point and not discontinuing study treatment 
due to adverse event or lack of efficacy through that time point.  
… 
Any missing data that are not p receded by [CONTACT_463208] a predefined multiple imputation model as described for the primary efficacy 
variable.  
… 
3. Intercurrent event handling = An intercurrent event is defined as discontinuation of st udy 
treatment due to an AE or lack of efficacy prior to the time point being summarized. A 
hypothetical strategy will be implemented in which outcomes for subjects without an 
intercurrent event are as observed at the given time point, and outcomes for subj ects with an 
intercurrent event are treated as though they had completed the randomized study treatment 
through the time point being summarized. A multiple imputation strategy will be used to 
impute data following an intercurrent event.  
… 
Has been changed to: 
… 
3. Intercurrent event handling = An intercurrent event is defined as discontinuation of study 
treatment due to adverse event or lack of efficacy  prior to the time point being summarized. A 
composite strategy will be implemented in which a positive cl inical outcome is defined as 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  182 of 187 achieving the given variable at the specified time point and not discontinuing study treatment 
due to adverse event or lack of efficacy  through that time point.  
… 
Any missing data that are not preceded by [CONTACT_463208] a predefined multiple imputation model  NRI as described for the primary and 
secondar y efficacy variable s. 
… 
3. Intercurrent event handling = An intercurrent event is defined as discontinuation of study 
treatment due to an AE or lack of efficacy  prior to the time point being summarized. A 
hypothetical strategy will be implemented in which outcomes for subjects without an 
intercurrent event are as observed at the given time point, and outcomes for subjects with an 
intercurrent event are treated as though they had completed the randomized study treatment 
through the time point being summarized. A multiple imputation strategy will be used to 
impute data following an intercurrent event.  
… 
 
Change #31  
Section 15.7, Handl ing of dropouts or missing data, paragraphs 1 and 2, bullet #1 and 
paragraph 4  
The analysis for the primary and secondary efficacy variables will include the use of MI. In MI, 
the missing value is replaced by a set of plausible values, where each value is a Bayesian draw 
from the conditional distribution of the missing data given the observed data. Intermittent 
missing data will be imputed using the MCMC method, followed by [CONTACT_463222]. The multiple imputation procedures planned for  the primary and secondary 
efficacy analyses are based on an assumption of data missing at random (MAR).  
The sensitivity of results to the approach for handling missing data will be evaluated via 
supportive analyses using different missing data mechanisms . The following supportive analyses 
for the primary efficacy variable and for those secondary efficacy variables that are part of the 
hierarchical testing will be conducted:  
1.  Deviations from the MAR pattern will be evaluated using a reference -based MI approach. 
Intermittent missing data will be imputed using the MCMC method. The remaining monotone 
missing data will be assumed to follow a missing not at random (MNAR) pattern. Th ese data 
will be imputed using a reference -based approach in which the MI model is based on data 
from the placebo group, thereby [CONTACT_397168] a trajectory 
similar to the placebo group (Mallinckrodt,  2013). The estimand in this  procedure is the 
difference in outcome improvement in all randomized subjects at the planned endpoint of the 
study attributable to the initially randomized medication (Mallinckrodt  et al, 2012).  
… 
The same procedure described as in the primary efficacy a nalyses will be used.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  183 of 187 … 
Has been changed to:  
The primary analysis for the primary and secondary efficacy  variable s will use a conservative 
approach to handling missing data that is similar to non -responder imputation. The 
sensitivity of results to the appr oach for handling missing data will be evaluated via 
supportive analyses using different missing data mechanisms.  
In instances where  include the use of MI. In  MI is used , the missing value is replaced by a set 
of plausible values, where each value is a Bay esian draw from the conditional distribution of the 
missing data given the observed data. Intermittent missing data will be imputed using the 
MCMC method, followed by [CONTACT_463209]. The planned  multiple 
imputation procedures planned for the primary and secondary efficacy analyses  are based on an 
assumption of data missing at random (MAR).  
The sensitivity of results to the approach for handling missing data will be evaluated via 
supportive analyses using different missing data mechani sms. The following supportive analyses 
for the primary efficacy variable and for those secondary efficacy variables that are part of the 
hierarchical testing will be conducted:  
1.  Deviations from the MAR pattern will be evaluated using a reference -based MI approach. 
Intermittent missing data will be imputed using the MCMC method. The remaining monotone 
missing data will be assumed to follow a missing not at random (MNAR) pattern. These data 
will be imputed using a reference -based approach in which the MI model is based on data 
from the placebo group, thereby [CONTACT_397168] a trajectory 
similar to the placebo group (Mallinckrodt,  2013). The estimand in this procedure is the 
difference in outcome improvement in all randomized subj ects at the planned endpoint of the 
study attributable to the initially randomized medication (Mallinckrodt  et al, 2012).  Multiple 
imputation as described above will be performed using the modified composite estimand 
as specified for the use with the secon dary variables. The definition of an intercurrent 
event is changed from all treatment discontinuation, to discontinuation of treatment due 
to AE or lack of efficacy.  
… 
The same procedure described as in the primary efficacy analyses will be used.  For the 
secondary and other efficacy variables, the binary endpoints will be analyzed using 
modified NRI , MI and OC , and the continuous endpoints will be analyzed using MI and 
OC. 
… 
 
Change #32  
Section 15.8.1, Interim analyses, paragraph 1  
Two interim analyses will  be performed: one after all randomized subjects have completed the 
Double -Blind Treatment Period and the Week [ADDRESS_593329] 
completed Week 52.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  184 of 187 Has been changed to:  
Two interim analyses will be performed: one after all the planned number of randomized 
subjects have completed the Double -Blind Treatment Period and the Week [ADDRESS_593330] completed Week 52.  
In addition, t he following text has been added:  
Additional interim analyses and data cuts may be performed for regulatory purposes.  
 
Change #33  
Section 15.8.2 Data monitoring and Adjudication Committees  
The following text has been added:  
Other adjudication committees may be added as necessary.  
 
Change #34  
Section  15.9.2, Power calculations for secondary endpoints in the hierarchical testing  
… 
For change from Baseline in BASDAI at Week 16, an adjusted between -treatment difference 
of - 1.38 with an SD=1.8 for bimekizumab and SD=1.4 for placebo was used. With those 
assumptions, the endpoint is powered with >99% at the planned sample size.  
… 
For change from Baseline in nocturnal spi[INVESTIGATOR_58942] 16, the AS data from the 
certolizumab pegol study AS001 were used. An adjusted between -treatment difference of -1.88 
with an SD=2.9 for bimekizumab and SD=2.4 for placebo was used. With those assumptions, the 
endpoint is powered with >99% at the planned sample size.  
For change from Baseline in ASQoL at Week 16, an adjusted between -treatment difference 
of - 2.39 with an  SD=4.5 for bimekizumab and placebo was used. With those assumptions, the 
endpoint is powered with >99% at the planned sample size.  
For change from Baseline in SF -36 at Week 16, an adjusted between -treatment difference of 4.56 
with an SD=8.1 for bimekizuma b and SD=5.8 for placebo was used. With those assumptions, the 
endpoint is powered with >99% at the planned sample size.  
… 
Has been changed to:  
… 
For change from Baseline in BASDAI total score  at Week 16, an adjusted between -treatment 
difference of - 1.38 with an SD=1.8 for bimekizumab and SD=1.4 for placebo was used. With 
those assumptions, the endpoint is powered with >99% at the planned sample size.  
… 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   16 Feb 2021  
Clinical Study Protocol  Bimekizumab  AS0011  
   
Confidential  Page  185 of 187 For change from Baseline in nocturnal spi[INVESTIGATOR_463171] 16, the AS data from the 
certolizumab pe gol study AS001 were used. An adjusted between -treatment difference of -1.88 
with an SD=2.9 for bimekizumab and SD=2.4 for placebo was used. With those assumptions, the 
endpoint is powered with >99% at the planned sample size.  
For change from Baseline in A SQoL total score  at Week 16, an adjusted between -treatment 
difference of - 2.39 with an SD=4.5 for bimekizumab and placebo was used. With those 
assumptions, the endpoint is powered with >99% at the planned sample size.  
For change from Baseline in SF -36 PCS  score  at Week 16, an adjusted between -treatment 
difference of 4.56 with an SD=8.1 for bimekizumab and SD=5.8 for placebo was used. With 
those assumptions, the endpoint is powered with >99% at the planned sample size.  
… 
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   [ADDRESS_593331].  
Investigator:  
 
   
Printed name    [CONTACT_1782]/Signature  
 
[CONTACT_463224].
UCB   [ADDRESS_593332] this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.  
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
Approval Signatures
Name: [INVESTIGATOR_17174]0011-protocol-amend-4
Version: 1 . 0
Document Number: CLIN-000166877
Title: AS0011 Protocol Amendment 4 - Phase 3 - Placebo-controlled - Double-blind
Approved Date: [ADDRESS_593333]: ApprovedName: 
[CONTACT_18469]: Medical
Date of Signature: 16-Feb-2021 11:37:45 GMT[PHONE_006]
Approval
Verdict: ApprovedName: 
[CONTACT_18469]: Qualified Person
Date of Signature: 16-Feb-2021 14:12:45 GMT[PHONE_006]
Approval
Verdict: ApprovedName: 
[CONTACT_18469]: Clinical
Date of Signature: 17-Feb-2021 12:16:53 GMT[PHONE_006]
PUBLIC COPY 
 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.